{"sentence": "Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.", "drug1": "Mephenytoin", "drug2": "anti-infective medicines", "relation": "EFFECT", "source_file": "Mephenytoin.xml", "sentence_id": "DDI-DrugBank.d636.s3", "pair_id": "DDI-DrugBank.d636.s3.p2"} {"sentence": "Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ", "drug1": "coumarin anticoagulants", "drug2": "desipramine", "relation": "NONE", "source_file": "Methylphenidate.xml", "sentence_id": "DDI-DrugBank.d638.s2", "pair_id": "DDI-DrugBank.d638.s2.p18"} {"sentence": "Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).", "drug1": "methsuximide", "drug2": "antiepileptic drugs", "relation": "ADVISE", "source_file": "Methsuximide.xml", "sentence_id": "DDI-DrugBank.d587.s0", "pair_id": "DDI-DrugBank.d587.s0.p5"} {"sentence": "Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ", "drug1": "erythromycin", "drug2": "midazolam", "relation": "MECHANISM", "source_file": "Midazolam.xml", "sentence_id": "DDI-DrugBank.d752.s1", "pair_id": "DDI-DrugBank.d752.s1.p5"} {"sentence": "Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. ", "drug1": "Sulfamethizole", "drug2": "barbiturates", "relation": "EFFECT", "source_file": "Sulfamethizole.xml", "sentence_id": "DDI-DrugBank.d649.s0", "pair_id": "DDI-DrugBank.d649.s0.p0"} {"sentence": "Combination therapy with Cerezyme (imiglucerase) and ZAVESCA is not indicated.", "drug1": "Cerezyme", "drug2": "ZAVESCA", "relation": "ADVISE", "source_file": "Miglustat.xml", "sentence_id": "DDI-DrugBank.d695.s1", "pair_id": "DDI-DrugBank.d695.s1.p1"} {"sentence": "Mexitil does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum digoxin levels. ", "drug1": "magnesium-aluminum hydroxide", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Mexiletine.xml", "sentence_id": "DDI-DrugBank.d633.s15", "pair_id": "DDI-DrugBank.d633.s15.p8"} {"sentence": "Gentamicin: Animal data have suggested the possibility of interaction between perindopril and gentamicin. ", "drug1": "perindopril", "drug2": "gentamicin", "relation": "INT", "source_file": "Perindopril.xml", "sentence_id": "DDI-DrugBank.d781.s12", "pair_id": "DDI-DrugBank.d781.s12.p2"} {"sentence": "Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors. ", "drug1": "TRENTAL", "drug2": "anticoagulants", "relation": "EFFECT", "source_file": "Pentoxifylline.xml", "sentence_id": "DDI-DrugBank.d659.s0", "pair_id": "DDI-DrugBank.d659.s0.p0"} {"sentence": "These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ", "drug1": "GH", "drug2": "anticonvulsants", "relation": "MECHANISM", "source_file": "Somatropin recombinant.xml", "sentence_id": "DDI-DrugBank.d599.s7", "pair_id": "DDI-DrugBank.d599.s7.p2"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "absorbent-type anti-diarrhea medicines", "drug2": "kaolin", "relation": "NONE", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p238"} {"sentence": "As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy. ", "drug1": "mesalazine", "drug2": "thioguanine", "relation": "MECHANISM", "source_file": "Thioguanine.xml", "sentence_id": "DDI-DrugBank.d722.s1", "pair_id": "DDI-DrugBank.d722.s1.p8"} {"sentence": "Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ", "drug1": "saquinavir", "drug2": "fluconazole", "relation": "NONE", "source_file": "Methylergonovine.xml", "sentence_id": "DDI-DrugBank.d675.s4", "pair_id": "DDI-DrugBank.d675.s4.p1"} {"sentence": "Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ", "drug1": "anticonvulsants", "drug2": "phenylbutazone", "relation": "NONE", "source_file": "Methylphenidate.xml", "sentence_id": "DDI-DrugBank.d638.s2", "pair_id": "DDI-DrugBank.d638.s2.p22"} {"sentence": "Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended. ", "drug1": "methyldopa", "drug2": "ferrous gluconate", "relation": "ADVISE", "source_file": "Methyldopa.xml", "sentence_id": "DDI-DrugBank.d779.s9", "pair_id": "DDI-DrugBank.d779.s9.p1"} {"sentence": "The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. ", "drug1": "ginseng stem-and-leaf saponins", "drug2": "inactivated ND vaccines", "relation": "NONE", "source_file": "21844260.xml", "sentence_id": "DDI-MedLine.d154.s2", "pair_id": "DDI-MedLine.d154.s2.p1"} {"sentence": "In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving methadone, treatment with PEG-Intron once weekly for 4 weeks was associated with a mean increase of 16% in methadone AUC; ", "drug1": "methadone", "drug2": "PEG-Intron", "relation": "MECHANISM", "source_file": "Peginterferon alfa-2b.xml", "sentence_id": "DDI-DrugBank.d741.s0", "pair_id": "DDI-DrugBank.d741.s0.p0"} {"sentence": "Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ", "drug1": "antipyrine", "drug2": "carbamazepine", "relation": "NONE", "source_file": "Pantoprazole.xml", "sentence_id": "DDI-DrugBank.d680.s1", "pair_id": "DDI-DrugBank.d680.s1.p70"} {"sentence": "During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). ", "drug1": "DIPRIVAN", "drug2": "analgesic agents", "relation": "ADVISE", "source_file": "Propofol.xml", "sentence_id": "DDI-DrugBank.d628.s3", "pair_id": "DDI-DrugBank.d628.s3.p0"} {"sentence": "Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ", "drug1": "MEPERIDINE", "drug2": "ALCOHOL", "relation": "ADVISE", "source_file": "Meperidine.xml", "sentence_id": "DDI-DrugBank.d703.s0", "pair_id": "DDI-DrugBank.d703.s0.p18"} {"sentence": "After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. ", "drug1": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "drug2": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "relation": "NONE", "source_file": "21705423.xml", "sentence_id": "DDI-MedLine.d161.s5", "pair_id": "DDI-MedLine.d161.s5.p1"} {"sentence": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "drug1": "Melatonin", "drug2": "corticosteroids", "relation": "INT", "source_file": "Melatonin.xml", "sentence_id": "DDI-DrugBank.d643.s0", "pair_id": "DDI-DrugBank.d643.s0.p12"} {"sentence": "The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ", "drug1": "DIPRIVAN", "drug2": "fentanyl", "relation": "EFFECT", "source_file": "Propofol.xml", "sentence_id": "DDI-DrugBank.d628.s0", "pair_id": "DDI-DrugBank.d628.s0.p3"} {"sentence": "Diuretics: Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. ", "drug1": "Furosemide", "drug2": "metolazone", "relation": "EFFECT", "source_file": "Metolazone.xml", "sentence_id": "DDI-DrugBank.d588.s0", "pair_id": "DDI-DrugBank.d588.s0.p4"} {"sentence": "Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ", "drug1": "Vasopressors", "drug2": "halothane", "relation": "EFFECT", "source_file": "Phenylpropanolamine.xml", "sentence_id": "DDI-DrugBank.d689.s0", "pair_id": "DDI-DrugBank.d689.s0.p1"} {"sentence": "Coumarin-type anticoagulants: Prothrombin time may be increased in patients receiving concomitant DIFLUCAN and coumarin-type anticoagulants. ", "drug1": "DIFLUCAN", "drug2": "coumarin-type anticoagulants", "relation": "EFFECT", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s6", "pair_id": "DDI-DrugBank.d776.s6.p2"} {"sentence": "John's Wort with hormonal contraceptive agents may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies. ", "drug1": "John's Wort", "drug2": "hormonal contraceptive agents", "relation": "EFFECT", "source_file": "Thalidomide.xml", "sentence_id": "DDI-DrugBank.d604.s5", "pair_id": "DDI-DrugBank.d604.s5.p0"} {"sentence": "Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ", "drug1": "carbamazepine", "drug2": "ondansetron", "relation": "MECHANISM", "source_file": "Ondansetron.xml", "sentence_id": "DDI-DrugBank.d763.s3", "pair_id": "DDI-DrugBank.d763.s3.p24"} {"sentence": "Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ", "drug1": "tetracyclines", "drug2": "iron", "relation": "MECHANISM", "source_file": "Minocycline.xml", "sentence_id": "DDI-DrugBank.d711.s2", "pair_id": "DDI-DrugBank.d711.s2.p4"} {"sentence": "Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ", "drug1": "terfenadine", "drug2": "erythromycin", "relation": "ADVISE", "source_file": "Terfenadine.xml", "sentence_id": "DDI-DrugBank.d743.s12", "pair_id": "DDI-DrugBank.d743.s12.p1"} {"sentence": "Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ", "drug1": "ritonavir", "drug2": "telithromycin", "relation": "NONE", "source_file": "Sunitinib.xml", "sentence_id": "DDI-DrugBank.d639.s0", "pair_id": "DDI-DrugBank.d639.s0.p69"} {"sentence": "Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.\r\n", "drug1": "Lapatinib", "drug2": "herceptin", "relation": "EFFECT", "source_file": "21868551.xml", "sentence_id": "DDI-MedLine.d164.s0", "pair_id": "DDI-MedLine.d164.s0.p0"} {"sentence": "Neuromuscular blocking agents (such as suxamethonium chloride): Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade. ", "drug1": "procaine hydrochloride", "drug2": "neuromuscular blocking agents", "relation": "EFFECT", "source_file": "Procaine.xml", "sentence_id": "DDI-DrugBank.d780.s6", "pair_id": "DDI-DrugBank.d780.s6.p5"} {"sentence": "Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ", "drug1": "digoxin", "drug2": "perindoprilat", "relation": "MECHANISM", "source_file": "Perindopril.xml", "sentence_id": "DDI-DrugBank.d781.s11", "pair_id": "DDI-DrugBank.d781.s11.p13"} {"sentence": "The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics. ", "drug1": "metoclopramide", "drug2": "anticholinergic drugs", "relation": "EFFECT", "source_file": "Metoclopramide.xml", "sentence_id": "DDI-DrugBank.d652.s0", "pair_id": "DDI-DrugBank.d652.s0.p0"} {"sentence": "You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ", "drug1": "mazindol", "drug2": "Nardil", "relation": "ADVISE", "source_file": "Mazindol.xml", "sentence_id": "DDI-DrugBank.d716.s0", "pair_id": "DDI-DrugBank.d716.s0.p7"} {"sentence": "A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ", "drug1": "fluconazole", "drug2": "rifampin", "relation": "NONE", "source_file": "Micafungin.xml", "sentence_id": "DDI-DrugBank.d735.s0", "pair_id": "DDI-DrugBank.d735.s0.p43"} {"sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "drug1": "benzodiazepines", "drug2": "MAO inhibitors", "relation": "NONE", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s0", "pair_id": "DDI-DrugBank.d585.s0.p77"} {"sentence": "To determine whether the co-injection of extracellular matrix degrading enzymes improves retinal transduction following intravitreal delivery of adeno-associated virus-2 (AAV2).", "drug1": "adeno-associated virus-2", "drug2": "AAV2", "relation": "NONE", "source_file": "21750604.xml", "sentence_id": "DDI-MedLine.d190.s1", "pair_id": "DDI-MedLine.d190.s1.p0"} {"sentence": "Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. ", "drug1": "trimetrexate", "drug2": "rifabutin", "relation": "EFFECT", "source_file": "Trimetrexate.xml", "sentence_id": "DDI-DrugBank.d766.s1", "pair_id": "DDI-DrugBank.d766.s1.p2"} {"sentence": "In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron. ", "drug1": "calcium", "drug2": "heme iron", "relation": "MECHANISM", "source_file": "21795430.xml", "sentence_id": "DDI-MedLine.d169.s10", "pair_id": "DDI-MedLine.d169.s10.p1"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "MIVACRON", "drug2": "anesthetics", "relation": "INT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p26"} {"sentence": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "drug1": "aspirin", "drug2": "corticosteroids", "relation": "NONE", "source_file": "Melatonin.xml", "sentence_id": "DDI-DrugBank.d643.s0", "pair_id": "DDI-DrugBank.d643.s0.p27"} {"sentence": "Mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly.", "drug1": "lorazepam", "drug2": "pyrimethamine", "relation": "EFFECT", "source_file": "Pyrimethamine.xml", "sentence_id": "DDI-DrugBank.d631.s3", "pair_id": "DDI-DrugBank.d631.s3.p0"} {"sentence": "The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ", "drug1": "DIPRIVAN", "drug2": "narcotics", "relation": "EFFECT", "source_file": "Propofol.xml", "sentence_id": "DDI-DrugBank.d628.s0", "pair_id": "DDI-DrugBank.d628.s0.p0"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "MIVACRON", "drug2": "bacitracin", "relation": "INT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p18"} {"sentence": "Reduction of PTH by cinacalcet is associated with a decrease in darbepoetin requirement. ", "drug1": "cinacalcet", "drug2": "darbepoetin", "relation": "EFFECT", "source_file": "21762640.xml", "sentence_id": "DDI-MedLine.d166.s17", "pair_id": "DDI-MedLine.d166.s17.p0"} {"sentence": "Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ", "drug1": "SUTENT", "drug2": "ritonavir", "relation": "MECHANISM", "source_file": "Sunitinib.xml", "sentence_id": "DDI-DrugBank.d639.s0", "pair_id": "DDI-DrugBank.d639.s0.p7"} {"sentence": "The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see", "drug1": "AGGRASTAT", "drug2": "heparin", "relation": "EFFECT", "source_file": "Tirofiban.xml", "sentence_id": "DDI-DrugBank.d751.s1", "pair_id": "DDI-DrugBank.d751.s1.p0"} {"sentence": "Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). ", "drug1": "pantoprazole", "drug2": "ketoconazole", "relation": "MECHANISM", "source_file": "Pantoprazole.xml", "sentence_id": "DDI-DrugBank.d680.s8", "pair_id": "DDI-DrugBank.d680.s8.p0"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "Methscopolamine", "drug2": "MAO inhibitors", "relation": "INT", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p2"} {"sentence": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "drug1": "paricalcitol", "drug2": "clarithromycin", "relation": "ADVISE", "source_file": "Paricalcitol.xml", "sentence_id": "DDI-DrugBank.d726.s1", "pair_id": "DDI-DrugBank.d726.s1.p56"} {"sentence": "The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ", "drug1": "magnesium", "drug2": "SKELID", "relation": "MECHANISM", "source_file": "Tiludronate.xml", "sentence_id": "DDI-DrugBank.d721.s0", "pair_id": "DDI-DrugBank.d721.s0.p26"} {"sentence": "Acetazolamide: Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine.", "drug1": "acetazolamide", "drug2": "procaine hydrochloride", "relation": "MECHANISM", "source_file": "Procaine.xml", "sentence_id": "DDI-DrugBank.d780.s8", "pair_id": "DDI-DrugBank.d780.s8.p3"} {"sentence": "Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.", "drug1": "alcohol", "drug2": "methyprylon", "relation": "EFFECT", "source_file": "Methyprylon.xml", "sentence_id": "DDI-DrugBank.d600.s1", "pair_id": "DDI-DrugBank.d600.s1.p1"} {"sentence": "Anticoagulants: Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants; ", "drug1": "Metolazone", "drug2": "anticoagulants", "relation": "EFFECT", "source_file": "Metolazone.xml", "sentence_id": "DDI-DrugBank.d588.s13", "pair_id": "DDI-DrugBank.d588.s13.p4"} {"sentence": "Lithium renal clearance is reduced by thiazides, increasing the risk of lithium toxicity. ", "drug1": "Lithium", "drug2": "thiazides", "relation": "MECHANISM", "source_file": "Methyclothiazide.xml", "sentence_id": "DDI-DrugBank.d736.s6", "pair_id": "DDI-DrugBank.d736.s6.p0"} {"sentence": "TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.", "drug1": "TOBI", "drug2": "urea", "relation": "ADVISE", "source_file": "Tobramycin.xml", "sentence_id": "DDI-DrugBank.d624.s3", "pair_id": "DDI-DrugBank.d624.s3.p2"} {"sentence": "In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. ", "drug1": "quinpirole", "drug2": "amphetamine", "relation": "EFFECT", "source_file": "21753255.xml", "sentence_id": "DDI-MedLine.d184.s5", "pair_id": "DDI-MedLine.d184.s5.p0"} {"sentence": "Rifampin: Rifampin enhances the metabolism of concurrently administered DIFLUCAN. ", "drug1": "Rifampin", "drug2": "DIFLUCAN", "relation": "MECHANISM", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s16", "pair_id": "DDI-DrugBank.d776.s16.p2"} {"sentence": "saline + saline, ephedrine (10 mg/kg) + saline, saline + dexmedetomidine (15 g/kg) and ephedrine (10 mg/kg) + dexmedetomidine (15 g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ", "drug1": "ephedrine", "drug2": "dexmedetomidine", "relation": "NONE", "source_file": "21876510.xml", "sentence_id": "DDI-MedLine.d227.s6", "pair_id": "DDI-MedLine.d227.s6.p2"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "clindamycin", "drug2": "quinidine", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p98"} {"sentence": "Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ", "drug1": "fluoxetine", "drug2": "clotrimazole", "relation": "NONE", "source_file": "Methylergonovine.xml", "sentence_id": "DDI-DrugBank.d675.s4", "pair_id": "DDI-DrugBank.d675.s4.p17"} {"sentence": "Cyclosporine: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine. ", "drug1": "Cyclosporine", "drug2": "ezetimibe", "relation": "NONE", "source_file": "Ezetimibe.xml", "sentence_id": "DDI-DrugBank.d572.s9", "pair_id": "DDI-DrugBank.d572.s9.p0"} {"sentence": "Caution should be used when administering MOBIC with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.", "drug1": "warfarin", "drug2": "warfarin", "relation": "NONE", "source_file": "Meloxicam.xml", "sentence_id": "DDI-DrugBank.d597.s30", "pair_id": "DDI-DrugBank.d597.s30.p2"} {"sentence": "Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). ", "drug1": "3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine", "drug2": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "relation": "NONE", "source_file": "21705423.xml", "sentence_id": "DDI-MedLine.d161.s4", "pair_id": "DDI-MedLine.d161.s4.p6"} {"sentence": "Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ", "drug1": "dexamethasone", "drug2": "phenytoin", "relation": "NONE", "source_file": "Sunitinib.xml", "sentence_id": "DDI-DrugBank.d639.s2", "pair_id": "DDI-DrugBank.d639.s2.p8"} {"sentence": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "drug1": "paricalcitol", "drug2": "ketoconazole", "relation": "ADVISE", "source_file": "Paricalcitol.xml", "sentence_id": "DDI-DrugBank.d726.s1", "pair_id": "DDI-DrugBank.d726.s1.p54"} {"sentence": "Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ", "drug1": "MEPERIDINE", "drug2": "NARCOTIC ANALGESICS", "relation": "ADVISE", "source_file": "Meperidine.xml", "sentence_id": "DDI-DrugBank.d703.s0", "pair_id": "DDI-DrugBank.d703.s0.p10"} {"sentence": "Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ", "drug1": "butyrophenones", "drug2": "MIRAPEX", "relation": "EFFECT", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s10", "pair_id": "DDI-DrugBank.d737.s10.p41"} {"sentence": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "drug1": "melatonin", "drug2": "corticosteroids", "relation": "NONE", "source_file": "Melatonin.xml", "sentence_id": "DDI-DrugBank.d643.s0", "pair_id": "DDI-DrugBank.d643.s0.p57"} {"sentence": "Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ", "drug1": "itraconazole", "drug2": "midazolam", "relation": "MECHANISM", "source_file": "Midazolam.xml", "sentence_id": "DDI-DrugBank.d752.s1", "pair_id": "DDI-DrugBank.d752.s1.p20"} {"sentence": "You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ", "drug1": "mazindol", "drug2": "Marplan", "relation": "ADVISE", "source_file": "Mazindol.xml", "sentence_id": "DDI-DrugBank.d716.s0", "pair_id": "DDI-DrugBank.d716.s0.p3"} {"sentence": "This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil dose is changed. ", "drug1": "Mexitil", "drug2": "Mexitil", "relation": "NONE", "source_file": "Mexiletine.xml", "sentence_id": "DDI-DrugBank.d633.s18", "pair_id": "DDI-DrugBank.d633.s18.p21"} {"sentence": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ", "drug1": "itraconazole", "drug2": "DETROL LA", "relation": "ADVISE", "source_file": "Tolterodine.xml", "sentence_id": "DDI-DrugBank.d765.s1", "pair_id": "DDI-DrugBank.d765.s1.p23"} {"sentence": "Caution is recommended when administering doxorubicin with NEXAVAR. ", "drug1": "doxorubicin", "drug2": "NEXAVAR", "relation": "ADVISE", "source_file": "Sorafenib.xml", "sentence_id": "DDI-DrugBank.d602.s2", "pair_id": "DDI-DrugBank.d602.s2.p0"} {"sentence": "Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ", "drug1": "spironolactone", "drug2": "ACE inhibitors", "relation": "EFFECT", "source_file": "Moexipril.xml", "sentence_id": "DDI-DrugBank.d640.s3", "pair_id": "DDI-DrugBank.d640.s3.p8"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "phenelzine", "drug2": "absorbent-type anti-diarrhea medicines", "relation": "NONE", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p94"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "phenelzine", "drug2": "tranylcypromine", "relation": "NONE", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p83"} {"sentence": "A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ", "drug1": "MYCAMINE", "drug2": "ritonavir", "relation": "NONE", "source_file": "Micafungin.xml", "sentence_id": "DDI-DrugBank.d735.s0", "pair_id": "DDI-DrugBank.d735.s0.p7"} {"sentence": "This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil dose is changed. ", "drug1": "Theophylline", "drug2": "Mexitil", "relation": "MECHANISM", "source_file": "Mexiletine.xml", "sentence_id": "DDI-DrugBank.d633.s18", "pair_id": "DDI-DrugBank.d633.s18.p8"} {"sentence": "Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ", "drug1": "SUTENT", "drug2": "ketoconazole", "relation": "MECHANISM", "source_file": "Sunitinib.xml", "sentence_id": "DDI-DrugBank.d639.s0", "pair_id": "DDI-DrugBank.d639.s0.p0"} {"sentence": "Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers. ", "drug1": "sulfonamides", "drug2": "ganglion blockers", "relation": "ADVISE", "source_file": "Mecamylamine.xml", "sentence_id": "DDI-DrugBank.d579.s0", "pair_id": "DDI-DrugBank.d579.s0.p2"} {"sentence": "DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants). ", "drug1": "DIPRIVAN", "drug2": "nondepolarizing muscle relaxants", "relation": "NONE", "source_file": "Propofol.xml", "sentence_id": "DDI-DrugBank.d628.s6", "pair_id": "DDI-DrugBank.d628.s6.p2"} {"sentence": "Paliperidone may antagonize the effect of levodopa and other dopamine agonists. ", "drug1": "Paliperidone", "drug2": "dopamine agonists", "relation": "EFFECT", "source_file": "Paliperidone.xml", "sentence_id": "DDI-DrugBank.d670.s7", "pair_id": "DDI-DrugBank.d670.s7.p1"} {"sentence": "Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ", "drug1": "sirolimus", "drug2": "MYCAMINE", "relation": "ADVISE", "source_file": "Micafungin.xml", "sentence_id": "DDI-DrugBank.d735.s5", "pair_id": "DDI-DrugBank.d735.s5.p1"} {"sentence": "Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ", "drug1": "MEPERIDINE", "drug2": "SEDATIVE-HYPNOTICS", "relation": "ADVISE", "source_file": "Meperidine.xml", "sentence_id": "DDI-DrugBank.d703.s0", "pair_id": "DDI-DrugBank.d703.s0.p14"} {"sentence": "Cholestyramine: Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe approximately 55%. ", "drug1": "cholestyramine", "drug2": "ezetimibe", "relation": "MECHANISM", "source_file": "Ezetimibe.xml", "sentence_id": "DDI-DrugBank.d572.s0", "pair_id": "DDI-DrugBank.d572.s0.p2"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "nondepolarizing agents", "drug2": "procainamide", "relation": "INT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p13"} {"sentence": "Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ", "drug1": "penicillins", "drug2": "pramipexole", "relation": "MECHANISM", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s6", "pair_id": "DDI-DrugBank.d737.s6.p84"} {"sentence": "Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.", "drug1": "antichlolinergic", "drug2": "TCA", "relation": "NONE", "source_file": "Mequitazine.xml", "sentence_id": "DDI-DrugBank.d699.s0", "pair_id": "DDI-DrugBank.d699.s0.p9"} {"sentence": "The 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine treatment also had a significant effect on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced loss of norepinephrine neurons in the locus coeruleus and adjoining A5 and A7 noradrenaline cell groups. ", "drug1": "3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine", "drug2": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "relation": "EFFECT", "source_file": "21705423.xml", "sentence_id": "DDI-MedLine.d161.s7", "pair_id": "DDI-MedLine.d161.s7.p0"} {"sentence": "Interactions for Vitamin B2 (Riboflavin): Alcohol - impairs the intestinal absorption of riboflavin", "drug1": "Alcohol", "drug2": "riboflavin", "relation": "MECHANISM", "source_file": "Riboflavin.xml", "sentence_id": "DDI-DrugBank.d698.s0", "pair_id": "DDI-DrugBank.d698.s0.p5"} {"sentence": "However, the impairment of motor skills produced by REMERON has been shown to be additive with those caused by diazepam. ", "drug1": "REMERON", "drug2": "diazepam", "relation": "EFFECT", "source_file": "Mirtazapine.xml", "sentence_id": "DDI-DrugBank.d742.s10", "pair_id": "DDI-DrugBank.d742.s10.p0"} {"sentence": "Concurrent use of Mexitil and theophylline may lead to increased plasma theophylline levels. ", "drug1": "Mexitil", "drug2": "theophylline", "relation": "MECHANISM", "source_file": "Mexiletine.xml", "sentence_id": "DDI-DrugBank.d633.s16", "pair_id": "DDI-DrugBank.d633.s16.p0"} {"sentence": "Selegiline: In healthy volunteers (N= 11), selegiline did not influence the pharmacokinetics of pramipexole. ", "drug1": "Selegiline", "drug2": "pramipexole", "relation": "NONE", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s2", "pair_id": "DDI-DrugBank.d737.s2.p1"} {"sentence": "In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen. ", "drug1": "piperine", "drug2": "ibuprofen", "relation": "EFFECT", "source_file": "22029226.xml", "sentence_id": "DDI-MedLine.d195.s4", "pair_id": "DDI-MedLine.d195.s4.p0"} {"sentence": "Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ", "drug1": "rifampin", "drug2": "midazolam", "relation": "MECHANISM", "source_file": "Midazolam.xml", "sentence_id": "DDI-DrugBank.d752.s6", "pair_id": "DDI-DrugBank.d752.s6.p2"} {"sentence": "However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. ", "drug1": "calcium", "drug2": "iron", "relation": "MECHANISM", "source_file": "21795430.xml", "sentence_id": "DDI-MedLine.d169.s2", "pair_id": "DDI-MedLine.d169.s2.p0"} {"sentence": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ", "drug1": "phenytoin", "drug2": "methylprednisolone", "relation": "MECHANISM", "source_file": "Methylprednisolone.xml", "sentence_id": "DDI-DrugBank.d578.s4", "pair_id": "DDI-DrugBank.d578.s4.p5"} {"sentence": "Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.", "drug1": "Tetracycline", "drug2": "antibiotic", "relation": "NONE", "source_file": "Oxacillin.xml", "sentence_id": "DDI-DrugBank.d747.s0", "pair_id": "DDI-DrugBank.d747.s0.p0"} {"sentence": "Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).", "drug1": "Celontin", "drug2": "antiepileptic drugs", "relation": "ADVISE", "source_file": "Methsuximide.xml", "sentence_id": "DDI-DrugBank.d587.s0", "pair_id": "DDI-DrugBank.d587.s0.p1"} {"sentence": "In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ", "drug1": "TOBI", "drug2": "dornase alfa", "relation": "EFFECT", "source_file": "Tobramycin.xml", "sentence_id": "DDI-DrugBank.d624.s0", "pair_id": "DDI-DrugBank.d624.s0.p7"} {"sentence": "The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants, including alcohol. ", "drug1": "propoxyphene", "drug2": "CNS depressants", "relation": "EFFECT", "source_file": "Propoxyphene.xml", "sentence_id": "DDI-DrugBank.d690.s0", "pair_id": "DDI-DrugBank.d690.s0.p0"} {"sentence": "With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. ", "drug1": "diethyldithiocarbamate", "drug2": "ketoconazole", "relation": "NONE", "source_file": "21741958.xml", "sentence_id": "DDI-MedLine.d189.s9", "pair_id": "DDI-MedLine.d189.s9.p4"} {"sentence": "Thiazide drugs may increase the responsiveness of tubocurarine. ", "drug1": "Thiazide drugs", "drug2": "tubocurarine", "relation": "EFFECT", "source_file": "Methyclothiazide.xml", "sentence_id": "DDI-DrugBank.d736.s5", "pair_id": "DDI-DrugBank.d736.s5.p0"} {"sentence": "Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ", "drug1": "Antacids", "drug2": "aluminum", "relation": "NONE", "source_file": "Mycophenolic acid.xml", "sentence_id": "DDI-DrugBank.d700.s0", "pair_id": "DDI-DrugBank.d700.s0.p2"} {"sentence": "Interactions for Vitamin B1 (Thiamine): Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants", "drug1": "Thiamine", "drug2": "Tricyclic Antidepressants", "relation": "INT", "source_file": "Thiamine.xml", "sentence_id": "DDI-DrugBank.d697.s0", "pair_id": "DDI-DrugBank.d697.s0.p8"} {"sentence": "Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ", "drug1": "Myfortic", "drug2": "azathioprine", "relation": "ADVISE", "source_file": "Mycophenolic acid.xml", "sentence_id": "DDI-DrugBank.d700.s6", "pair_id": "DDI-DrugBank.d700.s6.p18"} {"sentence": "Prothrombin time or other suitable anticoagulation test should be monitored if tigecycline is administered with warfarin. ", "drug1": "tigecycline", "drug2": "warfarin", "relation": "ADVISE", "source_file": "Tigecycline.xml", "sentence_id": "DDI-DrugBank.d642.s0", "pair_id": "DDI-DrugBank.d642.s0.p0"} {"sentence": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ", "drug1": "macrolide antibiotics", "drug2": "oxybutynin", "relation": "MECHANISM", "source_file": "Oxybutynin.xml", "sentence_id": "DDI-DrugBank.d784.s4", "pair_id": "DDI-DrugBank.d784.s4.p17"} {"sentence": "Anticholinergics or other medications with anticholinergic activity when used concurrently with opioid analgesics may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. ", "drug1": "Anticholinergics", "drug2": "opioid analgesics", "relation": "EFFECT", "source_file": "Oxymorphone.xml", "sentence_id": "DDI-DrugBank.d753.s2", "pair_id": "DDI-DrugBank.d753.s2.p0"} {"sentence": "Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ", "drug1": "Triprolidine", "drug2": "central nervous system depressants", "relation": "EFFECT", "source_file": "Triprolidine.xml", "sentence_id": "DDI-DrugBank.d615.s0", "pair_id": "DDI-DrugBank.d615.s0.p0"} {"sentence": "Mazindol may reduce the effects of guanethidine (Ismelin). ", "drug1": "Mazindol", "drug2": "Ismelin", "relation": "EFFECT", "source_file": "Mazindol.xml", "sentence_id": "DDI-DrugBank.d716.s2", "pair_id": "DDI-DrugBank.d716.s2.p1"} {"sentence": "Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ", "drug1": "ibuprofen", "drug2": "diazoxide", "relation": "NONE", "source_file": "Raloxifene.xml", "sentence_id": "DDI-DrugBank.d648.s6", "pair_id": "DDI-DrugBank.d648.s6.p19"} {"sentence": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ", "drug1": "erythromycin", "drug2": "delavirdine", "relation": "NONE", "source_file": "Methylergonovine.xml", "sentence_id": "DDI-DrugBank.d675.s2", "pair_id": "DDI-DrugBank.d675.s2.p20"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "isocarboxazid", "drug2": "anticholinergics", "relation": "NONE", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p139"} {"sentence": "Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.", "drug1": "Mephenytoin", "drug2": "theophylline", "relation": "EFFECT", "source_file": "Mephenytoin.xml", "sentence_id": "DDI-DrugBank.d636.s3", "pair_id": "DDI-DrugBank.d636.s3.p4"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "MIVACRON", "drug2": "polymyxins", "relation": "INT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p19"} {"sentence": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "drug1": "Melatonin", "drug2": "aspirin", "relation": "INT", "source_file": "Melatonin.xml", "sentence_id": "DDI-DrugBank.d643.s0", "pair_id": "DDI-DrugBank.d643.s0.p0"} {"sentence": "Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.", "drug1": "neuromuscular blocking agents", "drug2": "cholinergic agonists", "relation": "NONE", "source_file": "Rivastigmine.xml", "sentence_id": "DDI-DrugBank.d596.s9", "pair_id": "DDI-DrugBank.d596.s9.p18"} {"sentence": "Aspirin may decrease bioavailability of SKELID by up to 50% when taken 2 hours after SKELID. ", "drug1": "Aspirin", "drug2": "SKELID", "relation": "NONE", "source_file": "Tiludronate.xml", "sentence_id": "DDI-DrugBank.d721.s1", "pair_id": "DDI-DrugBank.d721.s1.p1"} {"sentence": "Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ", "drug1": "SUTENT", "drug2": "rifampin", "relation": "MECHANISM", "source_file": "Sunitinib.xml", "sentence_id": "DDI-DrugBank.d639.s2", "pair_id": "DDI-DrugBank.d639.s2.p3"} {"sentence": "Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme. ", "drug1": "omeprazole", "drug2": "clopidogrel", "relation": "MECHANISM", "source_file": "21771377.xml", "sentence_id": "DDI-MedLine.d143.s3", "pair_id": "DDI-MedLine.d143.s3.p0"} {"sentence": "Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ", "drug1": "sirolimus", "drug2": "sirolimus", "relation": "NONE", "source_file": "Micafungin.xml", "sentence_id": "DDI-DrugBank.d735.s5", "pair_id": "DDI-DrugBank.d735.s5.p4"} {"sentence": "Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ", "drug1": "NARCOTIC ANALGESICS", "drug2": "TRICYCLIC ANTIDEPRESSANTS", "relation": "NONE", "source_file": "Meperidine.xml", "sentence_id": "DDI-DrugBank.d703.s0", "pair_id": "DDI-DrugBank.d703.s0.p24"} {"sentence": "The effect of corticosteroids on oral anticoagulants is variable. ", "drug1": "corticosteroids", "drug2": "anticoagulants", "relation": "EFFECT", "source_file": "Prednisone.xml", "sentence_id": "DDI-DrugBank.d653.s7", "pair_id": "DDI-DrugBank.d653.s7.p0"} {"sentence": "Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. ", "drug1": "rivastigmine", "drug2": "fluoxetine", "relation": "NONE", "source_file": "Rivastigmine.xml", "sentence_id": "DDI-DrugBank.d596.s6", "pair_id": "DDI-DrugBank.d596.s6.p3"} {"sentence": "Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective. ", "drug1": "antibacterial drugs", "drug2": "contraceptives", "relation": "EFFECT", "source_file": "Tigecycline.xml", "sentence_id": "DDI-DrugBank.d642.s1", "pair_id": "DDI-DrugBank.d642.s1.p0"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "antidepressants", "drug2": "antihistamines", "relation": "NONE", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p32"} {"sentence": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ", "drug1": "cyclosporine", "drug2": "DETROL LA", "relation": "ADVISE", "source_file": "Tolterodine.xml", "sentence_id": "DDI-DrugBank.d765.s1", "pair_id": "DDI-DrugBank.d765.s1.p43"} {"sentence": "The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ", "drug1": "MIVACRON", "drug2": "monoamine oxidase inhibitors", "relation": "EFFECT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s11", "pair_id": "DDI-DrugBank.d775.s11.p2"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "Methscopolamine", "drug2": "tricyclic", "relation": "INT", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p1"} {"sentence": "In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase therapy.", "drug1": "dipyridamole", "drug2": "Retavase", "relation": "EFFECT", "source_file": "Reteplase.xml", "sentence_id": "DDI-DrugBank.d618.s1", "pair_id": "DDI-DrugBank.d618.s1.p13"} {"sentence": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "drug1": "Lomefloxacin", "drug2": "multi-minerals", "relation": "MECHANISM", "source_file": "21715267.xml", "sentence_id": "DDI-MedLine.d231.s8", "pair_id": "DDI-MedLine.d231.s8.p8"} {"sentence": "Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. ", "drug1": "ketoconazole", "drug2": "corticosteroids", "relation": "MECHANISM", "source_file": "Prednisone.xml", "sentence_id": "DDI-DrugBank.d653.s2", "pair_id": "DDI-DrugBank.d653.s2.p2"} {"sentence": "When administered concurrently, testolactone may increase the effects of oral anticoagulants; ", "drug1": "testolactone", "drug2": "anticoagulants", "relation": "EFFECT", "source_file": "Testolactone.xml", "sentence_id": "DDI-DrugBank.d658.s0", "pair_id": "DDI-DrugBank.d658.s0.p0"} {"sentence": "Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. ", "drug1": "trimetrexate", "drug2": "rifampin", "relation": "EFFECT", "source_file": "Trimetrexate.xml", "sentence_id": "DDI-DrugBank.d766.s1", "pair_id": "DDI-DrugBank.d766.s1.p1"} {"sentence": "Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. ", "drug1": "miconazole", "drug2": "trimetrexate", "relation": "MECHANISM", "source_file": "Trimetrexate.xml", "sentence_id": "DDI-DrugBank.d766.s3", "pair_id": "DDI-DrugBank.d766.s3.p9"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "phenelzine", "drug2": "chlorpromazine", "relation": "NONE", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p98"} {"sentence": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "drug1": "Lomefloxacin", "drug2": "sucralfate", "relation": "MECHANISM", "source_file": "21715267.xml", "sentence_id": "DDI-MedLine.d231.s8", "pair_id": "DDI-MedLine.d231.s8.p5"} {"sentence": "Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ", "drug1": "Myfortic", "drug2": "magnesium", "relation": "MECHANISM", "source_file": "Mycophenolic acid.xml", "sentence_id": "DDI-DrugBank.d700.s0", "pair_id": "DDI-DrugBank.d700.s0.p5"} {"sentence": "There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. ", "drug1": "mercaptopurine", "drug2": "Thioguanine", "relation": "EFFECT", "source_file": "Thioguanine.xml", "sentence_id": "DDI-DrugBank.d722.s0", "pair_id": "DDI-DrugBank.d722.s0.p4"} {"sentence": "Aspirin may decrease bioavailability of SKELID by up to 50% when taken 2 hours after SKELID. ", "drug1": "Aspirin", "drug2": "SKELID", "relation": "MECHANISM", "source_file": "Tiludronate.xml", "sentence_id": "DDI-DrugBank.d721.s1", "pair_id": "DDI-DrugBank.d721.s1.p0"} {"sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "drug1": "antipsychotic agents", "drug2": "nitrates", "relation": "NONE", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s0", "pair_id": "DDI-DrugBank.d585.s0.p65"} {"sentence": "Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine", "drug1": "Vindesine", "drug2": "Mitomycin-C", "relation": "INT", "source_file": "Vindesine.xml", "sentence_id": "DDI-DrugBank.d782.s0", "pair_id": "DDI-DrugBank.d782.s0.p3"} {"sentence": "Concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth. ", "drug1": "bacteriostatic antibiotics", "drug2": "penicillins", "relation": "EFFECT", "source_file": "Penicillin G.xml", "sentence_id": "DDI-DrugBank.d665.s0", "pair_id": "DDI-DrugBank.d665.s0.p2"} {"sentence": "SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.", "drug1": "SKELAXIN", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Metaxalone.xml", "sentence_id": "DDI-DrugBank.d605.s0", "pair_id": "DDI-DrugBank.d605.s0.p0"} {"sentence": "ACE inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibitors. ", "drug1": "NSAIDs", "drug2": "angiotensin-converting enzyme (ACE) inhibitors", "relation": "EFFECT", "source_file": "Meloxicam.xml", "sentence_id": "DDI-DrugBank.d597.s0", "pair_id": "DDI-DrugBank.d597.s0.p2"} {"sentence": "Cholestyramine: Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe approximately 55%. ", "drug1": "Cholestyramine", "drug2": "ezetimibe", "relation": "NONE", "source_file": "Ezetimibe.xml", "sentence_id": "DDI-DrugBank.d572.s0", "pair_id": "DDI-DrugBank.d572.s0.p1"} {"sentence": "Limited evidence suggests that ascorbic acid may influence the intensity and duration of action of bishydroxycoumarin.", "drug1": "ascorbic acid", "drug2": "bishydroxycoumarin", "relation": "MECHANISM", "source_file": "Vitamin C.xml", "sentence_id": "DDI-DrugBank.d759.s0", "pair_id": "DDI-DrugBank.d759.s0.p0"} {"sentence": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "drug1": "Moxifloxacin", "drug2": "gelusil", "relation": "MECHANISM", "source_file": "21715267.xml", "sentence_id": "DDI-MedLine.d231.s8", "pair_id": "DDI-MedLine.d231.s8.p2"} {"sentence": "Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ", "drug1": "triamterene", "drug2": "pramipexole", "relation": "MECHANISM", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s6", "pair_id": "DDI-DrugBank.d737.s6.p39"} {"sentence": "Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. ", "drug1": "ergotamine", "drug2": "methysergide", "relation": "NONE", "source_file": "Sumatriptan.xml", "sentence_id": "DDI-DrugBank.d720.s1", "pair_id": "DDI-DrugBank.d720.s1.p2"} {"sentence": "Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine. ", "drug1": "folic acid", "drug2": "sulfasalazine", "relation": "MECHANISM", "source_file": "Sulfasalazine.xml", "sentence_id": "DDI-DrugBank.d693.s0", "pair_id": "DDI-DrugBank.d693.s0.p1"} {"sentence": "Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ", "drug1": "calcium channel blockers", "drug2": "salicylate analgesics", "relation": "NONE", "source_file": "Rivastigmine.xml", "sentence_id": "DDI-DrugBank.d596.s7", "pair_id": "DDI-DrugBank.d596.s7.p27"} {"sentence": "Other short-acting beta adrenergic aerosol bronchodilators should not be used concomitantly with MAXAIR AUTOHALER because they may have additive effects.", "drug1": "short-acting beta adrenergic aerosol bronchodilators", "drug2": "MAXAIR AUTOHALER", "relation": "ADVISE", "source_file": "Pirbuterol.xml", "sentence_id": "DDI-DrugBank.d635.s0", "pair_id": "DDI-DrugBank.d635.s0.p0"} {"sentence": "Neuromuscular blocking agents (such as suxamethonium chloride): Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade. ", "drug1": "Neuromuscular blocking agents", "drug2": "suxamethonium chloride", "relation": "NONE", "source_file": "Procaine.xml", "sentence_id": "DDI-DrugBank.d780.s6", "pair_id": "DDI-DrugBank.d780.s6.p0"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "MIVACRON", "drug2": "tetracyclines", "relation": "INT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p17"} {"sentence": "Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ", "drug1": "Salicylate", "drug2": "naproxen", "relation": "MECHANISM", "source_file": "Salsalate.xml", "sentence_id": "DDI-DrugBank.d576.s6", "pair_id": "DDI-DrugBank.d576.s6.p6"} {"sentence": "Thus, SYMLIN and insulin should not be mixed and must be administered separately.", "drug1": "SYMLIN", "drug2": "insulin", "relation": "NONE", "source_file": "Pramlintide.xml", "sentence_id": "DDI-DrugBank.d632.s7", "pair_id": "DDI-DrugBank.d632.s7.p0"} {"sentence": "Systemic and apparent oral midazolam clearance were 24% (269 73 vs. 354 102 ml/min, P = 0.022) and 31% (479 190 vs. 688 265 ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). ", "drug1": "midazolam", "drug2": "cyclosporine", "relation": "MECHANISM", "source_file": "21753749.xml", "sentence_id": "DDI-MedLine.d213.s3", "pair_id": "DDI-MedLine.d213.s3.p0"} {"sentence": "Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.", "drug1": "cholinesterase inhibitors", "drug2": "bethanechol", "relation": "EFFECT", "source_file": "Rivastigmine.xml", "sentence_id": "DDI-DrugBank.d596.s9", "pair_id": "DDI-DrugBank.d596.s9.p14"} {"sentence": "- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ", "drug1": "cisapride", "drug2": "macrolide antibacterials", "relation": "MECHANISM", "source_file": "Roxithromycin.xml", "sentence_id": "DDI-DrugBank.d709.s4", "pair_id": "DDI-DrugBank.d709.s4.p8"} {"sentence": "At a 1.6-g dose, sulfamethoxazole produced a slight but significant increase in the half-life of phenytoin but did not produce a corresponding decrease in the metabolic clearance rate. ", "drug1": "sulfamethoxazole", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Sulfamethoxazole.xml", "sentence_id": "DDI-DrugBank.d577.s4", "pair_id": "DDI-DrugBank.d577.s4.p0"} {"sentence": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ", "drug1": "HIV protease inhibitors", "drug2": "ketoconazole", "relation": "NONE", "source_file": "Methylergonovine.xml", "sentence_id": "DDI-DrugBank.d675.s2", "pair_id": "DDI-DrugBank.d675.s2.p52"} {"sentence": "ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ", "drug1": "desglymidodrine", "drug2": "flecainide", "relation": "MECHANISM", "source_file": "Midodrine.xml", "sentence_id": "DDI-DrugBank.d603.s5", "pair_id": "DDI-DrugBank.d603.s5.p68"} {"sentence": "If ZEMURON is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed. ", "drug1": "ZEMURON", "drug2": "succinylcholine", "relation": "ADVISE", "source_file": "Rocuronium.xml", "sentence_id": "DDI-DrugBank.d661.s1", "pair_id": "DDI-DrugBank.d661.s1.p0"} {"sentence": "There are reports of enhanced as well as diminished effects of anticoagulant when given concurrently with corticosteroids. ", "drug1": "anticoagulant", "drug2": "corticosteroids", "relation": "EFFECT", "source_file": "Methylprednisolone.xml", "sentence_id": "DDI-DrugBank.d578.s11", "pair_id": "DDI-DrugBank.d578.s11.p0"} {"sentence": "Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent (metaproterenol sulfate USP) because they may have additive effects. ", "drug1": "beta adrenergic aerosol bronchodilators", "drug2": "metaproterenol sulfate", "relation": "ADVISE", "source_file": "Orciprenaline.xml", "sentence_id": "DDI-DrugBank.d611.s0", "pair_id": "DDI-DrugBank.d611.s0.p1"} {"sentence": "Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ", "drug1": "Triprolidine", "drug2": "tranquillisers", "relation": "EFFECT", "source_file": "Triprolidine.xml", "sentence_id": "DDI-DrugBank.d615.s0", "pair_id": "DDI-DrugBank.d615.s0.p6"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "Methscopolamine", "drug2": "antacids", "relation": "INT", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p15"} {"sentence": "Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). ", "drug1": "pantoprazole", "drug2": "iron", "relation": "MECHANISM", "source_file": "Pantoprazole.xml", "sentence_id": "DDI-DrugBank.d680.s8", "pair_id": "DDI-DrugBank.d680.s8.p2"} {"sentence": "Improved parathyroid hormone control by cinacalcet is associated with reduction in darbepoetin requirement in patients with end-stage renal disease.\r\n", "drug1": "cinacalcet", "drug2": "darbepoetin", "relation": "NONE", "source_file": "21762640.xml", "sentence_id": "DDI-MedLine.d166.s0", "pair_id": "DDI-MedLine.d166.s0.p0"} {"sentence": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ", "drug1": "azole antifungals", "drug2": "DETROL LA", "relation": "ADVISE", "source_file": "Tolterodine.xml", "sentence_id": "DDI-DrugBank.d765.s1", "pair_id": "DDI-DrugBank.d765.s1.p16"} {"sentence": "Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ", "drug1": "EVISTA", "drug2": "naproxen", "relation": "ADVISE", "source_file": "Raloxifene.xml", "sentence_id": "DDI-DrugBank.d648.s6", "pair_id": "DDI-DrugBank.d648.s6.p2"} {"sentence": "Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ", "drug1": "potassium-sparing diuretics", "drug2": "cyclosporine", "relation": "NONE", "source_file": "Perindopril.xml", "sentence_id": "DDI-DrugBank.d781.s6", "pair_id": "DDI-DrugBank.d781.s6.p6"} {"sentence": "Ketoconazole: Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events, e.g. ", "drug1": "ketoconazole", "drug2": "terfenadine", "relation": "EFFECT", "source_file": "Terfenadine.xml", "sentence_id": "DDI-DrugBank.d743.s0", "pair_id": "DDI-DrugBank.d743.s0.p2"} {"sentence": "Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).", "drug1": "methsuximide", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Methsuximide.xml", "sentence_id": "DDI-DrugBank.d587.s0", "pair_id": "DDI-DrugBank.d587.s0.p12"} {"sentence": "Theophylline: Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; ", "drug1": "Theophylline", "drug2": "theophylline", "relation": "NONE", "source_file": "Methimazole.xml", "sentence_id": "DDI-DrugBank.d634.s5", "pair_id": "DDI-DrugBank.d634.s5.p1"} {"sentence": "When DIFLUCAN is used concomitantly with these or other sulfonylurea oral hypoglycemic agents, blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary. ", "drug1": "DIFLUCAN", "drug2": "sulfonylurea oral hypoglycemic agents", "relation": "ADVISE", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s5", "pair_id": "DDI-DrugBank.d776.s5.p0"} {"sentence": "Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ", "drug1": "SUTENT", "drug2": "voriconizole", "relation": "MECHANISM", "source_file": "Sunitinib.xml", "sentence_id": "DDI-DrugBank.d639.s0", "pair_id": "DDI-DrugBank.d639.s0.p10"} {"sentence": "Phenytoin: DIFLUCAN increases the plasma concentrations of phenytoin. ", "drug1": "Phenytoin", "drug2": "DIFLUCAN", "relation": "NONE", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s10", "pair_id": "DDI-DrugBank.d776.s10.p0"} {"sentence": "Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. ", "drug1": "dihydroergotamine", "drug2": "sumatriptan", "relation": "ADVISE", "source_file": "Sumatriptan.xml", "sentence_id": "DDI-DrugBank.d720.s1", "pair_id": "DDI-DrugBank.d720.s1.p8"} {"sentence": "Rifampin: Rifampin enhances the metabolism of concurrently administered DIFLUCAN. ", "drug1": "Rifampin", "drug2": "Rifampin", "relation": "NONE", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s16", "pair_id": "DDI-DrugBank.d776.s16.p0"} {"sentence": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "drug1": "amoxapine", "drug2": "desipramine", "relation": "NONE", "source_file": "Mazindol.xml", "sentence_id": "DDI-DrugBank.d716.s5", "pair_id": "DDI-DrugBank.d716.s5.p56"} {"sentence": "Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. ", "drug1": "Insulin", "drug2": "human insulin", "relation": "NONE", "source_file": "Pramlintide.xml", "sentence_id": "DDI-DrugBank.d632.s6", "pair_id": "DDI-DrugBank.d632.s6.p4"} {"sentence": "Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. ", "drug1": "NSAIDs", "drug2": "furosemide", "relation": "EFFECT", "source_file": "Meloxicam.xml", "sentence_id": "DDI-DrugBank.d597.s14", "pair_id": "DDI-DrugBank.d597.s14.p3"} {"sentence": "Mazindol may reduce the effects of guanethidine (Ismelin). ", "drug1": "Mazindol", "drug2": "guanethidine", "relation": "EFFECT", "source_file": "Mazindol.xml", "sentence_id": "DDI-DrugBank.d716.s2", "pair_id": "DDI-DrugBank.d716.s2.p0"} {"sentence": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "drug1": "antiretroviral", "drug2": "Implanon", "relation": "EFFECT", "source_file": "21729965.xml", "sentence_id": "DDI-MedLine.d208.s3", "pair_id": "DDI-MedLine.d208.s3.p0"} {"sentence": "Although single or concurrent use of sunitinib and docetaxel has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity. ", "drug1": "sunitinib", "drug2": "docetaxel", "relation": "EFFECT", "source_file": "21796416.xml", "sentence_id": "DDI-MedLine.d179.s6", "pair_id": "DDI-MedLine.d179.s6.p0"} {"sentence": "Caution should be exercised when Methergine (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.", "drug1": "Methergine", "drug2": "vasoconstrictors", "relation": "ADVISE", "source_file": "Methylergonovine.xml", "sentence_id": "DDI-DrugBank.d675.s7", "pair_id": "DDI-DrugBank.d675.s7.p1"} {"sentence": "Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.", "drug1": "DEMSER", "drug2": "CNS depressants", "relation": "EFFECT", "source_file": "Metyrosine.xml", "sentence_id": "DDI-DrugBank.d715.s1", "pair_id": "DDI-DrugBank.d715.s1.p1"} {"sentence": "Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ", "drug1": "Salicylate", "drug2": "warfarin", "relation": "MECHANISM", "source_file": "Salsalate.xml", "sentence_id": "DDI-DrugBank.d576.s6", "pair_id": "DDI-DrugBank.d576.s6.p7"} {"sentence": "Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia. ", "drug1": "Aspirin", "drug2": "corticosteroids", "relation": "ADVISE", "source_file": "Methylprednisolone.xml", "sentence_id": "DDI-DrugBank.d578.s9", "pair_id": "DDI-DrugBank.d578.s9.p0"} {"sentence": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "drug1": "cyclosporine", "drug2": "phenytoin", "relation": "NONE", "source_file": "Sulfoxone.xml", "sentence_id": "DDI-DrugBank.d682.s1", "pair_id": "DDI-DrugBank.d682.s1.p12"} {"sentence": "This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously. ", "drug1": "midazolam", "drug2": "fluconazole", "relation": "EFFECT", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s36", "pair_id": "DDI-DrugBank.d776.s36.p0"} {"sentence": "The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ", "drug1": "VERSED Syrup", "drug2": "ketamine", "relation": "EFFECT", "source_file": "Midazolam.xml", "sentence_id": "DDI-DrugBank.d752.s10", "pair_id": "DDI-DrugBank.d752.s10.p5"} {"sentence": "John s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ", "drug1": "phenobarbital", "drug2": "mifepristone", "relation": "NONE", "source_file": "Mifepristone.xml", "sentence_id": "DDI-DrugBank.d668.s2", "pair_id": "DDI-DrugBank.d668.s2.p11"} {"sentence": "Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ", "drug1": "Triprolidine", "drug2": "hypnotics", "relation": "EFFECT", "source_file": "Triprolidine.xml", "sentence_id": "DDI-DrugBank.d615.s0", "pair_id": "DDI-DrugBank.d615.s0.p3"} {"sentence": "Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol. ", "drug1": "Scopolamine", "drug2": "tranquilizers", "relation": "ADVISE", "source_file": "Scopolamine.xml", "sentence_id": "DDI-DrugBank.d771.s1", "pair_id": "DDI-DrugBank.d771.s1.p1"} {"sentence": "Caution should be used if TOLECTIN is administered concomitantly with methotrexate. ", "drug1": "TOLECTIN", "drug2": "methotrexate", "relation": "ADVISE", "source_file": "Tolmetin.xml", "sentence_id": "DDI-DrugBank.d608.s4", "pair_id": "DDI-DrugBank.d608.s4.p0"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "nondepolarizing agents", "drug2": "magnesium", "relation": "INT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p10"} {"sentence": "Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ", "drug1": "neuroleptics", "drug2": "Permax", "relation": "ADVISE", "source_file": "Pergolide.xml", "sentence_id": "DDI-DrugBank.d650.s0", "pair_id": "DDI-DrugBank.d650.s0.p11"} {"sentence": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "drug1": "Melatonin", "drug2": "fluoxetine", "relation": "INT", "source_file": "Melatonin.xml", "sentence_id": "DDI-DrugBank.d643.s0", "pair_id": "DDI-DrugBank.d643.s0.p7"} {"sentence": "Probenecid - concurrent use decreases gastrointestinal absorption of riboflavin; ", "drug1": "Probenecid", "drug2": "riboflavin", "relation": "MECHANISM", "source_file": "Riboflavin.xml", "sentence_id": "DDI-DrugBank.d698.s1", "pair_id": "DDI-DrugBank.d698.s1.p0"} {"sentence": "If EVISTA is given concurrently with warfarin, prothrombin time should be monitored. ", "drug1": "EVISTA", "drug2": "warfarin", "relation": "ADVISE", "source_file": "Raloxifene.xml", "sentence_id": "DDI-DrugBank.d648.s3", "pair_id": "DDI-DrugBank.d648.s3.p0"} {"sentence": "Given the primary CNS effects of paliperidone, INVEGA should be used with caution in combination with other centrally acting drugs and alcohol. ", "drug1": "paliperidone", "drug2": "alcohol", "relation": "ADVISE", "source_file": "Paliperidone.xml", "sentence_id": "DDI-DrugBank.d670.s6", "pair_id": "DDI-DrugBank.d670.s6.p2"} {"sentence": "CRM197 induced apoptosis, and furthermore, the combination of CRM197 plus doxorubicin enhanced cytotoxicity in a T-ALL cell line. ", "drug1": "CRM197", "drug2": "doxorubicin", "relation": "EFFECT", "source_file": "21873163.xml", "sentence_id": "DDI-MedLine.d201.s9", "pair_id": "DDI-MedLine.d201.s9.p2"} {"sentence": "Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. ", "drug1": "dihydroergotamine", "drug2": "methysergide", "relation": "NONE", "source_file": "Sumatriptan.xml", "sentence_id": "DDI-DrugBank.d720.s1", "pair_id": "DDI-DrugBank.d720.s1.p7"} {"sentence": "Therefore, use of zidovudine in combination with ZERIT should be avoided. ", "drug1": "zidovudine", "drug2": "ZERIT", "relation": "ADVISE", "source_file": "Stavudine.xml", "sentence_id": "DDI-DrugBank.d727.s1", "pair_id": "DDI-DrugBank.d727.s1.p0"} {"sentence": "Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.", "drug1": "docetaxel", "drug2": "sunitinib", "relation": "EFFECT", "source_file": "21796416.xml", "sentence_id": "DDI-MedLine.d179.s10", "pair_id": "DDI-MedLine.d179.s10.p4"} {"sentence": "The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ", "drug1": "neuromuscular blocking agents", "drug2": "phenytoin", "relation": "EFFECT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s11", "pair_id": "DDI-DrugBank.d775.s11.p18"} {"sentence": "Concomitant administration of substances that are also tubularly secreted (e.g., probenecid) could potentially result in delayed clearance of ALIMTA. ", "drug1": "probenecid", "drug2": "ALIMTA", "relation": "MECHANISM", "source_file": "Pemetrexed.xml", "sentence_id": "DDI-DrugBank.d641.s2", "pair_id": "DDI-DrugBank.d641.s2.p0"} {"sentence": "The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ", "drug1": "DIPRIVAN", "drug2": "meperidine", "relation": "EFFECT", "source_file": "Propofol.xml", "sentence_id": "DDI-DrugBank.d628.s0", "pair_id": "DDI-DrugBank.d628.s0.p2"} {"sentence": "Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ", "drug1": "Anticoagulants", "drug2": "TNKase", "relation": "EFFECT", "source_file": "Tenecteplase.xml", "sentence_id": "DDI-DrugBank.d773.s2", "pair_id": "DDI-DrugBank.d773.s2.p4"} {"sentence": "Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ", "drug1": "SSRIs", "drug2": "sumatriptan", "relation": "EFFECT", "source_file": "Sumatriptan.xml", "sentence_id": "DDI-DrugBank.d720.s3", "pair_id": "DDI-DrugBank.d720.s3.p25"} {"sentence": "ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ", "drug1": "Alpha-adrenergic blocking agents", "drug2": "ProAmatine", "relation": "EFFECT", "source_file": "Midodrine.xml", "sentence_id": "DDI-DrugBank.d603.s5", "pair_id": "DDI-DrugBank.d603.s5.p16"} {"sentence": "Imexon and dacarbazine show additive effects in vitro but not in vivo in human A375 melanoma cells.", "drug1": "Imexon", "drug2": "dacarbazine", "relation": "EFFECT", "source_file": "21868520.xml", "sentence_id": "DDI-MedLine.d147.s8", "pair_id": "DDI-MedLine.d147.s8.p0"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "tricyclic", "drug2": "selegiline", "relation": "NONE", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p48"} {"sentence": "No clinically significant changes to lamivudine or zidovudine pharmacokinetics were observed following concomitant administration of abacavir. ", "drug1": "lamivudine", "drug2": "zidovudine", "relation": "NONE", "source_file": "Abacavir.xml", "sentence_id": "DDI-DrugBank.d610.s1", "pair_id": "DDI-DrugBank.d610.s1.p0"} {"sentence": "Our data demonstrate that chronic treatment with the metabotropic glutamate receptor 5 antagonist, 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine, significantly reduces 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity towards dopaminergic and noradrenergic cell groups in non-human primates. ", "drug1": "3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine", "drug2": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "relation": "EFFECT", "source_file": "21705423.xml", "sentence_id": "DDI-MedLine.d161.s9", "pair_id": "DDI-MedLine.d161.s9.p0"} {"sentence": "Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days. ", "drug1": "digoxin", "drug2": "sitagliptin", "relation": "MECHANISM", "source_file": "Sitagliptin.xml", "sentence_id": "DDI-DrugBank.d694.s0", "pair_id": "DDI-DrugBank.d694.s0.p2"} {"sentence": "Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol. ", "drug1": "sedatives", "drug2": "alcohol", "relation": "NONE", "source_file": "Scopolamine.xml", "sentence_id": "DDI-DrugBank.d771.s1", "pair_id": "DDI-DrugBank.d771.s1.p4"} {"sentence": "Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells.\r\n", "drug1": "celecoxib", "drug2": "anti-cancer drugs", "relation": "EFFECT", "source_file": "21763710.xml", "sentence_id": "DDI-MedLine.d217.s0", "pair_id": "DDI-MedLine.d217.s0.p0"} {"sentence": "CRM197 induced apoptosis, and furthermore, the combination of CRM197 plus doxorubicin enhanced cytotoxicity in a T-ALL cell line. ", "drug1": "CRM197", "drug2": "CRM197", "relation": "NONE", "source_file": "21873163.xml", "sentence_id": "DDI-MedLine.d201.s9", "pair_id": "DDI-MedLine.d201.s9.p0"} {"sentence": "However, in a drug-drug interaction study, mean levonorgesterol AUC was decreased by 15% when coadministered with mycophenolate mofetil. ", "drug1": "levonorgesterol", "drug2": "mycophenolate mofetil", "relation": "MECHANISM", "source_file": "Mycophenolic acid.xml", "sentence_id": "DDI-DrugBank.d700.s10", "pair_id": "DDI-DrugBank.d700.s10.p0"} {"sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "drug1": "antipsychotic agents", "drug2": "narcotic analgesics", "relation": "NONE", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s0", "pair_id": "DDI-DrugBank.d585.s0.p63"} {"sentence": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ", "drug1": "vinblastine", "drug2": "DETROL LA", "relation": "ADVISE", "source_file": "Tolterodine.xml", "sentence_id": "DDI-DrugBank.d765.s1", "pair_id": "DDI-DrugBank.d765.s1.p44"} {"sentence": "Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ", "drug1": "fluvoxamine", "drug2": "clotrimazole", "relation": "NONE", "source_file": "Methylergonovine.xml", "sentence_id": "DDI-DrugBank.d675.s4", "pair_id": "DDI-DrugBank.d675.s4.p19"} {"sentence": "Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. ", "drug1": "troleandomycin", "drug2": "corticosteroids", "relation": "MECHANISM", "source_file": "Prednisone.xml", "sentence_id": "DDI-DrugBank.d653.s2", "pair_id": "DDI-DrugBank.d653.s2.p1"} {"sentence": "Implanon failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "drug1": "Implanon", "drug2": "antiretroviral", "relation": "EFFECT", "source_file": "21729965.xml", "sentence_id": "DDI-MedLine.d208.s0", "pair_id": "DDI-MedLine.d208.s0.p0"} {"sentence": "Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ", "drug1": "Thalidomide", "drug2": "rifabutin", "relation": "NONE", "source_file": "Thalidomide.xml", "sentence_id": "DDI-DrugBank.d604.s4", "pair_id": "DDI-DrugBank.d604.s4.p6"} {"sentence": "Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. ", "drug1": "quinidine", "drug2": "precocene I", "relation": "EFFECT", "source_file": "21741958.xml", "sentence_id": "DDI-MedLine.d189.s10", "pair_id": "DDI-MedLine.d189.s10.p5"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "tetracyclines", "drug2": "magnesium", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p60"} {"sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "drug1": "anticholinergic drugs", "drug2": "benzodiazepines", "relation": "EFFECT", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s0", "pair_id": "DDI-DrugBank.d585.s0.p6"} {"sentence": "ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ", "drug1": "terazosin", "drug2": "metformin", "relation": "NONE", "source_file": "Midodrine.xml", "sentence_id": "DDI-DrugBank.d603.s5", "pair_id": "DDI-DrugBank.d603.s5.p39"} {"sentence": "It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ", "drug1": "tamoxifen", "drug2": "SSRI antidepressants", "relation": "ADVISE", "source_file": "21751753.xml", "sentence_id": "DDI-MedLine.d209.s9", "pair_id": "DDI-MedLine.d209.s9.p0"} {"sentence": "Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. ", "drug1": "tetracyclines", "drug2": "anticoagulant", "relation": "ADVISE", "source_file": "Minocycline.xml", "sentence_id": "DDI-DrugBank.d711.s0", "pair_id": "DDI-DrugBank.d711.s0.p0"} {"sentence": "Co-administration of oral ketoconazole 200 mg twice daily increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of retapamulin ointment, 1% on the abraded skin of healthy adult males. ", "drug1": "ketoconazole", "drug2": "retapamulin", "relation": "MECHANISM", "source_file": "Retapamulin.xml", "sentence_id": "DDI-DrugBank.d654.s0", "pair_id": "DDI-DrugBank.d654.s0.p1"} {"sentence": "Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided. ", "drug1": "antacids", "drug2": "anticholinergic agents", "relation": "MECHANISM", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s6", "pair_id": "DDI-DrugBank.d585.s6.p0"} {"sentence": "Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. ", "drug1": "Sulfoxone", "drug2": "uricosurics", "relation": "EFFECT", "source_file": "Sulfoxone.xml", "sentence_id": "DDI-DrugBank.d682.s0", "pair_id": "DDI-DrugBank.d682.s0.p2"} {"sentence": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "drug1": "melatonin", "drug2": "progestin", "relation": "NONE", "source_file": "Melatonin.xml", "sentence_id": "DDI-DrugBank.d643.s0", "pair_id": "DDI-DrugBank.d643.s0.p50"} {"sentence": "Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine. ", "drug1": "digoxin", "drug2": "sulfasalazine", "relation": "MECHANISM", "source_file": "Sulfasalazine.xml", "sentence_id": "DDI-DrugBank.d693.s0", "pair_id": "DDI-DrugBank.d693.s0.p2"} {"sentence": "Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ", "drug1": "ranitidine", "drug2": "diltiazem", "relation": "NONE", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s6", "pair_id": "DDI-DrugBank.d737.s6.p13"} {"sentence": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "drug1": "sulfonylurea agents", "drug2": "warfarin", "relation": "NONE", "source_file": "Sulfamethizole.xml", "sentence_id": "DDI-DrugBank.d649.s1", "pair_id": "DDI-DrugBank.d649.s1.p13"} {"sentence": "Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ", "drug1": "MEPERIDINE", "drug2": "PHENOTHIAZINES", "relation": "ADVISE", "source_file": "Meperidine.xml", "sentence_id": "DDI-DrugBank.d703.s0", "pair_id": "DDI-DrugBank.d703.s0.p12"} {"sentence": "It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin. ", "drug1": "sulfamethoxazole", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Sulfamethoxazole.xml", "sentence_id": "DDI-DrugBank.d577.s1", "pair_id": "DDI-DrugBank.d577.s1.p1"} {"sentence": "In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. ", "drug1": "lithium", "drug2": "lithium", "relation": "NONE", "source_file": "Meloxicam.xml", "sentence_id": "DDI-DrugBank.d597.s20", "pair_id": "DDI-DrugBank.d597.s20.p0"} {"sentence": "In addition, CNS toxicity has been reported (confusion, disorientation, respiratory depression, apnea, seizures) following coadministration of cimetidine with opioid analgesics; ", "drug1": "cimetidine", "drug2": "opioid analgesics", "relation": "EFFECT", "source_file": "Oxymorphone.xml", "sentence_id": "DDI-DrugBank.d753.s4", "pair_id": "DDI-DrugBank.d753.s4.p0"} {"sentence": "Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ", "drug1": "diphenylhydantoin", "drug2": "tricyclic drugs", "relation": "NONE", "source_file": "Methylphenidate.xml", "sentence_id": "DDI-DrugBank.d638.s2", "pair_id": "DDI-DrugBank.d638.s2.p36"} {"sentence": "Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ", "drug1": "NARCOTIC ANALGESICS", "drug2": "ANESTHETICS", "relation": "NONE", "source_file": "Meperidine.xml", "sentence_id": "DDI-DrugBank.d703.s0", "pair_id": "DDI-DrugBank.d703.s0.p19"} {"sentence": "Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ", "drug1": "ibuprofen", "drug2": "diazepam", "relation": "NONE", "source_file": "Raloxifene.xml", "sentence_id": "DDI-DrugBank.d648.s6", "pair_id": "DDI-DrugBank.d648.s6.p18"} {"sentence": "These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ", "drug1": "Phenytoin", "drug2": "Rifampin", "relation": "NONE", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s2", "pair_id": "DDI-DrugBank.d776.s2.p28"} {"sentence": "Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ", "drug1": "digoxin", "drug2": "tetracycline", "relation": "NONE", "source_file": "Metoclopramide.xml", "sentence_id": "DDI-DrugBank.d652.s3", "pair_id": "DDI-DrugBank.d652.s3.p2"} {"sentence": "The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ", "drug1": "VERSED Syrup", "drug2": "propofol", "relation": "EFFECT", "source_file": "Midazolam.xml", "sentence_id": "DDI-DrugBank.d752.s10", "pair_id": "DDI-DrugBank.d752.s10.p4"} {"sentence": "Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ", "drug1": "thyroxine", "drug2": "corticosteroids", "relation": "NONE", "source_file": "Salsalate.xml", "sentence_id": "DDI-DrugBank.d576.s6", "pair_id": "DDI-DrugBank.d576.s6.p33"} {"sentence": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "drug1": "thiazides", "drug2": "sulfonylurea agents", "relation": "NONE", "source_file": "Sulfamethizole.xml", "sentence_id": "DDI-DrugBank.d649.s1", "pair_id": "DDI-DrugBank.d649.s1.p1"} {"sentence": "DRUG INTERACTIONS There are no known drug/drug interactions with oral ALKERAN Vaccinations with live organism vaccines are not recommended in immunocompromised individuals Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis. ", "drug1": "Nalidixic acid", "drug2": "melphalan", "relation": "EFFECT", "source_file": "Melphalan.xml", "sentence_id": "DDI-DrugBank.d625.s0", "pair_id": "DDI-DrugBank.d625.s0.p5"} {"sentence": "Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. ", "drug1": "anticholinesterase agents", "drug2": "anticholinesterases", "relation": "NONE", "source_file": "Procaine.xml", "sentence_id": "DDI-DrugBank.d780.s0", "pair_id": "DDI-DrugBank.d780.s0.p7"} {"sentence": "Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ", "drug1": "morphine", "drug2": "metformin", "relation": "NONE", "source_file": "Trospium.xml", "sentence_id": "DDI-DrugBank.d713.s2", "pair_id": "DDI-DrugBank.d713.s2.p31"} {"sentence": "MAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine. ", "drug1": "beta adrenergic blockers", "drug2": "pseudoephedrine", "relation": "EFFECT", "source_file": "Pseudoephedrine.xml", "sentence_id": "DDI-DrugBank.d606.s0", "pair_id": "DDI-DrugBank.d606.s0.p2"} {"sentence": "Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.", "drug1": "Beta adrenergic agonists", "drug2": "monoamine oxidase inhibitors", "relation": "ADVISE", "source_file": "Orciprenaline.xml", "sentence_id": "DDI-DrugBank.d611.s1", "pair_id": "DDI-DrugBank.d611.s1.p0"} {"sentence": "Some anticonvulsants may interact with Mephenytoin. ", "drug1": "anticonvulsants", "drug2": "Mephenytoin", "relation": "INT", "source_file": "Mephenytoin.xml", "sentence_id": "DDI-DrugBank.d636.s0", "pair_id": "DDI-DrugBank.d636.s0.p0"} {"sentence": "DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. ", "drug1": "DIFLUCAN", "drug2": "glyburide", "relation": "MECHANISM", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s4", "pair_id": "DDI-DrugBank.d776.s4.p1"} {"sentence": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "drug1": "beta blockers", "drug2": "melatonin", "relation": "NONE", "source_file": "Melatonin.xml", "sentence_id": "DDI-DrugBank.d643.s0", "pair_id": "DDI-DrugBank.d643.s0.p84"} {"sentence": "When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. ", "drug1": "methyldopa", "drug2": "antihypertensive drugs", "relation": "EFFECT", "source_file": "Methyldopa.xml", "sentence_id": "DDI-DrugBank.d779.s0", "pair_id": "DDI-DrugBank.d779.s0.p0"} {"sentence": "Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ", "drug1": "SUTENT", "drug2": "telithromycin", "relation": "MECHANISM", "source_file": "Sunitinib.xml", "sentence_id": "DDI-DrugBank.d639.s0", "pair_id": "DDI-DrugBank.d639.s0.p9"} {"sentence": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "drug1": "Anafranil", "drug2": "desipramine", "relation": "NONE", "source_file": "Mazindol.xml", "sentence_id": "DDI-DrugBank.d716.s5", "pair_id": "DDI-DrugBank.d716.s5.p128"} {"sentence": "Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ", "drug1": "butorphanol", "drug2": "opioid agonist analgesic", "relation": "ADVISE", "source_file": "Morphine.xml", "sentence_id": "DDI-DrugBank.d637.s2", "pair_id": "DDI-DrugBank.d637.s2.p19"} {"sentence": "Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ", "drug1": "metaraminol", "drug2": "halothane", "relation": "EFFECT", "source_file": "Phenylpropanolamine.xml", "sentence_id": "DDI-DrugBank.d689.s0", "pair_id": "DDI-DrugBank.d689.s0.p2"} {"sentence": "Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. ", "drug1": "fluvoxamine", "drug2": "ropivacaine", "relation": "NONE", "source_file": "Ropivacaine.xml", "sentence_id": "DDI-DrugBank.d591.s3", "pair_id": "DDI-DrugBank.d591.s3.p2"} {"sentence": "Careful monitoring of prothrombin time in patients receiving DIFLUCAN and coumarin-type anticoagulants is recommended. ", "drug1": "DIFLUCAN", "drug2": "coumarin-type anticoagulants", "relation": "ADVISE", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s8", "pair_id": "DDI-DrugBank.d776.s8.p0"} {"sentence": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ", "drug1": "erythromycin", "drug2": "oxybutynin", "relation": "MECHANISM", "source_file": "Oxybutynin.xml", "sentence_id": "DDI-DrugBank.d784.s4", "pair_id": "DDI-DrugBank.d784.s4.p19"} {"sentence": "Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ", "drug1": "SUTENT", "drug2": "dexamethasone", "relation": "MECHANISM", "source_file": "Sunitinib.xml", "sentence_id": "DDI-DrugBank.d639.s2", "pair_id": "DDI-DrugBank.d639.s2.p0"} {"sentence": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "drug1": "paricalcitol", "drug2": "indinavir", "relation": "ADVISE", "source_file": "Paricalcitol.xml", "sentence_id": "DDI-DrugBank.d726.s1", "pair_id": "DDI-DrugBank.d726.s1.p57"} {"sentence": "Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ", "drug1": "potassium", "drug2": "ACE inhibitors", "relation": "EFFECT", "source_file": "Moexipril.xml", "sentence_id": "DDI-DrugBank.d640.s3", "pair_id": "DDI-DrugBank.d640.s3.p14"} {"sentence": "Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ", "drug1": "central nervous system depressants", "drug2": "hypnotics", "relation": "NONE", "source_file": "Triprolidine.xml", "sentence_id": "DDI-DrugBank.d615.s0", "pair_id": "DDI-DrugBank.d615.s0.p9"} {"sentence": "Concomitant use of alcohol with phentermine hydrochloride may result in an adverse drug interaction.", "drug1": "alcohol", "drug2": "phentermine hydrochloride", "relation": "INT", "source_file": "Phentermine.xml", "sentence_id": "DDI-DrugBank.d750.s0", "pair_id": "DDI-DrugBank.d750.s0.p0"} {"sentence": "Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ", "drug1": "SUTENT", "drug2": "rifapentin", "relation": "MECHANISM", "source_file": "Sunitinib.xml", "sentence_id": "DDI-DrugBank.d639.s2", "pair_id": "DDI-DrugBank.d639.s2.p5"} {"sentence": "Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ", "drug1": "butyrophenones", "drug2": "Permax", "relation": "ADVISE", "source_file": "Pergolide.xml", "sentence_id": "DDI-DrugBank.d650.s0", "pair_id": "DDI-DrugBank.d650.s0.p20"} {"sentence": "and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) ", "drug1": "doxycycline", "drug2": "1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine", "relation": "NONE", "source_file": "21809690.xml", "sentence_id": "DDI-MedLine.d214.s2", "pair_id": "DDI-MedLine.d214.s2.p3"} {"sentence": "Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ", "drug1": "Ritalin", "drug2": "clomipramine", "relation": "MECHANISM", "source_file": "Methylphenidate.xml", "sentence_id": "DDI-DrugBank.d638.s2", "pair_id": "DDI-DrugBank.d638.s2.p8"} {"sentence": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "drug1": "paricalcitol", "drug2": "telithromycin", "relation": "ADVISE", "source_file": "Paricalcitol.xml", "sentence_id": "DDI-DrugBank.d726.s1", "pair_id": "DDI-DrugBank.d726.s1.p63"} {"sentence": "Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ", "drug1": "SUTENT", "drug2": "phenobarbital", "relation": "MECHANISM", "source_file": "Sunitinib.xml", "sentence_id": "DDI-DrugBank.d639.s2", "pair_id": "DDI-DrugBank.d639.s2.p6"} {"sentence": "Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.", "drug1": "ketoconazole", "drug2": "ropivacaine", "relation": "MECHANISM", "source_file": "Ropivacaine.xml", "sentence_id": "DDI-DrugBank.d591.s6", "pair_id": "DDI-DrugBank.d591.s6.p2"} {"sentence": "Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ", "drug1": "Anticoagulants", "drug2": "acetylsalicylic acid", "relation": "NONE", "source_file": "Tenecteplase.xml", "sentence_id": "DDI-DrugBank.d773.s2", "pair_id": "DDI-DrugBank.d773.s2.p2"} {"sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.", "drug1": "theophylline", "drug2": "corticosteroids", "relation": "NONE", "source_file": "Secobarbital.xml", "sentence_id": "DDI-DrugBank.d601.s0", "pair_id": "DDI-DrugBank.d601.s0.p22"} {"sentence": "Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%. ", "drug1": "Paroxetine", "drug2": "endoxifen", "relation": "MECHANISM", "source_file": "21751753.xml", "sentence_id": "DDI-MedLine.d209.s5", "pair_id": "DDI-MedLine.d209.s5.p1"} {"sentence": "Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ", "drug1": "piroxicam", "drug2": "metoprolol", "relation": "NONE", "source_file": "Pantoprazole.xml", "sentence_id": "DDI-DrugBank.d680.s1", "pair_id": "DDI-DrugBank.d680.s1.p201"} {"sentence": "The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine . Therefore, caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction. ", "drug1": "phenylpropanolamine", "drug2": "ProAmatine", "relation": "EFFECT", "source_file": "Midodrine.xml", "sentence_id": "DDI-DrugBank.d603.s2", "pair_id": "DDI-DrugBank.d603.s2.p16"} {"sentence": "John s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ", "drug1": "phenytoin", "drug2": "mifepristone", "relation": "MECHANISM", "source_file": "Mifepristone.xml", "sentence_id": "DDI-DrugBank.d668.s2", "pair_id": "DDI-DrugBank.d668.s2.p7"} {"sentence": "In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ", "drug1": "TOBI", "drug2": "corticosteroids", "relation": "NONE", "source_file": "Tobramycin.xml", "sentence_id": "DDI-DrugBank.d624.s0", "pair_id": "DDI-DrugBank.d624.s0.p4"} {"sentence": "Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ", "drug1": "Hormonal Contraceptives", "drug2": "carbamazepine", "relation": "NONE", "source_file": "Thalidomide.xml", "sentence_id": "DDI-DrugBank.d604.s4", "pair_id": "DDI-DrugBank.d604.s4.p16"} {"sentence": "Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ", "drug1": "butyrophenones", "drug2": "thioxanthenes", "relation": "NONE", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s10", "pair_id": "DDI-DrugBank.d737.s10.p39"} {"sentence": "Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.", "drug1": "Mequitazine", "drug2": "TCA", "relation": "INT", "source_file": "Mequitazine.xml", "sentence_id": "DDI-DrugBank.d699.s0", "pair_id": "DDI-DrugBank.d699.s0.p2"} {"sentence": "In vivo, the plasma clearance of ropivacaine was reduced by 70% during coadministration of fluvoxamine (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor. ", "drug1": "ropivacaine", "drug2": "fluvoxamine", "relation": "MECHANISM", "source_file": "Ropivacaine.xml", "sentence_id": "DDI-DrugBank.d591.s2", "pair_id": "DDI-DrugBank.d591.s2.p0"} {"sentence": "Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and cyclosporine. ", "drug1": "DIFLUCAN", "drug2": "cyclosporine", "relation": "ADVISE", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s14", "pair_id": "DDI-DrugBank.d776.s14.p2"} {"sentence": "In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin. ", "drug1": "fluconazole", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s7", "pair_id": "DDI-DrugBank.d776.s7.p2"} {"sentence": "Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ", "drug1": "Triprolidine", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Triprolidine.xml", "sentence_id": "DDI-DrugBank.d615.s0", "pair_id": "DDI-DrugBank.d615.s0.p1"} {"sentence": "Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ", "drug1": "nifedipine", "drug2": "MYCAMINE", "relation": "ADVISE", "source_file": "Micafungin.xml", "sentence_id": "DDI-DrugBank.d735.s5", "pair_id": "DDI-DrugBank.d735.s5.p6"} {"sentence": "In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin. ", "drug1": "stavudine", "drug2": "doxorubicin", "relation": "EFFECT", "source_file": "Stavudine.xml", "sentence_id": "DDI-DrugBank.d727.s2", "pair_id": "DDI-DrugBank.d727.s2.p0"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "MIVACRON", "drug2": "aminoglycosides", "relation": "INT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p16"} {"sentence": "Alcohol: Concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects. ", "drug1": "alcohol", "drug2": "mirtazapine", "relation": "MECHANISM", "source_file": "Mirtazapine.xml", "sentence_id": "DDI-DrugBank.d742.s7", "pair_id": "DDI-DrugBank.d742.s7.p2"} {"sentence": "When administered concomitantly with ProAmatine , cardiac glycosides may enhance or precipitate bradycardia, A.V. ", "drug1": "ProAmatine", "drug2": "cardiac glycosides", "relation": "EFFECT", "source_file": "Midodrine.xml", "sentence_id": "DDI-DrugBank.d603.s0", "pair_id": "DDI-DrugBank.d603.s0.p0"} {"sentence": "Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ", "drug1": "calcium channel antagonists", "drug2": "macrolide antibiotics", "relation": "NONE", "source_file": "Midazolam.xml", "sentence_id": "DDI-DrugBank.d752.s0", "pair_id": "DDI-DrugBank.d752.s0.p9"} {"sentence": "These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ", "drug1": "hypoglycemics", "drug2": "Tacrolimus", "relation": "NONE", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s2", "pair_id": "DDI-DrugBank.d776.s2.p9"} {"sentence": "Rifabutin: There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered. ", "drug1": "fluconazole", "drug2": "rifabutin", "relation": "EFFECT", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s31", "pair_id": "DDI-DrugBank.d776.s31.p2"} {"sentence": "Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. ", "drug1": "Sulfoxone", "drug2": "barbiturates", "relation": "EFFECT", "source_file": "Sulfoxone.xml", "sentence_id": "DDI-DrugBank.d682.s0", "pair_id": "DDI-DrugBank.d682.s0.p0"} {"sentence": "It is recommended that plasma lithium levels be monitored when initiating, adjusting and discontinuing FELDENE.", "drug1": "lithium", "drug2": "FELDENE", "relation": "ADVISE", "source_file": "Piroxicam.xml", "sentence_id": "DDI-DrugBank.d656.s3", "pair_id": "DDI-DrugBank.d656.s3.p0"} {"sentence": "Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. ", "drug1": "Furosemide", "drug2": "NSAIDs", "relation": "NONE", "source_file": "Meloxicam.xml", "sentence_id": "DDI-DrugBank.d597.s14", "pair_id": "DDI-DrugBank.d597.s14.p0"} {"sentence": "Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ", "drug1": "FELDENE", "drug2": "lithium", "relation": "MECHANISM", "source_file": "Piroxicam.xml", "sentence_id": "DDI-DrugBank.d656.s2", "pair_id": "DDI-DrugBank.d656.s2.p27"} {"sentence": "Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR = 1.73 [95% CI, 1.25-2.38]), fluoxetine (OR = 1.63 [95% CI, 1.11-2.38]), paroxetine (OR = 1.64 [95% CI, 1.27-2.12]), amitriptyline (OR = 1.47 [95% CI, 1.02-2.11]). ", "drug1": "Warfarin", "drug2": "fluoxetine", "relation": "EFFECT", "source_file": "21731754.xml", "sentence_id": "DDI-MedLine.d218.s8", "pair_id": "DDI-MedLine.d218.s8.p1"} {"sentence": "Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ", "drug1": "XENICAL", "drug2": "cyclosporine", "relation": "MECHANISM", "source_file": "Orlistat.xml", "sentence_id": "DDI-DrugBank.d761.s1", "pair_id": "DDI-DrugBank.d761.s1.p14"} {"sentence": "The action of Mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.", "drug1": "Mecamylamine", "drug2": "antihypertensive drugs", "relation": "EFFECT", "source_file": "Mecamylamine.xml", "sentence_id": "DDI-DrugBank.d579.s1", "pair_id": "DDI-DrugBank.d579.s1.p0"} {"sentence": "Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. ", "drug1": "ephedrine", "drug2": "levomepromazine", "relation": "EFFECT", "source_file": "Methotrimeprazine.xml", "sentence_id": "DDI-DrugBank.d756.s7", "pair_id": "DDI-DrugBank.d756.s7.p4"} {"sentence": "Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ", "drug1": "phenytoin", "drug2": "rifampicin", "relation": "NONE", "source_file": "Ondansetron.xml", "sentence_id": "DDI-DrugBank.d763.s3", "pair_id": "DDI-DrugBank.d763.s3.p19"} {"sentence": "There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ", "drug1": "tacrolimus", "drug2": "prednisolone", "relation": "NONE", "source_file": "Micafungin.xml", "sentence_id": "DDI-DrugBank.d735.s2", "pair_id": "DDI-DrugBank.d735.s2.p12"} {"sentence": "In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys. ", "drug1": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "drug2": "3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine", "relation": "EFFECT", "source_file": "21705423.xml", "sentence_id": "DDI-MedLine.d161.s8", "pair_id": "DDI-MedLine.d161.s8.p2"} {"sentence": "Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ", "drug1": "Posicor", "drug2": "tricyclic antidepressants", "relation": "MECHANISM", "source_file": "Mibefradil.xml", "sentence_id": "DDI-DrugBank.d783.s0", "pair_id": "DDI-DrugBank.d783.s0.p4"} {"sentence": "Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ", "drug1": "diclofenac", "drug2": "metoprolol", "relation": "NONE", "source_file": "Pantoprazole.xml", "sentence_id": "DDI-DrugBank.d680.s1", "pair_id": "DDI-DrugBank.d680.s1.p172"} {"sentence": "Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ", "drug1": "indomethacin", "drug2": "pramipexole", "relation": "MECHANISM", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s6", "pair_id": "DDI-DrugBank.d737.s6.p87"} {"sentence": "Terfenadine: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with terfenadine, interaction studies have been performed. ", "drug1": "azole antifungals", "drug2": "terfenadine", "relation": "EFFECT", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s20", "pair_id": "DDI-DrugBank.d776.s20.p2"} {"sentence": "When ZETIA is administered with an HMG-CoA reductase inhibitor in a woman of childbearing potential, refer to the pregnancy category and package labeling for the HMG-CoA reductase inhibitor. ", "drug1": "ZETIA", "drug2": "HMG-CoA reductase inhibitor", "relation": "NONE", "source_file": "Ezetimibe.xml", "sentence_id": "DDI-DrugBank.d572.s27", "pair_id": "DDI-DrugBank.d572.s27.p0"} {"sentence": "We have demonstrated appropriateness of inhospital administration of fixed amlodipine/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.", "drug1": "amlodipine", "drug2": "valsartan", "relation": "EFFECT", "source_file": "21878082.xml", "sentence_id": "DDI-MedLine.d200.s10", "pair_id": "DDI-MedLine.d200.s10.p0"} {"sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "drug1": "anticholinergic drugs", "drug2": "phenothiazines", "relation": "EFFECT", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s0", "pair_id": "DDI-DrugBank.d585.s0.p5"} {"sentence": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "drug1": "doxepin", "drug2": "Tofranil", "relation": "NONE", "source_file": "Mazindol.xml", "sentence_id": "DDI-DrugBank.d716.s5", "pair_id": "DDI-DrugBank.d716.s5.p74"} {"sentence": "ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. ", "drug1": "SALICYLATE DRUGS", "drug2": "DISALCID", "relation": "EFFECT", "source_file": "Salsalate.xml", "sentence_id": "DDI-DrugBank.d576.s1", "pair_id": "DDI-DrugBank.d576.s1.p3"} {"sentence": "In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ", "drug1": "contraceptives", "drug2": "norethindrone", "relation": "NONE", "source_file": "Montelukast.xml", "sentence_id": "DDI-DrugBank.d739.s10", "pair_id": "DDI-DrugBank.d739.s10.p30"} {"sentence": "Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ", "drug1": "terfenadine", "drug2": "ketoconazole", "relation": "NONE", "source_file": "Terfenadine.xml", "sentence_id": "DDI-DrugBank.d743.s9", "pair_id": "DDI-DrugBank.d743.s9.p9"} {"sentence": "There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.", "drug1": "contraceptives", "drug2": "hypoglycemics", "relation": "NONE", "source_file": "Terbinafine.xml", "sentence_id": "DDI-DrugBank.d645.s9", "pair_id": "DDI-DrugBank.d645.s9.p0"} {"sentence": "Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ", "drug1": "Matulane", "drug2": "amitriptyline HCl", "relation": "ADVISE", "source_file": "Procarbazine.xml", "sentence_id": "DDI-DrugBank.d676.s2", "pair_id": "DDI-DrugBank.d676.s2.p2"} {"sentence": "Patients on lithium treatment should be closely monitored when MOBIC is introduced or withdrawn. ", "drug1": "lithium", "drug2": "MOBIC", "relation": "ADVISE", "source_file": "Meloxicam.xml", "sentence_id": "DDI-DrugBank.d597.s22", "pair_id": "DDI-DrugBank.d597.s22.p0"} {"sentence": "Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that dasatinib-mediated induction of p27(Kip1) enhanced paclitaxel-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression. ", "drug1": "dasatinib", "drug2": "paclitaxel", "relation": "EFFECT", "source_file": "21813412.xml", "sentence_id": "DDI-MedLine.d194.s16", "pair_id": "DDI-MedLine.d194.s16.p0"} {"sentence": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "drug1": "melatonin", "drug2": "melatonin", "relation": "NONE", "source_file": "Melatonin.xml", "sentence_id": "DDI-DrugBank.d643.s0", "pair_id": "DDI-DrugBank.d643.s0.p93"} {"sentence": "Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with nifedipine alone. ", "drug1": "Nifedipine", "drug2": "MYCAMINE", "relation": "MECHANISM", "source_file": "Micafungin.xml", "sentence_id": "DDI-DrugBank.d735.s4", "pair_id": "DDI-DrugBank.d735.s4.p0"} {"sentence": "Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ", "drug1": "SUTENT", "drug2": "nefazodone", "relation": "MECHANISM", "source_file": "Sunitinib.xml", "sentence_id": "DDI-DrugBank.d639.s0", "pair_id": "DDI-DrugBank.d639.s0.p5"} {"sentence": "It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ", "drug1": "tamoxifen", "drug2": "paroxetine", "relation": "ADVISE", "source_file": "21751753.xml", "sentence_id": "DDI-MedLine.d209.s9", "pair_id": "DDI-MedLine.d209.s9.p1"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "selegiline", "drug2": "diphenhydramine", "relation": "NONE", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p152"} {"sentence": "Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.", "drug1": "Tetracycline", "drug2": "penicillin", "relation": "EFFECT", "source_file": "Oxacillin.xml", "sentence_id": "DDI-DrugBank.d747.s0", "pair_id": "DDI-DrugBank.d747.s0.p1"} {"sentence": "Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia. ", "drug1": "Aspirin", "drug2": "corticosteroids", "relation": "ADVISE", "source_file": "Prednisone.xml", "sentence_id": "DDI-DrugBank.d653.s6", "pair_id": "DDI-DrugBank.d653.s6.p0"} {"sentence": "Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine", "drug1": "Vindesine", "drug2": "vaccine", "relation": "NONE", "source_file": "Vindesine.xml", "sentence_id": "DDI-DrugBank.d782.s0", "pair_id": "DDI-DrugBank.d782.s0.p2"} {"sentence": "Patients receiving rifabutin and fluconazole concomitantly should be carefully monitored. ", "drug1": "rifabutin", "drug2": "fluconazole", "relation": "ADVISE", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s32", "pair_id": "DDI-DrugBank.d776.s32.p0"} {"sentence": "Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA.", "drug1": "ketamine", "drug2": "propofol", "relation": "EFFECT", "source_file": "21751692.xml", "sentence_id": "DDI-MedLine.d199.s4", "pair_id": "DDI-MedLine.d199.s4.p0"} {"sentence": "As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy. ", "drug1": "aminosalicylate derivatives", "drug2": "thioguanine", "relation": "MECHANISM", "source_file": "Thioguanine.xml", "sentence_id": "DDI-DrugBank.d722.s1", "pair_id": "DDI-DrugBank.d722.s1.p3"} {"sentence": "Use with Anticholinergics: Because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications. ", "drug1": "cholinesterase inhibitors", "drug2": "anticholinergic medications", "relation": "INT", "source_file": "Rivastigmine.xml", "sentence_id": "DDI-DrugBank.d596.s8", "pair_id": "DDI-DrugBank.d596.s8.p2"} {"sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.", "drug1": "anticoagulants", "drug2": "beta blockers", "relation": "NONE", "source_file": "Secobarbital.xml", "sentence_id": "DDI-DrugBank.d601.s0", "pair_id": "DDI-DrugBank.d601.s0.p27"} {"sentence": "Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ", "drug1": "rifampicin", "drug2": "ondansetron", "relation": "MECHANISM", "source_file": "Ondansetron.xml", "sentence_id": "DDI-DrugBank.d763.s3", "pair_id": "DDI-DrugBank.d763.s3.p25"} {"sentence": "Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ", "drug1": "Sanctura", "drug2": "morphine", "relation": "MECHANISM", "source_file": "Trospium.xml", "sentence_id": "DDI-DrugBank.d713.s2", "pair_id": "DDI-DrugBank.d713.s2.p11"} {"sentence": "Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. ", "drug1": "ergotamine", "drug2": "sumatriptan", "relation": "ADVISE", "source_file": "Sumatriptan.xml", "sentence_id": "DDI-DrugBank.d720.s1", "pair_id": "DDI-DrugBank.d720.s1.p3"} {"sentence": "Careful monitoring of phenytoin concentrations in patients receiving DIFLUCAN and phenytoin is recommended. ", "drug1": "DIFLUCAN", "drug2": "phenytoin", "relation": "ADVISE", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s11", "pair_id": "DDI-DrugBank.d776.s11.p2"} {"sentence": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "drug1": "Moxifloxacin", "drug2": "multi-minerals", "relation": "MECHANISM", "source_file": "21715267.xml", "sentence_id": "DDI-MedLine.d231.s8", "pair_id": "DDI-MedLine.d231.s8.p4"} {"sentence": "Co-administration of ZETIA with fibrates is not recommended until use in patients is studied. ", "drug1": "ZETIA", "drug2": "fibrates", "relation": "ADVISE", "source_file": "Ezetimibe.xml", "sentence_id": "DDI-DrugBank.d572.s5", "pair_id": "DDI-DrugBank.d572.s5.p0"} {"sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.", "drug1": "Barbiturates", "drug2": "antibiotics", "relation": "INT", "source_file": "Secobarbital.xml", "sentence_id": "DDI-DrugBank.d601.s0", "pair_id": "DDI-DrugBank.d601.s0.p1"} {"sentence": "Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ", "drug1": "midazolam", "drug2": "azole antimycotics", "relation": "ADVISE", "source_file": "Midazolam.xml", "sentence_id": "DDI-DrugBank.d752.s0", "pair_id": "DDI-DrugBank.d752.s0.p0"} {"sentence": "however, in patients with Paget's Disease prior diphosphonate use appears to reduce the anti-resorptive response to Calcitonin (salmon) nasal spray.", "drug1": "diphosphonate", "drug2": "Calcitonin (salmon)", "relation": "EFFECT", "source_file": "Salmon Calcitonin.xml", "sentence_id": "DDI-DrugBank.d770.s4", "pair_id": "DDI-DrugBank.d770.s4.p0"} {"sentence": "The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ", "drug1": "aluminum", "drug2": "SKELID", "relation": "MECHANISM", "source_file": "Tiludronate.xml", "sentence_id": "DDI-DrugBank.d721.s0", "pair_id": "DDI-DrugBank.d721.s0.p24"} {"sentence": "Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.\r\n", "drug1": "S-ketamine", "drug2": "ticlopidine", "relation": "EFFECT", "source_file": "21716267.xml", "sentence_id": "DDI-MedLine.d216.s0", "pair_id": "DDI-MedLine.d216.s0.p1"} {"sentence": "Although MIVACRON (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between MIVACRON and succinylcholine has not been systematically studied. ", "drug1": "MIVACRON", "drug2": "MIVACRON", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s0", "pair_id": "DDI-DrugBank.d775.s0.p0"} {"sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "drug1": "phenothiazines", "drug2": "nitrates", "relation": "NONE", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s0", "pair_id": "DDI-DrugBank.d585.s0.p73"} {"sentence": "Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ", "drug1": "Ritalin", "drug2": "imipramine", "relation": "MECHANISM", "source_file": "Methylphenidate.xml", "sentence_id": "DDI-DrugBank.d638.s2", "pair_id": "DDI-DrugBank.d638.s2.p7"} {"sentence": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ", "drug1": "antimycotic agents", "drug2": "oxybutynin", "relation": "MECHANISM", "source_file": "Oxybutynin.xml", "sentence_id": "DDI-DrugBank.d784.s4", "pair_id": "DDI-DrugBank.d784.s4.p5"} {"sentence": "The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ", "drug1": "VERSED Syrup", "drug2": "nitrous oxide", "relation": "EFFECT", "source_file": "Midazolam.xml", "sentence_id": "DDI-DrugBank.d752.s10", "pair_id": "DDI-DrugBank.d752.s10.p6"} {"sentence": "Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ", "drug1": "quinine", "drug2": "pramipexole", "relation": "MECHANISM", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s6", "pair_id": "DDI-DrugBank.d737.s6.p63"} {"sentence": "Ibuprofen plasma concentration was also increased when it was administered with piperine. ", "drug1": "Ibuprofen", "drug2": "piperine", "relation": "MECHANISM", "source_file": "22029226.xml", "sentence_id": "DDI-MedLine.d195.s5", "pair_id": "DDI-MedLine.d195.s5.p0"} {"sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "drug1": "antiarrhythmic agents of class I", "drug2": "tricyclic antidepressants", "relation": "NONE", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s0", "pair_id": "DDI-DrugBank.d585.s0.p38"} {"sentence": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "drug1": "Lomefloxacin", "drug2": "erythromycin", "relation": "MECHANISM", "source_file": "21715267.xml", "sentence_id": "DDI-MedLine.d231.s8", "pair_id": "DDI-MedLine.d231.s8.p7"} {"sentence": "Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ", "drug1": "fluconazole", "drug2": "clotrimazole", "relation": "NONE", "source_file": "Methylergonovine.xml", "sentence_id": "DDI-DrugBank.d675.s4", "pair_id": "DDI-DrugBank.d675.s4.p14"} {"sentence": "In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. ", "drug1": "S-ketamine", "drug2": "ticlopidine", "relation": "NONE", "source_file": "21716267.xml", "sentence_id": "DDI-MedLine.d216.s2", "pair_id": "DDI-MedLine.d216.s2.p0"} {"sentence": "Anticholinergics antagonize the effects of antiglaucoma agents. ", "drug1": "Anticholinergics", "drug2": "antiglaucoma agents", "relation": "EFFECT", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s1", "pair_id": "DDI-DrugBank.d585.s1.p0"} {"sentence": "Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. ", "drug1": "nelfinavir", "drug2": "midazolam", "relation": "MECHANISM", "source_file": "Midazolam.xml", "sentence_id": "DDI-DrugBank.d752.s3", "pair_id": "DDI-DrugBank.d752.s3.p2"} {"sentence": "Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ", "drug1": "clarithromycin", "drug2": "indinavir", "relation": "NONE", "source_file": "Sunitinib.xml", "sentence_id": "DDI-DrugBank.d639.s0", "pair_id": "DDI-DrugBank.d639.s0.p34"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "bacitracin", "drug2": "clindamycin", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p67"} {"sentence": "Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.", "drug1": "acetylcholine chloride", "drug2": "carbachol", "relation": "NONE", "source_file": "Suprofen.xml", "sentence_id": "DDI-DrugBank.d723.s0", "pair_id": "DDI-DrugBank.d723.s0.p1"} {"sentence": "Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin; ", "drug1": "Anticholinergic agents", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s3", "pair_id": "DDI-DrugBank.d585.s3.p0"} {"sentence": "No formal interaction studies have been performed to assess the effect of SYMLIN on the kinetics of oral antidiabetic agents. ", "drug1": "SYMLIN", "drug2": "antidiabetic agents", "relation": "NONE", "source_file": "Pramlintide.xml", "sentence_id": "DDI-DrugBank.d632.s5", "pair_id": "DDI-DrugBank.d632.s5.p0"} {"sentence": "SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.", "drug1": "SKELAXIN", "drug2": "CNS depressants", "relation": "EFFECT", "source_file": "Metaxalone.xml", "sentence_id": "DDI-DrugBank.d605.s0", "pair_id": "DDI-DrugBank.d605.s0.p2"} {"sentence": "Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ", "drug1": "amiloride", "drug2": "ACE inhibitors", "relation": "EFFECT", "source_file": "Moexipril.xml", "sentence_id": "DDI-DrugBank.d640.s3", "pair_id": "DDI-DrugBank.d640.s3.p13"} {"sentence": "Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine, resulting in elevated plasma terfenadine levels. ", "drug1": "ketoconazole", "drug2": "terfenadine", "relation": "MECHANISM", "source_file": "Terfenadine.xml", "sentence_id": "DDI-DrugBank.d743.s2", "pair_id": "DDI-DrugBank.d743.s2.p0"} {"sentence": "Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants", "drug1": "carbamazepine", "drug2": "cisplatin", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s13", "pair_id": "DDI-DrugBank.d775.s13.p26"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "Methscopolamine", "drug2": "diphenhydramine", "relation": "INT", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p12"} {"sentence": "In the hot plate test in mice, co-administration of 15 g/kg dexmedetomidine with 10 mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. ", "drug1": "dexmedetomidine", "drug2": "ephedrine", "relation": "EFFECT", "source_file": "21876510.xml", "sentence_id": "DDI-MedLine.d227.s7", "pair_id": "DDI-MedLine.d227.s7.p0"} {"sentence": "Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. ", "drug1": "coumarin", "drug2": "warfarin", "relation": "NONE", "source_file": "Metronidazole.xml", "sentence_id": "DDI-DrugBank.d629.s0", "pair_id": "DDI-DrugBank.d629.s0.p2"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "nondepolarizing agents", "drug2": "lithium", "relation": "INT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p11"} {"sentence": "Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ", "drug1": "naproxen", "drug2": "piroxicam", "relation": "NONE", "source_file": "Pantoprazole.xml", "sentence_id": "DDI-DrugBank.d680.s1", "pair_id": "DDI-DrugBank.d680.s1.p180"} {"sentence": "Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ", "drug1": "carbamazepine", "drug2": "glyburide", "relation": "NONE", "source_file": "Pantoprazole.xml", "sentence_id": "DDI-DrugBank.d680.s1", "pair_id": "DDI-DrugBank.d680.s1.p117"} {"sentence": "A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ", "drug1": "tacrolimus", "drug2": "prednisolone", "relation": "NONE", "source_file": "Micafungin.xml", "sentence_id": "DDI-DrugBank.d735.s0", "pair_id": "DDI-DrugBank.d735.s0.p24"} {"sentence": "Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ", "drug1": "diphenylhydantoin", "drug2": "phenylbutazone", "relation": "NONE", "source_file": "Methylphenidate.xml", "sentence_id": "DDI-DrugBank.d638.s2", "pair_id": "DDI-DrugBank.d638.s2.p35"} {"sentence": "Fat-soluble Vitamin Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with XENICAL. ", "drug1": "beta-carotene", "drug2": "XENICAL", "relation": "MECHANISM", "source_file": "Orlistat.xml", "sentence_id": "DDI-DrugBank.d761.s3", "pair_id": "DDI-DrugBank.d761.s3.p2"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "nondepolarizing agents", "drug2": "colistin", "relation": "INT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p8"} {"sentence": "There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids. ", "drug1": "anticoagulants", "drug2": "corticosteroids", "relation": "EFFECT", "source_file": "Prednisone.xml", "sentence_id": "DDI-DrugBank.d653.s8", "pair_id": "DDI-DrugBank.d653.s8.p0"} {"sentence": "Pantoprazole has a much weaker effect on clopidogrel's pharmacokinetics and on platelet reactivity during concomitant use. ", "drug1": "Pantoprazole", "drug2": "clopidogrel", "relation": "MECHANISM", "source_file": "21771377.xml", "sentence_id": "DDI-MedLine.d143.s4", "pair_id": "DDI-MedLine.d143.s4.p0"} {"sentence": "Adrenal steroids or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema. ", "drug1": "ACTH", "drug2": "adrenal cortical steroids", "relation": "NONE", "source_file": "Oxandrolone.xml", "sentence_id": "DDI-DrugBank.d584.s10", "pair_id": "DDI-DrugBank.d584.s10.p3"} {"sentence": "This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn. ", "drug1": "salicylate", "drug2": "methylprednisolone", "relation": "EFFECT", "source_file": "Methylprednisolone.xml", "sentence_id": "DDI-DrugBank.d578.s8", "pair_id": "DDI-DrugBank.d578.s8.p2"} {"sentence": "In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. ", "drug1": "tolbutamide", "drug2": "teniposide", "relation": "MECHANISM", "source_file": "Teniposide.xml", "sentence_id": "DDI-DrugBank.d575.s0", "pair_id": "DDI-DrugBank.d575.s0.p2"} {"sentence": "Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ", "drug1": "triamterene", "drug2": "ACE inhibitors", "relation": "EFFECT", "source_file": "Moexipril.xml", "sentence_id": "DDI-DrugBank.d640.s3", "pair_id": "DDI-DrugBank.d640.s3.p11"} {"sentence": "In total, 430,455 warfarin users contributed 407,370 person-years of warfarin use. ", "drug1": "warfarin", "drug2": "warfarin", "relation": "NONE", "source_file": "21731754.xml", "sentence_id": "DDI-MedLine.d218.s5", "pair_id": "DDI-MedLine.d218.s5.p0"} {"sentence": "Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR = 1.73 [95% CI, 1.25-2.38]), fluoxetine (OR = 1.63 [95% CI, 1.11-2.38]), paroxetine (OR = 1.64 [95% CI, 1.27-2.12]), amitriptyline (OR = 1.47 [95% CI, 1.02-2.11]). ", "drug1": "Warfarin", "drug2": "amitriptyline", "relation": "EFFECT", "source_file": "21731754.xml", "sentence_id": "DDI-MedLine.d218.s8", "pair_id": "DDI-MedLine.d218.s8.p3"} {"sentence": "Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ", "drug1": "metoclopramide", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Metoclopramide.xml", "sentence_id": "DDI-DrugBank.d652.s1", "pair_id": "DDI-DrugBank.d652.s1.p0"} {"sentence": "Methylprednisolone may increase the clearance of chronic high dose aspirin. ", "drug1": "Methylprednisolone", "drug2": "aspirin", "relation": "MECHANISM", "source_file": "Methylprednisolone.xml", "sentence_id": "DDI-DrugBank.d578.s7", "pair_id": "DDI-DrugBank.d578.s7.p0"} {"sentence": "Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ", "drug1": "erythromycin", "drug2": "ketoconazole", "relation": "NONE", "source_file": "Midazolam.xml", "sentence_id": "DDI-DrugBank.d752.s1", "pair_id": "DDI-DrugBank.d752.s1.p2"} {"sentence": "In vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen. ", "drug1": "raloxifene", "drug2": "tamoxifen", "relation": "NONE", "source_file": "Raloxifene.xml", "sentence_id": "DDI-DrugBank.d648.s5", "pair_id": "DDI-DrugBank.d648.s5.p2"} {"sentence": "Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of Zemplar Capsules.", "drug1": "cholestyramine", "drug2": "Zemplar", "relation": "MECHANISM", "source_file": "Paricalcitol.xml", "sentence_id": "DDI-DrugBank.d726.s3", "pair_id": "DDI-DrugBank.d726.s3.p2"} {"sentence": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "drug1": "fluvoxamine", "drug2": "melatonin", "relation": "NONE", "source_file": "Melatonin.xml", "sentence_id": "DDI-DrugBank.d643.s0", "pair_id": "DDI-DrugBank.d643.s0.p60"} {"sentence": "Diuretics: Patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of ACEON Tablets therapy. ", "drug1": "diuretics", "drug2": "ACEON", "relation": "EFFECT", "source_file": "Perindopril.xml", "sentence_id": "DDI-DrugBank.d781.s0", "pair_id": "DDI-DrugBank.d781.s0.p2"} {"sentence": "Moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections. ", "drug1": "Moxifloxacin", "drug2": "fluoroquinolone antibiotics", "relation": "NONE", "source_file": "21715267.xml", "sentence_id": "DDI-MedLine.d231.s1", "pair_id": "DDI-MedLine.d231.s1.p1"} {"sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "drug1": "anticholinergic drugs", "drug2": "nitrites", "relation": "EFFECT", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s0", "pair_id": "DDI-DrugBank.d585.s0.p11"} {"sentence": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ", "drug1": "phenobarbital", "drug2": "corticosteroid", "relation": "MECHANISM", "source_file": "Prednisone.xml", "sentence_id": "DDI-DrugBank.d653.s1", "pair_id": "DDI-DrugBank.d653.s1.p3"} {"sentence": "Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ", "drug1": "morphine", "drug2": "antihistaminics", "relation": "EFFECT", "source_file": "Morphine.xml", "sentence_id": "DDI-DrugBank.d637.s0", "pair_id": "DDI-DrugBank.d637.s0.p9"} {"sentence": "In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ", "drug1": "TOBI", "drug2": "PULMOZYME", "relation": "EFFECT", "source_file": "Tobramycin.xml", "sentence_id": "DDI-DrugBank.d624.s0", "pair_id": "DDI-DrugBank.d624.s0.p8"} {"sentence": "Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ", "drug1": "digoxin", "drug2": "metoclopramide", "relation": "MECHANISM", "source_file": "Metoclopramide.xml", "sentence_id": "DDI-DrugBank.d652.s3", "pair_id": "DDI-DrugBank.d652.s3.p0"} {"sentence": "The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ", "drug1": "VERSED Syrup", "drug2": "droperidol", "relation": "EFFECT", "source_file": "Midazolam.xml", "sentence_id": "DDI-DrugBank.d752.s10", "pair_id": "DDI-DrugBank.d752.s10.p8"} {"sentence": "The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.", "drug1": "adrenergic agents", "drug2": "tricyclic antidepressants", "relation": "EFFECT", "source_file": "Phenylpropanolamine.xml", "sentence_id": "DDI-DrugBank.d689.s3", "pair_id": "DDI-DrugBank.d689.s3.p0"} {"sentence": "a reduction of the doxorubicin dosage should be considered in patients receiving ZANOSAR concurrently. ", "drug1": "doxorubicin", "drug2": "ZANOSAR", "relation": "ADVISE", "source_file": "Streptozocin.xml", "sentence_id": "DDI-DrugBank.d647.s2", "pair_id": "DDI-DrugBank.d647.s2.p0"} {"sentence": "Aspirin: Rimantadine HCl, 100 mg, was given twice daily fro 13 days to 12 healthy volunteers. ", "drug1": "Aspirin", "drug2": "Rimantadine HCl", "relation": "NONE", "source_file": "Rimantadine.xml", "sentence_id": "DDI-DrugBank.d710.s6", "pair_id": "DDI-DrugBank.d710.s6.p0"} {"sentence": "Monoamine oxidase inhibitors or tricyclic antidepressants may potentiate the action of sympathomimetic amines. ", "drug1": "tricyclic antidepressants", "drug2": "sympathomimetic amines", "relation": "EFFECT", "source_file": "Metaraminol.xml", "sentence_id": "DDI-DrugBank.d746.s1", "pair_id": "DDI-DrugBank.d746.s1.p2"} {"sentence": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ", "drug1": "macrolide antibiotics", "drug2": "erythromycin", "relation": "NONE", "source_file": "Tolterodine.xml", "sentence_id": "DDI-DrugBank.d765.s1", "pair_id": "DDI-DrugBank.d765.s1.p30"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "isocarboxazid", "drug2": "antihistamines", "relation": "NONE", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p137"} {"sentence": "Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. ", "drug1": "SYMLIN", "drug2": "human insulin", "relation": "NONE", "source_file": "Pramlintide.xml", "sentence_id": "DDI-DrugBank.d632.s6", "pair_id": "DDI-DrugBank.d632.s6.p2"} {"sentence": "Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.", "drug1": "Metopirone", "drug2": "acetaminophen", "relation": "EFFECT", "source_file": "Metyrapone.xml", "sentence_id": "DDI-DrugBank.d678.s4", "pair_id": "DDI-DrugBank.d678.s4.p1"} {"sentence": "John s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ", "drug1": "carbamazepine", "drug2": "mifepristone", "relation": "MECHANISM", "source_file": "Mifepristone.xml", "sentence_id": "DDI-DrugBank.d668.s2", "pair_id": "DDI-DrugBank.d668.s2.p12"} {"sentence": "Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. ", "drug1": "Ethanol", "drug2": "abacavir", "relation": "MECHANISM", "source_file": "Abacavir.xml", "sentence_id": "DDI-DrugBank.d610.s3", "pair_id": "DDI-DrugBank.d610.s3.p0"} {"sentence": "The bioavailability of SKELID is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of diclofenac. ", "drug1": "SKELID", "drug2": "diclofenac", "relation": "NONE", "source_file": "Tiludronate.xml", "sentence_id": "DDI-DrugBank.d721.s2", "pair_id": "DDI-DrugBank.d721.s2.p1"} {"sentence": "The addition of aspirin to Streptokinase causes a minimal increase in the risk of minor bleeding (3.9% vs. 3.1%), but does not appear to increase the incidence of major bleeding (see", "drug1": "aspirin", "drug2": "Streptokinase", "relation": "EFFECT", "source_file": "Streptokinase.xml", "sentence_id": "DDI-DrugBank.d777.s5", "pair_id": "DDI-DrugBank.d777.s5.p0"} {"sentence": "Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid). ", "drug1": "ZOLINZA", "drug2": "HDAC inhibitors", "relation": "EFFECT", "source_file": "Vorinostat.xml", "sentence_id": "DDI-DrugBank.d769.s2", "pair_id": "DDI-DrugBank.d769.s2.p3"} {"sentence": "Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ", "drug1": "coumarin-type anticoagulants", "drug2": "FELDENE", "relation": "INT", "source_file": "Piroxicam.xml", "sentence_id": "DDI-DrugBank.d656.s1", "pair_id": "DDI-DrugBank.d656.s1.p4"} {"sentence": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ", "drug1": "miconazole", "drug2": "erythromycin", "relation": "NONE", "source_file": "Oxybutynin.xml", "sentence_id": "DDI-DrugBank.d784.s4", "pair_id": "DDI-DrugBank.d784.s4.p12"} {"sentence": "Corticosteroids may increase the clearance of chronic high dose aspirin. ", "drug1": "Corticosteroids", "drug2": "aspirin", "relation": "MECHANISM", "source_file": "Prednisone.xml", "sentence_id": "DDI-DrugBank.d653.s4", "pair_id": "DDI-DrugBank.d653.s4.p0"} {"sentence": "MAO-A inhibitors reduce sumatriptan clearance, significantly increasing systemic exposure. ", "drug1": "MAO-A inhibitors", "drug2": "sumatriptan", "relation": "MECHANISM", "source_file": "Sumatriptan.xml", "sentence_id": "DDI-DrugBank.d720.s2", "pair_id": "DDI-DrugBank.d720.s2.p0"} {"sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "drug1": "anticholinergic drugs", "drug2": "antihistamines", "relation": "EFFECT", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s0", "pair_id": "DDI-DrugBank.d585.s0.p3"} {"sentence": "Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ", "drug1": "Ritalin", "drug2": "anticonvulsants", "relation": "MECHANISM", "source_file": "Methylphenidate.xml", "sentence_id": "DDI-DrugBank.d638.s2", "pair_id": "DDI-DrugBank.d638.s2.p1"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "nondepolarizing agents", "drug2": "tetracyclines", "relation": "INT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p3"} {"sentence": "Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ", "drug1": "Salicylate", "drug2": "corticosteroids", "relation": "MECHANISM", "source_file": "Salsalate.xml", "sentence_id": "DDI-DrugBank.d576.s6", "pair_id": "DDI-DrugBank.d576.s6.p9"} {"sentence": "Theophylline: DIFLUCAN increases the serum concentrations of theophylline. ", "drug1": "DIFLUCAN", "drug2": "theophylline", "relation": "MECHANISM", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s18", "pair_id": "DDI-DrugBank.d776.s18.p2"} {"sentence": "Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates. ", "drug1": "levomepromazine", "drug2": "benzodiazepines", "relation": "EFFECT", "source_file": "Methotrimeprazine.xml", "sentence_id": "DDI-DrugBank.d756.s2", "pair_id": "DDI-DrugBank.d756.s2.p0"} {"sentence": "When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil , lowered Mexitil plasma levels have been reported. ", "drug1": "rifampin", "drug2": "Mexitil", "relation": "MECHANISM", "source_file": "Mexiletine.xml", "sentence_id": "DDI-DrugBank.d633.s9", "pair_id": "DDI-DrugBank.d633.s9.p5"} {"sentence": "The combined use of fluconazole with cisapride is contraindicated. ", "drug1": "fluconazole", "drug2": "cisapride", "relation": "ADVISE", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s27", "pair_id": "DDI-DrugBank.d776.s27.p0"} {"sentence": "Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ", "drug1": "levomepromazine", "drug2": "antiparkinsonian-agents", "relation": "ADVISE", "source_file": "Methotrimeprazine.xml", "sentence_id": "DDI-DrugBank.d756.s4", "pair_id": "DDI-DrugBank.d756.s4.p2"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "Methscopolamine", "drug2": "pectin", "relation": "INT", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p18"} {"sentence": "Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ", "drug1": "Sanctura", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Trospium.xml", "sentence_id": "DDI-DrugBank.d713.s2", "pair_id": "DDI-DrugBank.d713.s2.p8"} {"sentence": "Cimetidine: The effects of chronic cimetidine use on the metabolism of rimantadine are not known. ", "drug1": "Cimetidine", "drug2": "cimetidine", "relation": "NONE", "source_file": "Rimantadine.xml", "sentence_id": "DDI-DrugBank.d710.s0", "pair_id": "DDI-DrugBank.d710.s0.p0"} {"sentence": "The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see", "drug1": "AGGRASTAT", "drug2": "aspirin", "relation": "EFFECT", "source_file": "Tirofiban.xml", "sentence_id": "DDI-DrugBank.d751.s1", "pair_id": "DDI-DrugBank.d751.s1.p1"} {"sentence": "Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine", "drug1": "Vindesine", "drug2": "Phenytoin", "relation": "INT", "source_file": "Vindesine.xml", "sentence_id": "DDI-DrugBank.d782.s0", "pair_id": "DDI-DrugBank.d782.s0.p0"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "MIVACRON", "drug2": "lincomycin", "relation": "INT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p20"} {"sentence": "Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ", "drug1": "digoxin", "drug2": "contraceptive", "relation": "NONE", "source_file": "Pantoprazole.xml", "sentence_id": "DDI-DrugBank.d680.s1", "pair_id": "DDI-DrugBank.d680.s1.p211"} {"sentence": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "drug1": "melatonin", "drug2": "progestin", "relation": "EFFECT", "source_file": "Melatonin.xml", "sentence_id": "DDI-DrugBank.d643.s0", "pair_id": "DDI-DrugBank.d643.s0.p115"} {"sentence": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "drug1": "paricalcitol", "drug2": "itraconazole", "relation": "ADVISE", "source_file": "Paricalcitol.xml", "sentence_id": "DDI-DrugBank.d726.s1", "pair_id": "DDI-DrugBank.d726.s1.p58"} {"sentence": "Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ", "drug1": "Salicylate", "drug2": "triiodothyronine", "relation": "MECHANISM", "source_file": "Salsalate.xml", "sentence_id": "DDI-DrugBank.d576.s6", "pair_id": "DDI-DrugBank.d576.s6.p3"} {"sentence": "Concomitant administration of itraconazole and terfenadine is contraindicated. ", "drug1": "itraconazole", "drug2": "terfenadine", "relation": "ADVISE", "source_file": "Terfenadine.xml", "sentence_id": "DDI-DrugBank.d743.s7", "pair_id": "DDI-DrugBank.d743.s7.p0"} {"sentence": "Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ", "drug1": "verapamil", "drug2": "midazolam", "relation": "MECHANISM", "source_file": "Midazolam.xml", "sentence_id": "DDI-DrugBank.d752.s1", "pair_id": "DDI-DrugBank.d752.s1.p14"} {"sentence": "Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ", "drug1": "Sanctura", "drug2": "tenofovir", "relation": "MECHANISM", "source_file": "Trospium.xml", "sentence_id": "DDI-DrugBank.d713.s2", "pair_id": "DDI-DrugBank.d713.s2.p14"} {"sentence": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ", "drug1": "macrolide antibiotics", "drug2": "nelfinavir", "relation": "NONE", "source_file": "Methylergonovine.xml", "sentence_id": "DDI-DrugBank.d675.s2", "pair_id": "DDI-DrugBank.d675.s2.p7"} {"sentence": "Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. ", "drug1": "anticholinesterases", "drug2": "procaine hydrochloride", "relation": "MECHANISM", "source_file": "Procaine.xml", "sentence_id": "DDI-DrugBank.d780.s0", "pair_id": "DDI-DrugBank.d780.s0.p9"} {"sentence": "Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ", "drug1": "Triprolidine", "drug2": "barbiturates", "relation": "EFFECT", "source_file": "Triprolidine.xml", "sentence_id": "DDI-DrugBank.d615.s0", "pair_id": "DDI-DrugBank.d615.s0.p2"} {"sentence": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "drug1": "melatonin", "drug2": "melatonin", "relation": "NONE", "source_file": "Melatonin.xml", "sentence_id": "DDI-DrugBank.d643.s0", "pair_id": "DDI-DrugBank.d643.s0.p71"} {"sentence": "John s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ", "drug1": "anticonvulsants", "drug2": "mifepristone", "relation": "MECHANISM", "source_file": "Mifepristone.xml", "sentence_id": "DDI-DrugBank.d668.s2", "pair_id": "DDI-DrugBank.d668.s2.p3"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "antidepressants", "drug2": "promethazine", "relation": "NONE", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p42"} {"sentence": "Diuretics: Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. ", "drug1": "loop diuretics", "drug2": "metolazone", "relation": "EFFECT", "source_file": "Metolazone.xml", "sentence_id": "DDI-DrugBank.d588.s0", "pair_id": "DDI-DrugBank.d588.s0.p5"} {"sentence": "Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ", "drug1": "SUTENT", "drug2": "indinavir", "relation": "MECHANISM", "source_file": "Sunitinib.xml", "sentence_id": "DDI-DrugBank.d639.s0", "pair_id": "DDI-DrugBank.d639.s0.p4"} {"sentence": "Curariform Drugs: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea. ", "drug1": "Diuretic", "drug2": "curariform drugs", "relation": "EFFECT", "source_file": "Metolazone.xml", "sentence_id": "DDI-DrugBank.d588.s8", "pair_id": "DDI-DrugBank.d588.s8.p3"} {"sentence": "Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ", "drug1": "Warfarin", "drug2": "fluoxetine", "relation": "EFFECT", "source_file": "21731754.xml", "sentence_id": "DDI-MedLine.d218.s10", "pair_id": "DDI-MedLine.d218.s10.p1"} {"sentence": "Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ", "drug1": "digoxin", "drug2": "metformin", "relation": "NONE", "source_file": "Trospium.xml", "sentence_id": "DDI-DrugBank.d713.s2", "pair_id": "DDI-DrugBank.d713.s2.p19"} {"sentence": "Salicylates and Other Non-Steroidal Anti-Inflammatory Drugs: May decrease the antihypertensive effects of MYKROX Tablets. ", "drug1": "Salicylates", "drug2": "MYKROX", "relation": "EFFECT", "source_file": "Metolazone.xml", "sentence_id": "DDI-DrugBank.d588.s10", "pair_id": "DDI-DrugBank.d588.s10.p1"} {"sentence": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "drug1": "clarithromycin", "drug2": "itraconazole", "relation": "NONE", "source_file": "Paricalcitol.xml", "sentence_id": "DDI-DrugBank.d726.s1", "pair_id": "DDI-DrugBank.d726.s1.p85"} {"sentence": "Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ", "drug1": "metoclopramide", "drug2": "tranquilizers", "relation": "EFFECT", "source_file": "Metoclopramide.xml", "sentence_id": "DDI-DrugBank.d652.s1", "pair_id": "DDI-DrugBank.d652.s1.p4"} {"sentence": "The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.\r\n", "drug1": "dasatinib", "drug2": "paclitaxel", "relation": "EFFECT", "source_file": "21813412.xml", "sentence_id": "DDI-MedLine.d194.s0", "pair_id": "DDI-MedLine.d194.s0.p0"} {"sentence": "The synergistic antinociception activity of ibuprofen when administered with piperine can be attributed to increased plasma concentration of ibuprofen. ", "drug1": "ibuprofen", "drug2": "piperine", "relation": "MECHANISM", "source_file": "22029226.xml", "sentence_id": "DDI-MedLine.d195.s6", "pair_id": "DDI-MedLine.d195.s6.p0"} {"sentence": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "drug1": "Sinequan", "drug2": "nortriptyline", "relation": "NONE", "source_file": "Mazindol.xml", "sentence_id": "DDI-DrugBank.d716.s5", "pair_id": "DDI-DrugBank.d716.s5.p81"} {"sentence": "A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ", "drug1": "MYCAMINE", "drug2": "rifampin", "relation": "NONE", "source_file": "Micafungin.xml", "sentence_id": "DDI-DrugBank.d735.s0", "pair_id": "DDI-DrugBank.d735.s0.p8"} {"sentence": "Salicylates given concomitantly with anticoagulant drugs may predispose to systemic bleeding. ", "drug1": "Salicylates", "drug2": "anticoagulant drugs", "relation": "EFFECT", "source_file": "Salsalate.xml", "sentence_id": "DDI-DrugBank.d576.s4", "pair_id": "DDI-DrugBank.d576.s4.p0"} {"sentence": "Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ", "drug1": "Triprolidine", "drug2": "narcotic analgesics", "relation": "EFFECT", "source_file": "Triprolidine.xml", "sentence_id": "DDI-DrugBank.d615.s0", "pair_id": "DDI-DrugBank.d615.s0.p4"} {"sentence": "Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol. ", "drug1": "Scopolamine", "drug2": "sedatives", "relation": "ADVISE", "source_file": "Scopolamine.xml", "sentence_id": "DDI-DrugBank.d771.s1", "pair_id": "DDI-DrugBank.d771.s1.p0"} {"sentence": "- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone. ", "drug1": "prednisolone", "drug2": "prednisone", "relation": "NONE", "source_file": "Montelukast.xml", "sentence_id": "DDI-DrugBank.d739.s5", "pair_id": "DDI-DrugBank.d739.s5.p3"} {"sentence": "Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ", "drug1": "pentazocine", "drug2": "opioid agonist analgesic", "relation": "ADVISE", "source_file": "Morphine.xml", "sentence_id": "DDI-DrugBank.d637.s2", "pair_id": "DDI-DrugBank.d637.s2.p14"} {"sentence": "Prior administration of succinylcholine can potentiate the neuromuscular blocking effects of nondepolarizing agents. ", "drug1": "succinylcholine", "drug2": "nondepolarizing agents", "relation": "EFFECT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s1", "pair_id": "DDI-DrugBank.d775.s1.p0"} {"sentence": "In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ", "drug1": "TOBI", "drug2": "aminoglycosides", "relation": "EFFECT", "source_file": "Tobramycin.xml", "sentence_id": "DDI-DrugBank.d624.s0", "pair_id": "DDI-DrugBank.d624.s0.p12"} {"sentence": "Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ", "drug1": "Selective serotonin reuptake inhibitors", "drug2": "sumatriptan", "relation": "EFFECT", "source_file": "Sumatriptan.xml", "sentence_id": "DDI-DrugBank.d720.s3", "pair_id": "DDI-DrugBank.d720.s3.p20"} {"sentence": "These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ", "drug1": "sex steroids", "drug2": "anticonvulsants", "relation": "NONE", "source_file": "Somatropin recombinant.xml", "sentence_id": "DDI-DrugBank.d599.s7", "pair_id": "DDI-DrugBank.d599.s7.p7"} {"sentence": "Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.", "drug1": "carbachol", "drug2": "Carboptic", "relation": "NONE", "source_file": "Suprofen.xml", "sentence_id": "DDI-DrugBank.d723.s0", "pair_id": "DDI-DrugBank.d723.s0.p9"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "Methscopolamine", "drug2": "selegiline", "relation": "INT", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p7"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "MIVACRON", "drug2": "lithium", "relation": "INT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p25"} {"sentence": "Interactions for Vitamin B1 (Thiamine): Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants", "drug1": "Vitamin B1", "drug2": "Stavudine", "relation": "INT", "source_file": "Thiamine.xml", "sentence_id": "DDI-DrugBank.d697.s0", "pair_id": "DDI-DrugBank.d697.s0.p3"} {"sentence": "Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. ", "drug1": "trimetrexate", "drug2": "ketoconazole", "relation": "EFFECT", "source_file": "Trimetrexate.xml", "sentence_id": "DDI-DrugBank.d766.s1", "pair_id": "DDI-DrugBank.d766.s1.p3"} {"sentence": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ", "drug1": "phenytoin", "drug2": "corticosteroid", "relation": "MECHANISM", "source_file": "Prednisone.xml", "sentence_id": "DDI-DrugBank.d653.s1", "pair_id": "DDI-DrugBank.d653.s1.p6"} {"sentence": "If in certain cases, an antidepressant is considered necessary, it may be advisable to replace tamoxifen with anastrozole.", "drug1": "antidepressant", "drug2": "tamoxifen", "relation": "ADVISE", "source_file": "21751753.xml", "sentence_id": "DDI-MedLine.d209.s11", "pair_id": "DDI-MedLine.d209.s11.p0"} {"sentence": "Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ", "drug1": "cyclosporine", "drug2": "tricyclic antidepressants", "relation": "NONE", "source_file": "Mibefradil.xml", "sentence_id": "DDI-DrugBank.d783.s0", "pair_id": "DDI-DrugBank.d783.s0.p14"} {"sentence": "ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ", "drug1": "desglymidodrine", "drug2": "cimetidine", "relation": "MECHANISM", "source_file": "Midodrine.xml", "sentence_id": "DDI-DrugBank.d603.s5", "pair_id": "DDI-DrugBank.d603.s5.p64"} {"sentence": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "drug1": "paricalcitol", "drug2": "nelfinavir", "relation": "ADVISE", "source_file": "Paricalcitol.xml", "sentence_id": "DDI-DrugBank.d726.s1", "pair_id": "DDI-DrugBank.d726.s1.p60"} {"sentence": "Accordingly, patients should be advised to avoid diazepam and other similar drugs while taking REMERON SolTab.", "drug1": "diazepam", "drug2": "REMERON SolTab", "relation": "ADVISE", "source_file": "Mirtazapine.xml", "sentence_id": "DDI-DrugBank.d742.s11", "pair_id": "DDI-DrugBank.d742.s11.p0"} {"sentence": "Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided. ", "drug1": "clopidogrel", "drug2": "omeprazole", "relation": "ADVISE", "source_file": "21771377.xml", "sentence_id": "DDI-MedLine.d143.s6", "pair_id": "DDI-MedLine.d143.s6.p0"} {"sentence": "Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. ", "drug1": "Myfortic", "drug2": "cholestyramine", "relation": "ADVISE", "source_file": "Mycophenolic acid.xml", "sentence_id": "DDI-DrugBank.d700.s8", "pair_id": "DDI-DrugBank.d700.s8.p0"} {"sentence": "In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin. ", "drug1": "stavudine", "drug2": "ribavirin", "relation": "EFFECT", "source_file": "Stavudine.xml", "sentence_id": "DDI-DrugBank.d727.s2", "pair_id": "DDI-DrugBank.d727.s2.p1"} {"sentence": "Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.", "drug1": "Metopirone", "drug2": "acetaminophen", "relation": "MECHANISM", "source_file": "Metyrapone.xml", "sentence_id": "DDI-DrugBank.d678.s4", "pair_id": "DDI-DrugBank.d678.s4.p0"} {"sentence": "Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ", "drug1": "Myfortic", "drug2": "mycophenolate mofetil", "relation": "ADVISE", "source_file": "Mycophenolic acid.xml", "sentence_id": "DDI-DrugBank.d700.s6", "pair_id": "DDI-DrugBank.d700.s6.p19"} {"sentence": "Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants", "drug1": "phenytoin", "drug2": "neostigmine", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s13", "pair_id": "DDI-DrugBank.d775.s13.p17"} {"sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "drug1": "quinidine", "drug2": "MAO inhibitors", "relation": "NONE", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s0", "pair_id": "DDI-DrugBank.d585.s0.p43"} {"sentence": "Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR = 1.73 [95% CI, 1.25-2.38]), fluoxetine (OR = 1.63 [95% CI, 1.11-2.38]), paroxetine (OR = 1.64 [95% CI, 1.27-2.12]), amitriptyline (OR = 1.47 [95% CI, 1.02-2.11]). ", "drug1": "Warfarin", "drug2": "paroxetine", "relation": "EFFECT", "source_file": "21731754.xml", "sentence_id": "DDI-MedLine.d218.s8", "pair_id": "DDI-MedLine.d218.s8.p2"} {"sentence": "Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.", "drug1": "lapatinib", "drug2": "Herceptin", "relation": "EFFECT", "source_file": "21868551.xml", "sentence_id": "DDI-MedLine.d164.s1", "pair_id": "DDI-MedLine.d164.s1.p0"} {"sentence": "Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.", "drug1": "cholinesterase inhibitors", "drug2": "succinylcholine", "relation": "EFFECT", "source_file": "Rivastigmine.xml", "sentence_id": "DDI-DrugBank.d596.s9", "pair_id": "DDI-DrugBank.d596.s9.p11"} {"sentence": "While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. ", "drug1": "phenytoin", "drug2": "MIVACRON", "relation": "EFFECT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s12", "pair_id": "DDI-DrugBank.d775.s12.p1"} {"sentence": "Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ", "drug1": "carbamazepine", "drug2": "nifedipine", "relation": "NONE", "source_file": "Pantoprazole.xml", "sentence_id": "DDI-DrugBank.d680.s1", "pair_id": "DDI-DrugBank.d680.s1.p122"} {"sentence": "Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ", "drug1": "terfenadine", "drug2": "itraconazole", "relation": "MECHANISM", "source_file": "Terfenadine.xml", "sentence_id": "DDI-DrugBank.d743.s5", "pair_id": "DDI-DrugBank.d743.s5.p7"} {"sentence": "Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline class drugs in conjunction with penicillin. ", "drug1": "tetracycline class drugs", "drug2": "penicillin", "relation": "ADVISE", "source_file": "Minocycline.xml", "sentence_id": "DDI-DrugBank.d711.s1", "pair_id": "DDI-DrugBank.d711.s1.p2"} {"sentence": "Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ", "drug1": "metaraminol", "drug2": "halothane", "relation": "EFFECT", "source_file": "Phenylephrine.xml", "sentence_id": "DDI-DrugBank.d725.s0", "pair_id": "DDI-DrugBank.d725.s0.p2"} {"sentence": "Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ", "drug1": "phenothiazines", "drug2": "MIRAPEX", "relation": "EFFECT", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s10", "pair_id": "DDI-DrugBank.d737.s10.p38"} {"sentence": "While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.", "drug1": "calcium", "drug2": "paracetamol", "relation": "NONE", "source_file": "Pilocarpine.xml", "sentence_id": "DDI-DrugBank.d627.s4", "pair_id": "DDI-DrugBank.d627.s4.p21"} {"sentence": "Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly. ", "drug1": "DIFLUCAN", "drug2": "terfenadine", "relation": "MECHANISM", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s22", "pair_id": "DDI-DrugBank.d776.s22.p2"} {"sentence": "Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ", "drug1": "Matulane", "drug2": "sympathomimetic drugs", "relation": "ADVISE", "source_file": "Procarbazine.xml", "sentence_id": "DDI-DrugBank.d676.s2", "pair_id": "DDI-DrugBank.d676.s2.p0"} {"sentence": "Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ", "drug1": "desmethyldiazepam", "drug2": "metoprolol", "relation": "NONE", "source_file": "Pantoprazole.xml", "sentence_id": "DDI-DrugBank.d680.s1", "pair_id": "DDI-DrugBank.d680.s1.p156"} {"sentence": "Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. ", "drug1": "DEMSER", "drug2": "haloperidol", "relation": "ADVISE", "source_file": "Metyrosine.xml", "sentence_id": "DDI-DrugBank.d715.s0", "pair_id": "DDI-DrugBank.d715.s0.p1"} {"sentence": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "drug1": "tricyclic antidepressant", "drug2": "amoxapine", "relation": "NONE", "source_file": "Mazindol.xml", "sentence_id": "DDI-DrugBank.d716.s5", "pair_id": "DDI-DrugBank.d716.s5.p2"} {"sentence": "Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ", "drug1": "sumatriptan succinate", "drug2": "paroxetine", "relation": "NONE", "source_file": "Sumatriptan.xml", "sentence_id": "DDI-DrugBank.d720.s3", "pair_id": "DDI-DrugBank.d720.s3.p5"} {"sentence": "Methenamine: Efficacy may be decreased due to urinary alkalizing effect of metolazone. ", "drug1": "Methenamine", "drug2": "metolazone", "relation": "EFFECT", "source_file": "Metolazone.xml", "sentence_id": "DDI-DrugBank.d588.s12", "pair_id": "DDI-DrugBank.d588.s12.p0"} {"sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "drug1": "anticholinergic drugs", "drug2": "antiarrhythmic agents of class I", "relation": "EFFECT", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s0", "pair_id": "DDI-DrugBank.d585.s0.p1"} {"sentence": "Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL. ", "drug1": "tricyclic antidepressants", "drug2": "ELDEPRYL", "relation": "NONE", "source_file": "Selegiline.xml", "sentence_id": "DDI-DrugBank.d619.s4", "pair_id": "DDI-DrugBank.d619.s4.p2"} {"sentence": "Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ", "drug1": "levomepromazine", "drug2": "tricyclic antidepressants", "relation": "ADVISE", "source_file": "Methotrimeprazine.xml", "sentence_id": "DDI-DrugBank.d756.s4", "pair_id": "DDI-DrugBank.d756.s4.p1"} {"sentence": "Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL. ", "drug1": "selective serotonin reuptake inhibitors", "drug2": "ELDEPRYL", "relation": "EFFECT", "source_file": "Selegiline.xml", "sentence_id": "DDI-DrugBank.d619.s4", "pair_id": "DDI-DrugBank.d619.s4.p5"} {"sentence": "Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ", "drug1": "erythromycin", "drug2": "terfenadine", "relation": "MECHANISM", "source_file": "Terfenadine.xml", "sentence_id": "DDI-DrugBank.d743.s9", "pair_id": "DDI-DrugBank.d743.s9.p5"} {"sentence": "Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with sirolimus alone. ", "drug1": "Sirolimus", "drug2": "MYCAMINE", "relation": "MECHANISM", "source_file": "Micafungin.xml", "sentence_id": "DDI-DrugBank.d735.s3", "pair_id": "DDI-DrugBank.d735.s3.p0"} {"sentence": "Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of ethinyl estradiol were studied. ", "drug1": "Contraceptives", "drug2": "norethindrone acetate", "relation": "NONE", "source_file": "Thalidomide.xml", "sentence_id": "DDI-DrugBank.d604.s2", "pair_id": "DDI-DrugBank.d604.s2.p2"} {"sentence": "Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ", "drug1": "itraconazole", "drug2": "mifepristone", "relation": "MECHANISM", "source_file": "Mifepristone.xml", "sentence_id": "DDI-DrugBank.d668.s0", "pair_id": "DDI-DrugBank.d668.s0.p8"} {"sentence": "ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ", "drug1": "desglymidodrine", "drug2": "ranitidine", "relation": "MECHANISM", "source_file": "Midodrine.xml", "sentence_id": "DDI-DrugBank.d603.s5", "pair_id": "DDI-DrugBank.d603.s5.p65"} {"sentence": "In vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in trimetrexate metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites. ", "drug1": "cimetidine", "drug2": "trimetrexate", "relation": "MECHANISM", "source_file": "Trimetrexate.xml", "sentence_id": "DDI-DrugBank.d766.s2", "pair_id": "DDI-DrugBank.d766.s2.p0"} {"sentence": "As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy. ", "drug1": "sulphasalazine", "drug2": "thioguanine", "relation": "MECHANISM", "source_file": "Thioguanine.xml", "sentence_id": "DDI-DrugBank.d722.s1", "pair_id": "DDI-DrugBank.d722.s1.p9"} {"sentence": "The combination of minocycline and fosfomycin can be synergistic against MRSA. ", "drug1": "minocycline", "drug2": "fosfomycin", "relation": "EFFECT", "source_file": "21772306.xml", "sentence_id": "DDI-MedLine.d163.s7", "pair_id": "DDI-MedLine.d163.s7.p0"} {"sentence": "saline + saline, ephedrine (10 mg/kg) + saline, saline + dexmedetomidine (15 g/kg) and ephedrine (10 mg/kg) + dexmedetomidine (15 g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ", "drug1": "dexmedetomidine", "drug2": "ephedrine", "relation": "NONE", "source_file": "21876510.xml", "sentence_id": "DDI-MedLine.d227.s6", "pair_id": "DDI-MedLine.d227.s6.p3"} {"sentence": "Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ", "drug1": "metronidazole", "drug2": "ketoconazole", "relation": "NONE", "source_file": "Terfenadine.xml", "sentence_id": "DDI-DrugBank.d743.s8", "pair_id": "DDI-DrugBank.d743.s8.p12"} {"sentence": "Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ", "drug1": "Salicylate", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Salsalate.xml", "sentence_id": "DDI-DrugBank.d576.s6", "pair_id": "DDI-DrugBank.d576.s6.p4"} {"sentence": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ", "drug1": "rifampin", "drug2": "methylprednisolone", "relation": "ADVISE", "source_file": "Methylprednisolone.xml", "sentence_id": "DDI-DrugBank.d578.s4", "pair_id": "DDI-DrugBank.d578.s4.p8"} {"sentence": "Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ", "drug1": "quinidine", "drug2": "cephalosporins", "relation": "NONE", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s6", "pair_id": "DDI-DrugBank.d737.s6.p57"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "MIVACRON", "drug2": "magnesium", "relation": "INT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p24"} {"sentence": "Live Vaccines: During treatment with Myfortic, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective. ", "drug1": "Myfortic", "drug2": "live attenuated vaccines", "relation": "ADVISE", "source_file": "Mycophenolic acid.xml", "sentence_id": "DDI-DrugBank.d700.s12", "pair_id": "DDI-DrugBank.d700.s12.p2"} {"sentence": "Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ", "drug1": "morphine", "drug2": "CNS depressants", "relation": "EFFECT", "source_file": "Morphine.xml", "sentence_id": "DDI-DrugBank.d637.s0", "pair_id": "DDI-DrugBank.d637.s0.p6"} {"sentence": "The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics. ", "drug1": "metoclopramide", "drug2": "narcotic analgesics", "relation": "EFFECT", "source_file": "Metoclopramide.xml", "sentence_id": "DDI-DrugBank.d652.s0", "pair_id": "DDI-DrugBank.d652.s0.p1"} {"sentence": "Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. ", "drug1": "ketoconazole", "drug2": "trimetrexate", "relation": "MECHANISM", "source_file": "Trimetrexate.xml", "sentence_id": "DDI-DrugBank.d766.s3", "pair_id": "DDI-DrugBank.d766.s3.p8"} {"sentence": "Caution should be exercised when Methergine (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.", "drug1": "methylergonovine maleate", "drug2": "vasoconstrictors", "relation": "ADVISE", "source_file": "Methylergonovine.xml", "sentence_id": "DDI-DrugBank.d675.s7", "pair_id": "DDI-DrugBank.d675.s7.p3"} {"sentence": "Trimethoprim may inhibit the hepatic metabolism of phenytoin. ", "drug1": "Trimethoprim", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Trimethoprim.xml", "sentence_id": "DDI-DrugBank.d598.s0", "pair_id": "DDI-DrugBank.d598.s0.p0"} {"sentence": "Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. ", "drug1": "Thiazide diuretics", "drug2": "phenothiazines", "relation": "EFFECT", "source_file": "Prochlorperazine.xml", "sentence_id": "DDI-DrugBank.d734.s0", "pair_id": "DDI-DrugBank.d734.s0.p0"} {"sentence": "Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ", "drug1": "diazepam", "drug2": "phenytoin", "relation": "NONE", "source_file": "Pantoprazole.xml", "sentence_id": "DDI-DrugBank.d680.s1", "pair_id": "DDI-DrugBank.d680.s1.p141"} {"sentence": "Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ", "drug1": "Vasopressors", "drug2": "halothane", "relation": "EFFECT", "source_file": "Phenylephrine.xml", "sentence_id": "DDI-DrugBank.d725.s0", "pair_id": "DDI-DrugBank.d725.s0.p1"} {"sentence": "- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ", "drug1": "Cisapride", "drug2": "pimozide", "relation": "NONE", "source_file": "Roxithromycin.xml", "sentence_id": "DDI-DrugBank.d709.s4", "pair_id": "DDI-DrugBank.d709.s4.p2"} {"sentence": "Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ", "drug1": "SUTENT", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Sunitinib.xml", "sentence_id": "DDI-DrugBank.d639.s2", "pair_id": "DDI-DrugBank.d639.s2.p1"} {"sentence": "You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ", "drug1": "mazindol", "drug2": "tranylcypromine", "relation": "ADVISE", "source_file": "Mazindol.xml", "sentence_id": "DDI-DrugBank.d716.s0", "pair_id": "DDI-DrugBank.d716.s0.p4"} {"sentence": "ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ", "drug1": "ProAmatine", "drug2": "metformin", "relation": "NONE", "source_file": "Midodrine.xml", "sentence_id": "DDI-DrugBank.d603.s5", "pair_id": "DDI-DrugBank.d603.s5.p56"} {"sentence": "Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ", "drug1": "sucralfate", "drug2": "gelusil", "relation": "NONE", "source_file": "21715267.xml", "sentence_id": "DDI-MedLine.d231.s3", "pair_id": "DDI-MedLine.d231.s3.p9"} {"sentence": "The action of Mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.", "drug1": "antihypertensive drugs", "drug2": "alcohol", "relation": "NONE", "source_file": "Mecamylamine.xml", "sentence_id": "DDI-DrugBank.d579.s1", "pair_id": "DDI-DrugBank.d579.s1.p2"} {"sentence": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ", "drug1": "phenytoin", "drug2": "methylprednisolone", "relation": "ADVISE", "source_file": "Methylprednisolone.xml", "sentence_id": "DDI-DrugBank.d578.s4", "pair_id": "DDI-DrugBank.d578.s4.p6"} {"sentence": "Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.", "drug1": "aspirin", "drug2": "carbonic anhydrase inhibitors", "relation": "EFFECT", "source_file": "Methazolamide.xml", "sentence_id": "DDI-DrugBank.d630.s1", "pair_id": "DDI-DrugBank.d630.s1.p5"} {"sentence": "This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. ", "drug1": "S-ketamine", "drug2": "ticlopidine", "relation": "NONE", "source_file": "21716267.xml", "sentence_id": "DDI-MedLine.d216.s1", "pair_id": "DDI-MedLine.d216.s1.p0"} {"sentence": "Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.", "drug1": "Sympathomimetics", "drug2": "methyldopa", "relation": "EFFECT", "source_file": "Pseudoephedrine.xml", "sentence_id": "DDI-DrugBank.d606.s1", "pair_id": "DDI-DrugBank.d606.s1.p0"} {"sentence": "Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). ", "drug1": "pantoprazole", "drug2": "ampicillin", "relation": "MECHANISM", "source_file": "Pantoprazole.xml", "sentence_id": "DDI-DrugBank.d680.s8", "pair_id": "DDI-DrugBank.d680.s8.p1"} {"sentence": "We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.", "drug1": "dexmedetomidine", "drug2": "ephedrine", "relation": "EFFECT", "source_file": "21876510.xml", "sentence_id": "DDI-MedLine.d227.s9", "pair_id": "DDI-MedLine.d227.s9.p0"} {"sentence": "Live Vaccines: During treatment with Myfortic, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective. ", "drug1": "Live Vaccines", "drug2": "Myfortic", "relation": "NONE", "source_file": "Mycophenolic acid.xml", "sentence_id": "DDI-DrugBank.d700.s12", "pair_id": "DDI-DrugBank.d700.s12.p0"} {"sentence": "ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ", "drug1": "ProAmatine", "drug2": "doxazosin", "relation": "NONE", "source_file": "Midodrine.xml", "sentence_id": "DDI-DrugBank.d603.s5", "pair_id": "DDI-DrugBank.d603.s5.p3"} {"sentence": "Combination therapy with Cerezyme (imiglucerase) and ZAVESCA is not indicated.", "drug1": "imiglucerase", "drug2": "ZAVESCA", "relation": "ADVISE", "source_file": "Miglustat.xml", "sentence_id": "DDI-DrugBank.d695.s1", "pair_id": "DDI-DrugBank.d695.s1.p2"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "linezolid", "drug2": "pectin", "relation": "NONE", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p113"} {"sentence": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "drug1": "Lomefloxacin", "drug2": "gelusil", "relation": "MECHANISM", "source_file": "21715267.xml", "sentence_id": "DDI-MedLine.d231.s8", "pair_id": "DDI-MedLine.d231.s8.p6"} {"sentence": "Patients may require reduced doses of anesthetics when on methyldopa. ", "drug1": "anesthetics", "drug2": "methyldopa", "relation": "ADVISE", "source_file": "Methyldopa.xml", "sentence_id": "DDI-DrugBank.d779.s2", "pair_id": "DDI-DrugBank.d779.s2.p0"} {"sentence": "Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided. ", "drug1": "clopidogrel", "drug2": "esomeprazole", "relation": "ADVISE", "source_file": "21771377.xml", "sentence_id": "DDI-MedLine.d143.s6", "pair_id": "DDI-MedLine.d143.s6.p1"} {"sentence": "Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ", "drug1": "digoxin", "drug2": "procainamide", "relation": "NONE", "source_file": "Trospium.xml", "sentence_id": "DDI-DrugBank.d713.s2", "pair_id": "DDI-DrugBank.d713.s2.p15"} {"sentence": "The combined use of fluconazole at doses of 400 mg or greater with terfenadine is contraindicated. ", "drug1": "fluconazole", "drug2": "terfenadine", "relation": "ADVISE", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s23", "pair_id": "DDI-DrugBank.d776.s23.p0"} {"sentence": "When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). ", "drug1": "rimantadine HCl", "drug2": "Cimetidine", "relation": "MECHANISM", "source_file": "Rimantadine.xml", "sentence_id": "DDI-DrugBank.d710.s1", "pair_id": "DDI-DrugBank.d710.s1.p0"} {"sentence": "XENICAL inhibited absorption of a vitamin E acetate supplement by approximately 60%. ", "drug1": "XENICAL", "drug2": "vitamin E acetate", "relation": "MECHANISM", "source_file": "Orlistat.xml", "sentence_id": "DDI-DrugBank.d761.s4", "pair_id": "DDI-DrugBank.d761.s4.p0"} {"sentence": "It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ", "drug1": "tamoxifen", "drug2": "fluoxetine", "relation": "ADVISE", "source_file": "21751753.xml", "sentence_id": "DDI-MedLine.d209.s9", "pair_id": "DDI-MedLine.d209.s9.p2"} {"sentence": "Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous melphalan and who subsequently received cyclosporin to prevent graft-versus-host disease", "drug1": "melphalan", "drug2": "cyclosporin", "relation": "EFFECT", "source_file": "Melphalan.xml", "sentence_id": "DDI-DrugBank.d625.s1", "pair_id": "DDI-DrugBank.d625.s1.p0"} {"sentence": "In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. ", "drug1": "tolbutamide", "drug2": "cyclosporine", "relation": "NONE", "source_file": "Terbinafine.xml", "sentence_id": "DDI-DrugBank.d645.s0", "pair_id": "DDI-DrugBank.d645.s0.p6"} {"sentence": "While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ", "drug1": "fluconazole", "drug2": "ethinyl estradiol", "relation": "MECHANISM", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s41", "pair_id": "DDI-DrugBank.d776.s41.p0"} {"sentence": "CNS depressant medications: Concurrent use of procaine hydrochloride and CNS depressant medications may result in additive depressant effects. ", "drug1": "procaine hydrochloride", "drug2": "CNS depressant medications", "relation": "EFFECT", "source_file": "Procaine.xml", "sentence_id": "DDI-DrugBank.d780.s4", "pair_id": "DDI-DrugBank.d780.s4.p2"} {"sentence": "Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.", "drug1": "acetylcholine chloride", "drug2": "Miochol", "relation": "NONE", "source_file": "Suprofen.xml", "sentence_id": "DDI-DrugBank.d723.s0", "pair_id": "DDI-DrugBank.d723.s0.p0"} {"sentence": "Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ", "drug1": "naproxen", "drug2": "metoprolol", "relation": "NONE", "source_file": "Pantoprazole.xml", "sentence_id": "DDI-DrugBank.d680.s1", "pair_id": "DDI-DrugBank.d680.s1.p187"} {"sentence": "TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. ", "drug1": "nonsteroidal anti-inflammatory drugs", "drug2": "methotrexate", "relation": "MECHANISM", "source_file": "Tolmetin.xml", "sentence_id": "DDI-DrugBank.d608.s5", "pair_id": "DDI-DrugBank.d608.s5.p3"} {"sentence": "During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). ", "drug1": "DIPRIVAN", "drug2": "nitrous oxide", "relation": "ADVISE", "source_file": "Propofol.xml", "sentence_id": "DDI-DrugBank.d628.s3", "pair_id": "DDI-DrugBank.d628.s3.p1"} {"sentence": "ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ", "drug1": "Alpha-adrenergic blocking agents", "drug2": "quinidine", "relation": "NONE", "source_file": "Midodrine.xml", "sentence_id": "DDI-DrugBank.d603.s5", "pair_id": "DDI-DrugBank.d603.s5.p24"} {"sentence": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "drug1": "saquinavir", "drug2": "voriconazole", "relation": "NONE", "source_file": "Paricalcitol.xml", "sentence_id": "DDI-DrugBank.d726.s1", "pair_id": "DDI-DrugBank.d726.s1.p118"} {"sentence": "Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.", "drug1": "Mephenytoin", "drug2": "steroid medications", "relation": "EFFECT", "source_file": "Mephenytoin.xml", "sentence_id": "DDI-DrugBank.d636.s3", "pair_id": "DDI-DrugBank.d636.s3.p0"} {"sentence": "Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.", "drug1": "Carboptic", "drug2": "suprofen", "relation": "EFFECT", "source_file": "Suprofen.xml", "sentence_id": "DDI-DrugBank.d723.s0", "pair_id": "DDI-DrugBank.d723.s0.p13"} {"sentence": "Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ", "drug1": "metoclopramide", "drug2": "sedatives", "relation": "EFFECT", "source_file": "Metoclopramide.xml", "sentence_id": "DDI-DrugBank.d652.s1", "pair_id": "DDI-DrugBank.d652.s1.p1"} {"sentence": "ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ", "drug1": "desglymidodrine", "drug2": "quinidine", "relation": "MECHANISM", "source_file": "Midodrine.xml", "sentence_id": "DDI-DrugBank.d603.s5", "pair_id": "DDI-DrugBank.d603.s5.p69"} {"sentence": "Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with ketoconazole, a potent CYP3A4 inhibitor. ", "drug1": "DITROPAN XL", "drug2": "ketoconazole", "relation": "MECHANISM", "source_file": "Oxybutynin.xml", "sentence_id": "DDI-DrugBank.d784.s3", "pair_id": "DDI-DrugBank.d784.s3.p2"} {"sentence": "Physicians should carefully monitor PT and INR in patients concurrently administered ZOLINZA and coumarin derivatives. ", "drug1": "ZOLINZA", "drug2": "coumarin derivatives", "relation": "ADVISE", "source_file": "Vorinostat.xml", "sentence_id": "DDI-DrugBank.d769.s1", "pair_id": "DDI-DrugBank.d769.s1.p0"} {"sentence": "Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL. ", "drug1": "tricyclic antidepressants", "drug2": "ELDEPRYL", "relation": "EFFECT", "source_file": "Selegiline.xml", "sentence_id": "DDI-DrugBank.d619.s4", "pair_id": "DDI-DrugBank.d619.s4.p0"} {"sentence": "The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ", "drug1": "meperidine", "drug2": "nitrous oxide", "relation": "NONE", "source_file": "Midazolam.xml", "sentence_id": "DDI-DrugBank.d752.s10", "pair_id": "DDI-DrugBank.d752.s10.p27"} {"sentence": "Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ", "drug1": "Phenothiazines", "drug2": "anesthetics", "relation": "EFFECT", "source_file": "Thiethylperazine.xml", "sentence_id": "DDI-DrugBank.d677.s0", "pair_id": "DDI-DrugBank.d677.s0.p2"} {"sentence": "Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ", "drug1": "paroxetine", "drug2": "sumatriptan", "relation": "EFFECT", "source_file": "Sumatriptan.xml", "sentence_id": "DDI-DrugBank.d720.s3", "pair_id": "DDI-DrugBank.d720.s3.p34"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "kaolin", "drug2": "chlorpromazine", "relation": "NONE", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p245"} {"sentence": "A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ", "drug1": "sirolimus", "drug2": "ritonavir", "relation": "NONE", "source_file": "Micafungin.xml", "sentence_id": "DDI-DrugBank.d735.s0", "pair_id": "DDI-DrugBank.d735.s0.p37"} {"sentence": "The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ", "drug1": "ticagrelor", "drug2": "antiplatelet drug", "relation": "NONE", "source_file": "21897348.xml", "sentence_id": "DDI-MedLine.d193.s1", "pair_id": "DDI-MedLine.d193.s1.p1"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "nondepolarizing agents", "drug2": "lincomycin", "relation": "INT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p6"} {"sentence": "It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast. ", "drug1": "rifampin", "drug2": "montelukast", "relation": "ADVISE", "source_file": "Montelukast.xml", "sentence_id": "DDI-DrugBank.d739.s8", "pair_id": "DDI-DrugBank.d739.s8.p2"} {"sentence": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "drug1": "paricalcitol", "drug2": "ritonavir", "relation": "ADVISE", "source_file": "Paricalcitol.xml", "sentence_id": "DDI-DrugBank.d726.s1", "pair_id": "DDI-DrugBank.d726.s1.p61"} {"sentence": "Given the primary CNS effects of paliperidone, INVEGA should be used with caution in combination with other centrally acting drugs and alcohol. ", "drug1": "paliperidone", "drug2": "centrally acting drugs", "relation": "ADVISE", "source_file": "Paliperidone.xml", "sentence_id": "DDI-DrugBank.d670.s6", "pair_id": "DDI-DrugBank.d670.s6.p1"} {"sentence": "Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ", "drug1": "tricyclic antidepressant", "drug2": "tyramine", "relation": "NONE", "source_file": "Procarbazine.xml", "sentence_id": "DDI-DrugBank.d676.s2", "pair_id": "DDI-DrugBank.d676.s2.p11"} {"sentence": "Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%. ", "drug1": "Trimethoprim", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Trimethoprim.xml", "sentence_id": "DDI-DrugBank.d598.s1", "pair_id": "DDI-DrugBank.d598.s1.p1"} {"sentence": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ", "drug1": "phenobarbital", "drug2": "methylprednisolone", "relation": "MECHANISM", "source_file": "Methylprednisolone.xml", "sentence_id": "DDI-DrugBank.d578.s4", "pair_id": "DDI-DrugBank.d578.s4.p2"} {"sentence": "A study published in 2002 found that vigabatrin causes a statistically significant increase in plasma clearance of carbamazepine. ", "drug1": "vigabatrin", "drug2": "carbamazepine", "relation": "MECHANISM", "source_file": "Vigabatrin.xml", "sentence_id": "DDI-DrugBank.d613.s0", "pair_id": "DDI-DrugBank.d613.s0.p0"} {"sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.", "drug1": "Barbiturates", "drug2": "quinidine", "relation": "INT", "source_file": "Secobarbital.xml", "sentence_id": "DDI-DrugBank.d601.s0", "pair_id": "DDI-DrugBank.d601.s0.p2"} {"sentence": "Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ", "drug1": "SUTENT", "drug2": "nelfinavir", "relation": "MECHANISM", "source_file": "Sunitinib.xml", "sentence_id": "DDI-DrugBank.d639.s0", "pair_id": "DDI-DrugBank.d639.s0.p6"} {"sentence": "The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see", "drug1": "aspirin", "drug2": "aspirin", "relation": "NONE", "source_file": "Tirofiban.xml", "sentence_id": "DDI-DrugBank.d751.s1", "pair_id": "DDI-DrugBank.d751.s1.p8"} {"sentence": "In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. ", "drug1": "sulfonylureas", "drug2": "TOLECTIN", "relation": "NONE", "source_file": "Tolmetin.xml", "sentence_id": "DDI-DrugBank.d608.s3", "pair_id": "DDI-DrugBank.d608.s3.p1"} {"sentence": "Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.", "drug1": "Beta adrenergic agonists", "drug2": "tricyclic antidepressants", "relation": "ADVISE", "source_file": "Orciprenaline.xml", "sentence_id": "DDI-DrugBank.d611.s1", "pair_id": "DDI-DrugBank.d611.s1.p1"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "Methscopolamine", "drug2": "phenothiazines", "relation": "INT", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p19"} {"sentence": "Cholestyramine: Pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50%. ", "drug1": "cholestyramine", "drug2": "meloxicam", "relation": "MECHANISM", "source_file": "Meloxicam.xml", "sentence_id": "DDI-DrugBank.d597.s7", "pair_id": "DDI-DrugBank.d597.s7.p2"} {"sentence": "Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ", "drug1": "Streptase", "drug2": "antiplatelet agents", "relation": "EFFECT", "source_file": "Streptokinase.xml", "sentence_id": "DDI-DrugBank.d777.s1", "pair_id": "DDI-DrugBank.d777.s1.p10"} {"sentence": "Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.", "drug1": "Mephenytoin", "drug2": "furosemide", "relation": "EFFECT", "source_file": "Mephenytoin.xml", "sentence_id": "DDI-DrugBank.d636.s3", "pair_id": "DDI-DrugBank.d636.s3.p3"} {"sentence": "From this study it can be concluded that piperine can be used as a bioenhancer along with ibuprofen.", "drug1": "piperine", "drug2": "ibuprofen", "relation": "EFFECT", "source_file": "22029226.xml", "sentence_id": "DDI-MedLine.d195.s7", "pair_id": "DDI-MedLine.d195.s7.p0"} {"sentence": "Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ", "drug1": "amphetamine", "drug2": "quinpirole", "relation": "NONE", "source_file": "21753255.xml", "sentence_id": "DDI-MedLine.d184.s8", "pair_id": "DDI-MedLine.d184.s8.p4"} {"sentence": "Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants", "drug1": "carbamazepine", "drug2": "anesthetics", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s13", "pair_id": "DDI-DrugBank.d775.s13.p31"} {"sentence": "however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects. ", "drug1": "meloxicam", "drug2": "aspirin", "relation": "ADVISE", "source_file": "Meloxicam.xml", "sentence_id": "DDI-DrugBank.d597.s4", "pair_id": "DDI-DrugBank.d597.s4.p2"} {"sentence": "Increases of 5-FU plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 ELOXATIN dosed every 3 weeks. ", "drug1": "5-FU", "drug2": "ELOXATIN", "relation": "MECHANISM", "source_file": "Oxaliplatin.xml", "sentence_id": "DDI-DrugBank.d728.s2", "pair_id": "DDI-DrugBank.d728.s2.p0"} {"sentence": "Synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.", "drug1": "methylglyoxal", "drug2": "carbenicillin", "relation": "EFFECT", "source_file": "21800506.xml", "sentence_id": "DDI-MedLine.d204.s11", "pair_id": "DDI-MedLine.d204.s11.p0"} {"sentence": "While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.", "drug1": "calcium", "drug2": "levothyroxine sodium", "relation": "NONE", "source_file": "Pilocarpine.xml", "sentence_id": "DDI-DrugBank.d627.s4", "pair_id": "DDI-DrugBank.d627.s4.p15"} {"sentence": "Streptozocin has been reported to prolong the elimination half-life of doxorubicin and may lead to severe bone marrow suppression; ", "drug1": "Streptozocin", "drug2": "doxorubicin", "relation": "MECHANISM", "source_file": "Streptozocin.xml", "sentence_id": "DDI-DrugBank.d647.s1", "pair_id": "DDI-DrugBank.d647.s1.p0"} {"sentence": "Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ", "drug1": "Permax", "drug2": "dopamine agonist", "relation": "NONE", "source_file": "Pergolide.xml", "sentence_id": "DDI-DrugBank.d650.s0", "pair_id": "DDI-DrugBank.d650.s0.p27"} {"sentence": "Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ", "drug1": "vitamin K antagonists", "drug2": "TNKase", "relation": "EFFECT", "source_file": "Tenecteplase.xml", "sentence_id": "DDI-DrugBank.d773.s2", "pair_id": "DDI-DrugBank.d773.s2.p11"} {"sentence": "There are no clinical data on the use of MIVACRON with other nondepolarizing neuromuscular blocking agents. ", "drug1": "MIVACRON", "drug2": "nondepolarizing neuromuscular blocking agents", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s4", "pair_id": "DDI-DrugBank.d775.s4.p0"} {"sentence": "The rate and extent of perindopril absorption and elimination are not affected by concomitant diuretics. ", "drug1": "perindopril", "drug2": "diuretics", "relation": "NONE", "source_file": "Perindopril.xml", "sentence_id": "DDI-DrugBank.d781.s3", "pair_id": "DDI-DrugBank.d781.s3.p0"} {"sentence": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ", "drug1": "macrolide antibiotics", "drug2": "vinblastine", "relation": "NONE", "source_file": "Tolterodine.xml", "sentence_id": "DDI-DrugBank.d765.s1", "pair_id": "DDI-DrugBank.d765.s1.p33"} {"sentence": "In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase therapy.", "drug1": "heparin", "drug2": "Retavase", "relation": "EFFECT", "source_file": "Reteplase.xml", "sentence_id": "DDI-DrugBank.d618.s1", "pair_id": "DDI-DrugBank.d618.s1.p4"} {"sentence": "Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.", "drug1": "Sympathomimetics", "drug2": "reserpine", "relation": "EFFECT", "source_file": "Pseudoephedrine.xml", "sentence_id": "DDI-DrugBank.d606.s1", "pair_id": "DDI-DrugBank.d606.s1.p2"} {"sentence": "Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ", "drug1": "dipyridamole", "drug2": "TNKase", "relation": "EFFECT", "source_file": "Tenecteplase.xml", "sentence_id": "DDI-DrugBank.d773.s2", "pair_id": "DDI-DrugBank.d773.s2.p14"} {"sentence": "Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.", "drug1": "bacitracin", "drug2": "polymyxin B", "relation": "NONE", "source_file": "Vancomycin.xml", "sentence_id": "DDI-DrugBank.d669.s1", "pair_id": "DDI-DrugBank.d669.s1.p11"} {"sentence": "Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ", "drug1": "Fluconazole", "drug2": "ethinyl estradiol", "relation": "MECHANISM", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s38", "pair_id": "DDI-DrugBank.d776.s38.p0"} {"sentence": "Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ", "drug1": "penicillins", "drug2": "phenytoin", "relation": "NONE", "source_file": "Thalidomide.xml", "sentence_id": "DDI-DrugBank.d604.s4", "pair_id": "DDI-DrugBank.d604.s4.p37"} {"sentence": "Aspirin: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam. ", "drug1": "aspirin", "drug2": "meloxicam", "relation": "MECHANISM", "source_file": "Meloxicam.xml", "sentence_id": "DDI-DrugBank.d597.s2", "pair_id": "DDI-DrugBank.d597.s2.p2"} {"sentence": "Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. ", "drug1": "Terbinafine", "drug2": "rifampin", "relation": "MECHANISM", "source_file": "Terbinafine.xml", "sentence_id": "DDI-DrugBank.d645.s7", "pair_id": "DDI-DrugBank.d645.s7.p0"} {"sentence": "Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ", "drug1": "SUTENT", "drug2": "carbamazepine", "relation": "MECHANISM", "source_file": "Sunitinib.xml", "sentence_id": "DDI-DrugBank.d639.s2", "pair_id": "DDI-DrugBank.d639.s2.p2"} {"sentence": "Although ibuprofen (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance 80 mL/min), caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). ", "drug1": "ibuprofen", "drug2": "ALIMTA", "relation": "ADVISE", "source_file": "Pemetrexed.xml", "sentence_id": "DDI-DrugBank.d641.s3", "pair_id": "DDI-DrugBank.d641.s3.p5"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "MIVACRON", "drug2": "procainamide", "relation": "INT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p27"} {"sentence": "Mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin. ", "drug1": "Mitotane", "drug2": "warfarin", "relation": "NONE", "source_file": "Mitotane.xml", "sentence_id": "DDI-DrugBank.d717.s0", "pair_id": "DDI-DrugBank.d717.s0.p1"} {"sentence": "Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ", "drug1": "Sanctura", "drug2": "pancuronium", "relation": "MECHANISM", "source_file": "Trospium.xml", "sentence_id": "DDI-DrugBank.d713.s2", "pair_id": "DDI-DrugBank.d713.s2.p10"} {"sentence": "Given the primary CNS effects of paliperidone, INVEGA should be used with caution in combination with other centrally acting drugs and alcohol. ", "drug1": "INVEGA", "drug2": "centrally acting drugs", "relation": "ADVISE", "source_file": "Paliperidone.xml", "sentence_id": "DDI-DrugBank.d670.s6", "pair_id": "DDI-DrugBank.d670.s6.p3"} {"sentence": "In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy. ", "drug1": "vigabatrin", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Vigabatrin.xml", "sentence_id": "DDI-DrugBank.d613.s1", "pair_id": "DDI-DrugBank.d613.s1.p0"} {"sentence": "Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ", "drug1": "thioxanthines", "drug2": "Permax", "relation": "ADVISE", "source_file": "Pergolide.xml", "sentence_id": "DDI-DrugBank.d650.s0", "pair_id": "DDI-DrugBank.d650.s0.p23"} {"sentence": "requirements for riboflavin may be increased in patients receiving probenecid.", "drug1": "riboflavin", "drug2": "probenecid", "relation": "EFFECT", "source_file": "Riboflavin.xml", "sentence_id": "DDI-DrugBank.d698.s2", "pair_id": "DDI-DrugBank.d698.s2.p0"} {"sentence": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ", "drug1": "rifampin", "drug2": "corticosteroids", "relation": "MECHANISM", "source_file": "Prednisone.xml", "sentence_id": "DDI-DrugBank.d653.s1", "pair_id": "DDI-DrugBank.d653.s1.p7"} {"sentence": "The preclinical combination of lenalidomide with the mTOR inhibitor CCI-779 has displayed synergy in vitro and represents a novel combination in MM.", "drug1": "lenalidomide", "drug2": "CCI-779", "relation": "EFFECT", "source_file": "21825263.xml", "sentence_id": "DDI-MedLine.d211.s2", "pair_id": "DDI-MedLine.d211.s2.p0"} {"sentence": "These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ", "drug1": "GH", "drug2": "cyclosporin", "relation": "MECHANISM", "source_file": "Somatropin recombinant.xml", "sentence_id": "DDI-DrugBank.d599.s7", "pair_id": "DDI-DrugBank.d599.s7.p3"} {"sentence": "Sulfonamides: Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide. ", "drug1": "procaine hydrochloride", "drug2": "sulfonamides", "relation": "EFFECT", "source_file": "Procaine.xml", "sentence_id": "DDI-DrugBank.d780.s7", "pair_id": "DDI-DrugBank.d780.s7.p3"} {"sentence": "The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. ", "drug1": "atropine", "drug2": "triprolidine", "relation": "EFFECT", "source_file": "Triprolidine.xml", "sentence_id": "DDI-DrugBank.d615.s1", "pair_id": "DDI-DrugBank.d615.s1.p4"} {"sentence": "Therefore, it is recommended that oral contraceptives are co- administered with Myfortic with caution and additional birth control methods be considered. ", "drug1": "contraceptives", "drug2": "Myfortic", "relation": "ADVISE", "source_file": "Mycophenolic acid.xml", "sentence_id": "DDI-DrugBank.d700.s11", "pair_id": "DDI-DrugBank.d700.s11.p0"} {"sentence": "Aminoglutethimide administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of MPA. ", "drug1": "Aminoglutethimide", "drug2": "depo-subQ provera 104", "relation": "MECHANISM", "source_file": "Medroxyprogesterone.xml", "sentence_id": "DDI-DrugBank.d623.s1", "pair_id": "DDI-DrugBank.d623.s1.p0"} {"sentence": "The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ", "drug1": "MIVACRON", "drug2": "carbamazepine", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s11", "pair_id": "DDI-DrugBank.d775.s11.p5"} {"sentence": "Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ", "drug1": "potassium-sparing diuretics", "drug2": "potassium", "relation": "NONE", "source_file": "Perindopril.xml", "sentence_id": "DDI-DrugBank.d781.s6", "pair_id": "DDI-DrugBank.d781.s6.p3"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "aminoglycosides", "drug2": "lincomycin", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p45"} {"sentence": "Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ", "drug1": "Phenothiazines", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Thiethylperazine.xml", "sentence_id": "DDI-DrugBank.d677.s0", "pair_id": "DDI-DrugBank.d677.s0.p4"} {"sentence": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ", "drug1": "ketoconazole", "drug2": "erythromycin", "relation": "NONE", "source_file": "Tolterodine.xml", "sentence_id": "DDI-DrugBank.d765.s1", "pair_id": "DDI-DrugBank.d765.s1.p4"} {"sentence": "Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.", "drug1": "paclitaxel", "drug2": "HERCEPTIN", "relation": "MECHANISM", "source_file": "Trastuzumab.xml", "sentence_id": "DDI-DrugBank.d712.s1", "pair_id": "DDI-DrugBank.d712.s1.p0"} {"sentence": "Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. ", "drug1": "Caffeine", "drug2": "levomepromazine", "relation": "EFFECT", "source_file": "Methotrimeprazine.xml", "sentence_id": "DDI-DrugBank.d756.s7", "pair_id": "DDI-DrugBank.d756.s7.p2"} {"sentence": "ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ", "drug1": "terazosin", "drug2": "ProAmatine", "relation": "EFFECT", "source_file": "Midodrine.xml", "sentence_id": "DDI-DrugBank.d603.s5", "pair_id": "DDI-DrugBank.d603.s5.p37"} {"sentence": "Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ", "drug1": "azole-type antifungal agents", "drug2": "terfenadine", "relation": "ADVISE", "source_file": "Terfenadine.xml", "sentence_id": "DDI-DrugBank.d743.s8", "pair_id": "DDI-DrugBank.d743.s8.p5"} {"sentence": "This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn. ", "drug1": "salicylate", "drug2": "corticosteroid", "relation": "EFFECT", "source_file": "Prednisone.xml", "sentence_id": "DDI-DrugBank.d653.s5", "pair_id": "DDI-DrugBank.d653.s5.p2"} {"sentence": "The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. ", "drug1": "tetracycline", "drug2": "methoxyflurane", "relation": "EFFECT", "source_file": "Minocycline.xml", "sentence_id": "DDI-DrugBank.d711.s3", "pair_id": "DDI-DrugBank.d711.s3.p0"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "Methscopolamine", "drug2": "isocarboxazid", "relation": "INT", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p6"} {"sentence": "Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing and anaphylactoid reactions. ", "drug1": "vancomycin", "drug2": "anesthetic agents", "relation": "EFFECT", "source_file": "Vancomycin.xml", "sentence_id": "DDI-DrugBank.d669.s0", "pair_id": "DDI-DrugBank.d669.s0.p0"} {"sentence": "Amphetamine locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with quinpirole.\r\n", "drug1": "Amphetamine", "drug2": "quinpirole", "relation": "NONE", "source_file": "21753255.xml", "sentence_id": "DDI-MedLine.d184.s0", "pair_id": "DDI-MedLine.d184.s0.p0"} {"sentence": "Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ", "drug1": "neuroleptics", "drug2": "thioxanthenes", "relation": "NONE", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s10", "pair_id": "DDI-DrugBank.d737.s10.p32"} {"sentence": "Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants", "drug1": "corticosteroids", "drug2": "bacitracin", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s13", "pair_id": "DDI-DrugBank.d775.s13.p7"} {"sentence": "Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ", "drug1": "naproxen", "drug2": "methotrexate", "relation": "NONE", "source_file": "Salsalate.xml", "sentence_id": "DDI-DrugBank.d576.s6", "pair_id": "DDI-DrugBank.d576.s6.p50"} {"sentence": "Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ", "drug1": "rifampicin", "drug2": "ondansetron", "relation": "MECHANISM", "source_file": "Ondansetron.xml", "sentence_id": "DDI-DrugBank.d763.s3", "pair_id": "DDI-DrugBank.d763.s3.p26"} {"sentence": "Zidovudine competitively inhibits the intracellular phosphorylation of stavudine. ", "drug1": "Zidovudine", "drug2": "stavudine", "relation": "EFFECT", "source_file": "Stavudine.xml", "sentence_id": "DDI-DrugBank.d727.s0", "pair_id": "DDI-DrugBank.d727.s0.p0"} {"sentence": "Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ", "drug1": "Warfarin", "drug2": "amitriptyline", "relation": "EFFECT", "source_file": "21731754.xml", "sentence_id": "DDI-MedLine.d218.s10", "pair_id": "DDI-MedLine.d218.s10.p3"} {"sentence": "Anticholinergic drugs may antagonize the effects of drugs that alter gastrointestinal motility, such as metoclopramide. ", "drug1": "Anticholinergic drugs", "drug2": "metoclopramide", "relation": "EFFECT", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s5", "pair_id": "DDI-DrugBank.d585.s5.p0"} {"sentence": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ", "drug1": "phenytoin", "drug2": "corticosteroids", "relation": "MECHANISM", "source_file": "Prednisone.xml", "sentence_id": "DDI-DrugBank.d653.s1", "pair_id": "DDI-DrugBank.d653.s1.p5"} {"sentence": "Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.", "drug1": "contraceptives", "drug2": "contraceptives", "relation": "NONE", "source_file": "Minocycline.xml", "sentence_id": "DDI-DrugBank.d711.s4", "pair_id": "DDI-DrugBank.d711.s4.p2"} {"sentence": "The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ", "drug1": "sedatives", "drug2": "monoamine oxidase (MAO) inhibitors", "relation": "NONE", "source_file": "Oxymorphone.xml", "sentence_id": "DDI-DrugBank.d753.s0", "pair_id": "DDI-DrugBank.d753.s0.p15"} {"sentence": "While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.", "drug1": "multivitamins", "drug2": "naproxen", "relation": "NONE", "source_file": "Pilocarpine.xml", "sentence_id": "DDI-DrugBank.d627.s4", "pair_id": "DDI-DrugBank.d627.s4.p68"} {"sentence": "However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ", "drug1": "ondansetron", "drug2": "tramadol", "relation": "EFFECT", "source_file": "Ondansetron.xml", "sentence_id": "DDI-DrugBank.d763.s4", "pair_id": "DDI-DrugBank.d763.s4.p18"} {"sentence": "HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ", "drug1": "HMG-CoA reductase inhibitors", "drug2": "simvastatin", "relation": "NONE", "source_file": "Ezetimibe.xml", "sentence_id": "DDI-DrugBank.d572.s8", "pair_id": "DDI-DrugBank.d572.s8.p2"} {"sentence": "2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions; ", "drug1": "barbiturates", "drug2": "anticholinesterases", "relation": "EFFECT", "source_file": "Pralidoxime.xml", "sentence_id": "DDI-DrugBank.d622.s2", "pair_id": "DDI-DrugBank.d622.s2.p2"} {"sentence": "The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with perindopril. ", "drug1": "diuretic", "drug2": "perindopril", "relation": "EFFECT", "source_file": "Perindopril.xml", "sentence_id": "DDI-DrugBank.d781.s1", "pair_id": "DDI-DrugBank.d781.s1.p0"} {"sentence": "Careful monitoring of serum theophylline concentrations in patients receiving DIFLUCAN and theophylline is recommended. ", "drug1": "DIFLUCAN", "drug2": "theophylline", "relation": "ADVISE", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s19", "pair_id": "DDI-DrugBank.d776.s19.p2"} {"sentence": "Fat-soluble Vitamin Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with XENICAL. ", "drug1": "Fat-soluble Vitamin Supplements", "drug2": "XENICAL", "relation": "NONE", "source_file": "Orlistat.xml", "sentence_id": "DDI-DrugBank.d761.s3", "pair_id": "DDI-DrugBank.d761.s3.p1"} {"sentence": "Penicillin blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins. ", "drug1": "Penicillin", "drug2": "probenecid", "relation": "MECHANISM", "source_file": "Penicillin G.xml", "sentence_id": "DDI-DrugBank.d665.s6", "pair_id": "DDI-DrugBank.d665.s6.p0"} {"sentence": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ", "drug1": "HIV protease inhibitors", "drug2": "azole antifungals", "relation": "NONE", "source_file": "Methylergonovine.xml", "sentence_id": "DDI-DrugBank.d675.s2", "pair_id": "DDI-DrugBank.d675.s2.p51"} {"sentence": "ABT decreased the toxicity of precocene I, increased exposure to parent compound, and decreased metabolite levels in a dose-dependent manner. ", "drug1": "ABT", "drug2": "precocene I", "relation": "EFFECT", "source_file": "21741958.xml", "sentence_id": "DDI-MedLine.d189.s7", "pair_id": "DDI-MedLine.d189.s7.p0"} {"sentence": "DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. ", "drug1": "DIFLUCAN", "drug2": "tolbutamide", "relation": "MECHANISM", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s4", "pair_id": "DDI-DrugBank.d776.s4.p0"} {"sentence": "However, the co administration of SPIRIVA with other anticholinergic containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.", "drug1": "SPIRIVA", "drug2": "ipratropium", "relation": "ADVISE", "source_file": "Tiotropium.xml", "sentence_id": "DDI-DrugBank.d702.s2", "pair_id": "DDI-DrugBank.d702.s2.p1"} {"sentence": "The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. ", "drug1": "anticholinergic drugs", "drug2": "triprolidine", "relation": "EFFECT", "source_file": "Triprolidine.xml", "sentence_id": "DDI-DrugBank.d615.s1", "pair_id": "DDI-DrugBank.d615.s1.p2"} {"sentence": "TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. ", "drug1": "TOLECTIN", "drug2": "methotrexate", "relation": "MECHANISM", "source_file": "Tolmetin.xml", "sentence_id": "DDI-DrugBank.d608.s5", "pair_id": "DDI-DrugBank.d608.s5.p1"} {"sentence": "Dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids. ", "drug1": "opioids", "drug2": "levomepromazine", "relation": "EFFECT", "source_file": "Methotrimeprazine.xml", "sentence_id": "DDI-DrugBank.d756.s0", "pair_id": "DDI-DrugBank.d756.s0.p0"} {"sentence": "Therefore, caution should be exercised when administering TOLECTIN to patients on anticoagulants. ", "drug1": "TOLECTIN", "drug2": "anticoagulants", "relation": "ADVISE", "source_file": "Tolmetin.xml", "sentence_id": "DDI-DrugBank.d608.s2", "pair_id": "DDI-DrugBank.d608.s2.p0"} {"sentence": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "drug1": "amitriptyline", "drug2": "nortriptyline", "relation": "NONE", "source_file": "Mazindol.xml", "sentence_id": "DDI-DrugBank.d716.s5", "pair_id": "DDI-DrugBank.d716.s5.p21"} {"sentence": "Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. ", "drug1": "activated charcoal", "drug2": "Myfortic", "relation": "NONE", "source_file": "Mycophenolic acid.xml", "sentence_id": "DDI-DrugBank.d700.s8", "pair_id": "DDI-DrugBank.d700.s8.p5"} {"sentence": "Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. ", "drug1": "imidazole drugs", "drug2": "trimetrexate", "relation": "MECHANISM", "source_file": "Trimetrexate.xml", "sentence_id": "DDI-DrugBank.d766.s3", "pair_id": "DDI-DrugBank.d766.s3.p3"} {"sentence": "Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ", "drug1": "Carbamazepine", "drug2": "phenytoin", "relation": "NONE", "source_file": "Ondansetron.xml", "sentence_id": "DDI-DrugBank.d763.s3", "pair_id": "DDI-DrugBank.d763.s3.p8"} {"sentence": "Rifabutin: There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered. ", "drug1": "Rifabutin", "drug2": "fluconazole", "relation": "NONE", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s31", "pair_id": "DDI-DrugBank.d776.s31.p0"} {"sentence": "Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ", "drug1": "modafinil", "drug2": "phenytoin", "relation": "NONE", "source_file": "Thalidomide.xml", "sentence_id": "DDI-DrugBank.d604.s4", "pair_id": "DDI-DrugBank.d604.s4.p33"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "nondepolarizing agents", "drug2": "aminoglycosides", "relation": "INT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p2"} {"sentence": "Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.", "drug1": "Mequitazine", "drug2": "antichlolinergic", "relation": "INT", "source_file": "Mequitazine.xml", "sentence_id": "DDI-DrugBank.d699.s0", "pair_id": "DDI-DrugBank.d699.s0.p1"} {"sentence": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ", "drug1": "indinavir", "drug2": "itraconazole", "relation": "NONE", "source_file": "Methylergonovine.xml", "sentence_id": "DDI-DrugBank.d675.s2", "pair_id": "DDI-DrugBank.d675.s2.p74"} {"sentence": "Mutual inhibition of metabolism occurs with concurrent use of cyclosporin and methylprednisolone; ", "drug1": "cyclosporin", "drug2": "methylprednisolone", "relation": "MECHANISM", "source_file": "Methylprednisolone.xml", "sentence_id": "DDI-DrugBank.d578.s1", "pair_id": "DDI-DrugBank.d578.s1.p0"} {"sentence": "Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent (metaproterenol sulfate USP) because they may have additive effects. ", "drug1": "beta adrenergic aerosol bronchodilators", "drug2": "Alupent", "relation": "ADVISE", "source_file": "Orciprenaline.xml", "sentence_id": "DDI-DrugBank.d611.s0", "pair_id": "DDI-DrugBank.d611.s0.p0"} {"sentence": "Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. ", "drug1": "metronidazole", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Metronidazole.xml", "sentence_id": "DDI-DrugBank.d629.s0", "pair_id": "DDI-DrugBank.d629.s0.p1"} {"sentence": "Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ", "drug1": "procainamide", "drug2": "metformin", "relation": "NONE", "source_file": "Trospium.xml", "sentence_id": "DDI-DrugBank.d713.s2", "pair_id": "DDI-DrugBank.d713.s2.p24"} {"sentence": "Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.", "drug1": "vitamin K", "drug2": "XENICAL", "relation": "MECHANISM", "source_file": "Orlistat.xml", "sentence_id": "DDI-DrugBank.d761.s13", "pair_id": "DDI-DrugBank.d761.s13.p0"} {"sentence": "Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ", "drug1": "metoclopramide", "drug2": "MIRAPEX", "relation": "EFFECT", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s10", "pair_id": "DDI-DrugBank.d737.s10.p44"} {"sentence": "Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). ", "drug1": "SYMLIN", "drug2": "anticholinergic agents", "relation": "ADVISE", "source_file": "Pramlintide.xml", "sentence_id": "DDI-DrugBank.d632.s0", "pair_id": "DDI-DrugBank.d632.s0.p0"} {"sentence": "Ephedrine enhances the antinociceptive effect of dexmedetomidine in mice.\r\n", "drug1": "Ephedrine", "drug2": "dexmedetomidine", "relation": "EFFECT", "source_file": "21876510.xml", "sentence_id": "DDI-MedLine.d227.s0", "pair_id": "DDI-MedLine.d227.s0.p0"} {"sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.", "drug1": "Barbiturates", "drug2": "corticosteroids", "relation": "INT", "source_file": "Secobarbital.xml", "sentence_id": "DDI-DrugBank.d601.s0", "pair_id": "DDI-DrugBank.d601.s0.p4"} {"sentence": "Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron. ", "drug1": "Calcium", "drug2": "nonheme iron", "relation": "MECHANISM", "source_file": "21795430.xml", "sentence_id": "DDI-MedLine.d169.s1", "pair_id": "DDI-MedLine.d169.s1.p0"} {"sentence": "ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ", "drug1": "ProAmatine", "drug2": "cimetidine", "relation": "NONE", "source_file": "Midodrine.xml", "sentence_id": "DDI-DrugBank.d603.s5", "pair_id": "DDI-DrugBank.d603.s5.p7"} {"sentence": "ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. ", "drug1": "ASPIRIN", "drug2": "DISALCID", "relation": "EFFECT", "source_file": "Salsalate.xml", "sentence_id": "DDI-DrugBank.d576.s1", "pair_id": "DDI-DrugBank.d576.s1.p1"} {"sentence": "Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ", "drug1": "phenytoin", "drug2": "methotrexate", "relation": "NONE", "source_file": "Salsalate.xml", "sentence_id": "DDI-DrugBank.d576.s6", "pair_id": "DDI-DrugBank.d576.s6.p43"} {"sentence": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "drug1": "paricalcitol", "drug2": "nefazodone", "relation": "NONE", "source_file": "Paricalcitol.xml", "sentence_id": "DDI-DrugBank.d726.s1", "pair_id": "DDI-DrugBank.d726.s1.p36"} {"sentence": "The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ", "drug1": "DIPRIVAN", "drug2": "morphine", "relation": "EFFECT", "source_file": "Propofol.xml", "sentence_id": "DDI-DrugBank.d628.s0", "pair_id": "DDI-DrugBank.d628.s0.p1"} {"sentence": "While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.", "drug1": "medroxyprogesterone acetate", "drug2": "naproxen", "relation": "NONE", "source_file": "Pilocarpine.xml", "sentence_id": "DDI-DrugBank.d627.s4", "pair_id": "DDI-DrugBank.d627.s4.p59"} {"sentence": "Concomitant administrations not recommended: - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ", "drug1": "macrolides", "drug2": "astemizole", "relation": "INT", "source_file": "Roxithromycin.xml", "sentence_id": "DDI-DrugBank.d709.s1", "pair_id": "DDI-DrugBank.d709.s1.p8"} {"sentence": "Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. ", "drug1": "diuretics", "drug2": "aminoglycoside", "relation": "EFFECT", "source_file": "Tobramycin.xml", "sentence_id": "DDI-DrugBank.d624.s2", "pair_id": "DDI-DrugBank.d624.s2.p0"} {"sentence": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "drug1": "melatonin", "drug2": "fluoxetine", "relation": "NONE", "source_file": "Melatonin.xml", "sentence_id": "DDI-DrugBank.d643.s0", "pair_id": "DDI-DrugBank.d643.s0.p72"} {"sentence": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ", "drug1": "ACE inhibitors", "drug2": "lithium", "relation": "EFFECT", "source_file": "Moexipril.xml", "sentence_id": "DDI-DrugBank.d640.s6", "pair_id": "DDI-DrugBank.d640.s6.p9"} {"sentence": "Concomitant administration of ketoconazole and terfenadine is contraindicated. ", "drug1": "ketoconazole", "drug2": "terfenadine", "relation": "ADVISE", "source_file": "Terfenadine.xml", "sentence_id": "DDI-DrugBank.d743.s4", "pair_id": "DDI-DrugBank.d743.s4.p0"} {"sentence": "Coadministration of TRITEC with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%). ", "drug1": "TRITEC", "drug2": "clarithromycin", "relation": "MECHANISM", "source_file": "Ranitidine.xml", "sentence_id": "DDI-DrugBank.d590.s0", "pair_id": "DDI-DrugBank.d590.s0.p0"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "potassium chloride", "drug2": "phenothiazines", "relation": "NONE", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p229"} {"sentence": "Drug Interactions: Women on oral contraceptives have shown a significant increase in plasma vitamin A levels.", "drug1": "contraceptives", "drug2": "vitamin A", "relation": "MECHANISM", "source_file": "Vitamin A.xml", "sentence_id": "DDI-DrugBank.d651.s0", "pair_id": "DDI-DrugBank.d651.s0.p0"} {"sentence": "The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ", "drug1": "SKELID", "drug2": "magnesium", "relation": "NONE", "source_file": "Tiludronate.xml", "sentence_id": "DDI-DrugBank.d721.s0", "pair_id": "DDI-DrugBank.d721.s0.p4"} {"sentence": "Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ", "drug1": "Salicylate", "drug2": "thyroxine", "relation": "MECHANISM", "source_file": "Salsalate.xml", "sentence_id": "DDI-DrugBank.d576.s6", "pair_id": "DDI-DrugBank.d576.s6.p2"} {"sentence": "Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids. ", "drug1": "Anticholinergic drugs", "drug2": "corticosteroids", "relation": "EFFECT", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s2", "pair_id": "DDI-DrugBank.d585.s2.p0"} {"sentence": "Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ", "drug1": "terfenadine", "drug2": "troleandomycin", "relation": "ADVISE", "source_file": "Terfenadine.xml", "sentence_id": "DDI-DrugBank.d743.s12", "pair_id": "DDI-DrugBank.d743.s12.p2"} {"sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "drug1": "antiarrhythmic agents of class I", "drug2": "phenothiazines", "relation": "NONE", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s0", "pair_id": "DDI-DrugBank.d585.s0.p30"} {"sentence": "An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. ", "drug1": "rifampin", "drug2": "rosiglitazone", "relation": "MECHANISM", "source_file": "Rosiglitazone.xml", "sentence_id": "DDI-DrugBank.d609.s0", "pair_id": "DDI-DrugBank.d609.s0.p5"} {"sentence": "Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. ", "drug1": "metronidazole", "drug2": "coumarin", "relation": "EFFECT", "source_file": "Metronidazole.xml", "sentence_id": "DDI-DrugBank.d629.s0", "pair_id": "DDI-DrugBank.d629.s0.p0"} {"sentence": "In vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen. ", "drug1": "warfarin", "drug2": "tamoxifen", "relation": "NONE", "source_file": "Raloxifene.xml", "sentence_id": "DDI-DrugBank.d648.s5", "pair_id": "DDI-DrugBank.d648.s5.p4"} {"sentence": "Coadministration with a high dose of antacid (170 mEq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from TRITEC. ", "drug1": "antacid", "drug2": "TRITEC", "relation": "MECHANISM", "source_file": "Ranitidine.xml", "sentence_id": "DDI-DrugBank.d590.s2", "pair_id": "DDI-DrugBank.d590.s2.p1"} {"sentence": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "drug1": "progestin", "drug2": "benzodiazepenes", "relation": "NONE", "source_file": "Melatonin.xml", "sentence_id": "DDI-DrugBank.d643.s0", "pair_id": "DDI-DrugBank.d643.s0.p121"} {"sentence": "The findings suggest that the dosage of S-ketamine should be reduced in patients receiving ticlopidine.", "drug1": "S-ketamine", "drug2": "ticlopidine", "relation": "ADVISE", "source_file": "21716267.xml", "sentence_id": "DDI-MedLine.d216.s6", "pair_id": "DDI-MedLine.d216.s6.p0"} {"sentence": "Peak plasma concentrations and AUC of rimantadine were reduced approximately 10% in the presence of aspirin.", "drug1": "rimantadine", "drug2": "aspirin", "relation": "MECHANISM", "source_file": "Rimantadine.xml", "sentence_id": "DDI-DrugBank.d710.s9", "pair_id": "DDI-DrugBank.d710.s9.p0"} {"sentence": "Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ", "drug1": "FELDENE", "drug2": "antacids", "relation": "NONE", "source_file": "Piroxicam.xml", "sentence_id": "DDI-DrugBank.d656.s2", "pair_id": "DDI-DrugBank.d656.s2.p8"} {"sentence": "In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase therapy.", "drug1": "abciximab", "drug2": "Retavase", "relation": "EFFECT", "source_file": "Reteplase.xml", "sentence_id": "DDI-DrugBank.d618.s1", "pair_id": "DDI-DrugBank.d618.s1.p14"} {"sentence": "Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.", "drug1": "carbachol", "drug2": "suprofen", "relation": "EFFECT", "source_file": "Suprofen.xml", "sentence_id": "DDI-DrugBank.d723.s0", "pair_id": "DDI-DrugBank.d723.s0.p11"} {"sentence": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "drug1": "melatonin", "drug2": "corticosteroids", "relation": "EFFECT", "source_file": "Melatonin.xml", "sentence_id": "DDI-DrugBank.d643.s0", "pair_id": "DDI-DrugBank.d643.s0.p133"} {"sentence": "Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. ", "drug1": "ergot-type medications", "drug2": "sumatriptan", "relation": "ADVISE", "source_file": "Sumatriptan.xml", "sentence_id": "DDI-DrugBank.d720.s1", "pair_id": "DDI-DrugBank.d720.s1.p6"} {"sentence": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ", "drug1": "phenobarbital", "drug2": "phenytoin", "relation": "NONE", "source_file": "Methylprednisolone.xml", "sentence_id": "DDI-DrugBank.d578.s4", "pair_id": "DDI-DrugBank.d578.s4.p0"} {"sentence": "Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ", "drug1": "cisapride", "drug2": "nifedipine", "relation": "NONE", "source_file": "Pantoprazole.xml", "sentence_id": "DDI-DrugBank.d680.s1", "pair_id": "DDI-DrugBank.d680.s1.p62"} {"sentence": "Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.", "drug1": "cholinesterase inhibitors", "drug2": "cholinergic agonists", "relation": "EFFECT", "source_file": "Rivastigmine.xml", "sentence_id": "DDI-DrugBank.d596.s9", "pair_id": "DDI-DrugBank.d596.s9.p13"} {"sentence": "Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ", "drug1": "dexamethasone", "drug2": "carbamazepine", "relation": "NONE", "source_file": "Sunitinib.xml", "sentence_id": "DDI-DrugBank.d639.s2", "pair_id": "DDI-DrugBank.d639.s2.p9"} {"sentence": "Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ", "drug1": "SUTENT", "drug2": "atazanavir", "relation": "MECHANISM", "source_file": "Sunitinib.xml", "sentence_id": "DDI-DrugBank.d639.s0", "pair_id": "DDI-DrugBank.d639.s0.p3"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "linezolid", "drug2": "potassium chloride", "relation": "NONE", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p109"} {"sentence": "Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants", "drug1": "anesthetics", "drug2": "procaine", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s13", "pair_id": "DDI-DrugBank.d775.s13.p81"} {"sentence": "Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin. ", "drug1": "antacid", "drug2": "antacid", "relation": "NONE", "source_file": "Oxybutynin.xml", "sentence_id": "DDI-DrugBank.d784.s7", "pair_id": "DDI-DrugBank.d784.s7.p0"} {"sentence": "In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. ", "drug1": "lithium", "drug2": "meloxicam", "relation": "MECHANISM", "source_file": "Meloxicam.xml", "sentence_id": "DDI-DrugBank.d597.s20", "pair_id": "DDI-DrugBank.d597.s20.p3"} {"sentence": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ", "drug1": "miconazole", "drug2": "oxybutynin", "relation": "MECHANISM", "source_file": "Oxybutynin.xml", "sentence_id": "DDI-DrugBank.d784.s4", "pair_id": "DDI-DrugBank.d784.s4.p14"} {"sentence": "If short-acting benzodiazepines, which are metabolized by the cytochrome P450 system, are concomitantly administered with fluconazole, consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored. ", "drug1": "short-acting benzodiazepines", "drug2": "fluconazole", "relation": "ADVISE", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s37", "pair_id": "DDI-DrugBank.d776.s37.p0"} {"sentence": "Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine", "drug1": "Vindesine", "drug2": "Live virus vaccines", "relation": "INT", "source_file": "Vindesine.xml", "sentence_id": "DDI-DrugBank.d782.s0", "pair_id": "DDI-DrugBank.d782.s0.p1"} {"sentence": "Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.", "drug1": "cholinesterase inhibitors", "drug2": "neuromuscular blocking agents", "relation": "EFFECT", "source_file": "Rivastigmine.xml", "sentence_id": "DDI-DrugBank.d596.s9", "pair_id": "DDI-DrugBank.d596.s9.p12"} {"sentence": "At the same time, the locomotor inhibitory effect of dexmedetomidine was counteracted by ephedrine. ", "drug1": "dexmedetomidine", "drug2": "ephedrine", "relation": "EFFECT", "source_file": "21876510.xml", "sentence_id": "DDI-MedLine.d227.s8", "pair_id": "DDI-MedLine.d227.s8.p0"} {"sentence": "Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ", "drug1": "dopamine antagonists", "drug2": "MIRAPEX", "relation": "EFFECT", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s10", "pair_id": "DDI-DrugBank.d737.s10.p29"} {"sentence": "Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ", "drug1": "Matulane", "drug2": "imipramine HCl", "relation": "ADVISE", "source_file": "Procarbazine.xml", "sentence_id": "DDI-DrugBank.d676.s2", "pair_id": "DDI-DrugBank.d676.s2.p3"} {"sentence": "Concurrent administration of cimetidine and Mexitil has been reported to increase, decrease, or leave unchanged Mexitil plasma levels; ", "drug1": "cimetidine", "drug2": "Mexitil", "relation": "MECHANISM", "source_file": "Mexiletine.xml", "sentence_id": "DDI-DrugBank.d633.s13", "pair_id": "DDI-DrugBank.d633.s13.p0"} {"sentence": "Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ", "drug1": "Salicylate", "drug2": "thiopental", "relation": "MECHANISM", "source_file": "Salsalate.xml", "sentence_id": "DDI-DrugBank.d576.s6", "pair_id": "DDI-DrugBank.d576.s6.p1"} {"sentence": "Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ", "drug1": "nalbuphine", "drug2": "opioid agonist analgesic", "relation": "ADVISE", "source_file": "Morphine.xml", "sentence_id": "DDI-DrugBank.d637.s2", "pair_id": "DDI-DrugBank.d637.s2.p17"} {"sentence": "Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin. ", "drug1": "antacid", "drug2": "aluminum hydroxide", "relation": "NONE", "source_file": "Oxybutynin.xml", "sentence_id": "DDI-DrugBank.d784.s7", "pair_id": "DDI-DrugBank.d784.s7.p6"} {"sentence": "Caution is recommended when administering NEXAVAR with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g. irinotecan). ", "drug1": "NEXAVAR", "drug2": "irinotecan", "relation": "ADVISE", "source_file": "Sorafenib.xml", "sentence_id": "DDI-DrugBank.d602.s0", "pair_id": "DDI-DrugBank.d602.s0.p0"} {"sentence": "Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing MOBIC therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding. ", "drug1": "MOBIC", "drug2": "warfarin", "relation": "ADVISE", "source_file": "Meloxicam.xml", "sentence_id": "DDI-DrugBank.d597.s26", "pair_id": "DDI-DrugBank.d597.s26.p2"} {"sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "drug1": "antiarrhythmic agents of class I", "drug2": "quinidine", "relation": "NONE", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s0", "pair_id": "DDI-DrugBank.d585.s0.p27"} {"sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.", "drug1": "contraceptives", "drug2": "theophylline", "relation": "NONE", "source_file": "Secobarbital.xml", "sentence_id": "DDI-DrugBank.d601.s0", "pair_id": "DDI-DrugBank.d601.s0.p9"} {"sentence": "Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ", "drug1": "Streptase", "drug2": "anticoagulants", "relation": "EFFECT", "source_file": "Streptokinase.xml", "sentence_id": "DDI-DrugBank.d777.s1", "pair_id": "DDI-DrugBank.d777.s1.p11"} {"sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "drug1": "anticholinergic drugs", "drug2": "quinidine", "relation": "EFFECT", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s0", "pair_id": "DDI-DrugBank.d585.s0.p2"} {"sentence": "Concomitant administrations not recommended: - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ", "drug1": "macrolides", "drug2": "terfenadine", "relation": "INT", "source_file": "Roxithromycin.xml", "sentence_id": "DDI-DrugBank.d709.s1", "pair_id": "DDI-DrugBank.d709.s1.p7"} {"sentence": "Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants", "drug1": "cisplatin", "drug2": "edrophonium", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s13", "pair_id": "DDI-DrugBank.d775.s13.p46"} {"sentence": "We elucidated the expression of HB-EGF in T-ALL cell lines, and evaluated the effect of CRM197 on these cells alone or in combination with anticancer agent. ", "drug1": "CRM197", "drug2": "anticancer agent", "relation": "NONE", "source_file": "21873163.xml", "sentence_id": "DDI-MedLine.d201.s5", "pair_id": "DDI-MedLine.d201.s5.p0"} {"sentence": "Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ", "drug1": "Antiplatelet Agents", "drug2": "Streptase", "relation": "NONE", "source_file": "Streptokinase.xml", "sentence_id": "DDI-DrugBank.d777.s1", "pair_id": "DDI-DrugBank.d777.s1.p5"} {"sentence": "Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.", "drug1": "mecamylamine", "drug2": "veratrum alkaloids", "relation": "NONE", "source_file": "Pseudoephedrine.xml", "sentence_id": "DDI-DrugBank.d606.s1", "pair_id": "DDI-DrugBank.d606.s1.p8"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "nondepolarizing agents", "drug2": "antibiotics", "relation": "INT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p1"} {"sentence": "Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ", "drug1": "Agonist/antagonist analgesics", "drug2": "opioid agonist analgesic", "relation": "ADVISE", "source_file": "Morphine.xml", "sentence_id": "DDI-DrugBank.d637.s2", "pair_id": "DDI-DrugBank.d637.s2.p10"} {"sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "drug1": "narcotic analgesics", "drug2": "meperidine", "relation": "NONE", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s0", "pair_id": "DDI-DrugBank.d585.s0.p90"} {"sentence": "Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.", "drug1": "cimetidine", "drug2": "mebendazole", "relation": "MECHANISM", "source_file": "Mebendazole.xml", "sentence_id": "DDI-DrugBank.d679.s0", "pair_id": "DDI-DrugBank.d679.s0.p0"} {"sentence": "Coadministration with acetaminophen reduced the peak concentration and AUC values for rimantadine by approximately 11%. ", "drug1": "acetaminophen", "drug2": "rimantadine", "relation": "MECHANISM", "source_file": "Rimantadine.xml", "sentence_id": "DDI-DrugBank.d710.s5", "pair_id": "DDI-DrugBank.d710.s5.p0"} {"sentence": "ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ", "drug1": "desglymidodrine", "drug2": "procainamide", "relation": "MECHANISM", "source_file": "Midodrine.xml", "sentence_id": "DDI-DrugBank.d603.s5", "pair_id": "DDI-DrugBank.d603.s5.p66"} {"sentence": "Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ", "drug1": "pramipexole", "drug2": "pramipexole", "relation": "NONE", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s6", "pair_id": "DDI-DrugBank.d737.s6.p75"} {"sentence": "Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.", "drug1": "Sympathomimetics", "drug2": "mecamylamine", "relation": "EFFECT", "source_file": "Pseudoephedrine.xml", "sentence_id": "DDI-DrugBank.d606.s1", "pair_id": "DDI-DrugBank.d606.s1.p1"} {"sentence": "Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. ", "drug1": "amphetamine", "drug2": "levomepromazine", "relation": "EFFECT", "source_file": "Methotrimeprazine.xml", "sentence_id": "DDI-DrugBank.d756.s7", "pair_id": "DDI-DrugBank.d756.s7.p5"} {"sentence": "Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ", "drug1": "Ritalin", "drug2": "diphenylhydantoin", "relation": "MECHANISM", "source_file": "Methylphenidate.xml", "sentence_id": "DDI-DrugBank.d638.s2", "pair_id": "DDI-DrugBank.d638.s2.p3"} {"sentence": "Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%. ", "drug1": "Trimethoprim", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Trimethoprim.xml", "sentence_id": "DDI-DrugBank.d598.s1", "pair_id": "DDI-DrugBank.d598.s1.p0"} {"sentence": "Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ", "drug1": "Phenothiazines", "drug2": "CNS depressants", "relation": "EFFECT", "source_file": "Thiethylperazine.xml", "sentence_id": "DDI-DrugBank.d677.s0", "pair_id": "DDI-DrugBank.d677.s0.p0"} {"sentence": "When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity. ", "drug1": "methyldopa", "drug2": "lithium", "relation": "ADVISE", "source_file": "Methyldopa.xml", "sentence_id": "DDI-DrugBank.d779.s5", "pair_id": "DDI-DrugBank.d779.s5.p0"} {"sentence": "In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase therapy.", "drug1": "vitamin K antagonists", "drug2": "Retavase", "relation": "EFFECT", "source_file": "Reteplase.xml", "sentence_id": "DDI-DrugBank.d618.s1", "pair_id": "DDI-DrugBank.d618.s1.p8"} {"sentence": "Dose adjustment of Zemplar Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as ketoconazole. ", "drug1": "Zemplar", "drug2": "ketoconazole", "relation": "ADVISE", "source_file": "Paricalcitol.xml", "sentence_id": "DDI-DrugBank.d726.s2", "pair_id": "DDI-DrugBank.d726.s2.p0"} {"sentence": "Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants", "drug1": "carbamazepine", "drug2": "neostigmine", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s13", "pair_id": "DDI-DrugBank.d775.s13.p28"} {"sentence": "The bioavailability of SKELID is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of diclofenac. ", "drug1": "SKELID", "drug2": "indomethacin", "relation": "MECHANISM", "source_file": "Tiludronate.xml", "sentence_id": "DDI-DrugBank.d721.s2", "pair_id": "DDI-DrugBank.d721.s2.p0"} {"sentence": "The concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity. ", "drug1": "streptozocin", "drug2": "phenytoin", "relation": "EFFECT", "source_file": "Streptozocin.xml", "sentence_id": "DDI-DrugBank.d647.s3", "pair_id": "DDI-DrugBank.d647.s3.p0"} {"sentence": "ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ", "drug1": "desglymidodrine", "drug2": "triamterene", "relation": "MECHANISM", "source_file": "Midodrine.xml", "sentence_id": "DDI-DrugBank.d603.s5", "pair_id": "DDI-DrugBank.d603.s5.p67"} {"sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.", "drug1": "Barbiturates", "drug2": "theophylline", "relation": "INT", "source_file": "Secobarbital.xml", "sentence_id": "DDI-DrugBank.d601.s0", "pair_id": "DDI-DrugBank.d601.s0.p3"} {"sentence": "Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants", "drug1": "anesthetics", "drug2": "anesthetics", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s13", "pair_id": "DDI-DrugBank.d775.s13.p82"} {"sentence": "The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine . Therefore, caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction. ", "drug1": "ephedrine", "drug2": "ProAmatine", "relation": "EFFECT", "source_file": "Midodrine.xml", "sentence_id": "DDI-DrugBank.d603.s2", "pair_id": "DDI-DrugBank.d603.s2.p13"} {"sentence": "Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. ", "drug1": "ritonavir", "drug2": "midazolam", "relation": "MECHANISM", "source_file": "Midazolam.xml", "sentence_id": "DDI-DrugBank.d752.s3", "pair_id": "DDI-DrugBank.d752.s3.p1"} {"sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "drug1": "anticholinergic drugs", "drug2": "narcotic analgesics", "relation": "EFFECT", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s0", "pair_id": "DDI-DrugBank.d585.s0.p8"} {"sentence": "Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ", "drug1": "Ritalin", "drug2": "desipramine", "relation": "MECHANISM", "source_file": "Methylphenidate.xml", "sentence_id": "DDI-DrugBank.d638.s2", "pair_id": "DDI-DrugBank.d638.s2.p9"} {"sentence": "Cyclosporine: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine. ", "drug1": "ezetimibe", "drug2": "cyclosporine", "relation": "MECHANISM", "source_file": "Ezetimibe.xml", "sentence_id": "DDI-DrugBank.d572.s9", "pair_id": "DDI-DrugBank.d572.s9.p2"} {"sentence": "ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ", "drug1": "terazosin", "drug2": "cimetidine", "relation": "NONE", "source_file": "Midodrine.xml", "sentence_id": "DDI-DrugBank.d603.s5", "pair_id": "DDI-DrugBank.d603.s5.p40"} {"sentence": "Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ", "drug1": "phenothiazines", "drug2": "Permax", "relation": "ADVISE", "source_file": "Pergolide.xml", "sentence_id": "DDI-DrugBank.d650.s0", "pair_id": "DDI-DrugBank.d650.s0.p16"} {"sentence": "In the presence of ketoconazole, there was 1.6- and 1.8-fold increase in C (max) and AUC of panobinostat, respectively. ", "drug1": "ketoconazole", "drug2": "panobinostat", "relation": "MECHANISM", "source_file": "21706316.xml", "sentence_id": "DDI-MedLine.d185.s7", "pair_id": "DDI-MedLine.d185.s7.p0"} {"sentence": "Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ", "drug1": "MEPERIDINE", "drug2": "TRANQUILIZERS", "relation": "ADVISE", "source_file": "Meperidine.xml", "sentence_id": "DDI-DrugBank.d703.s0", "pair_id": "DDI-DrugBank.d703.s0.p13"} {"sentence": "Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ", "drug1": "Ritalin", "drug2": "tricyclic drugs", "relation": "MECHANISM", "source_file": "Methylphenidate.xml", "sentence_id": "DDI-DrugBank.d638.s2", "pair_id": "DDI-DrugBank.d638.s2.p6"} {"sentence": "The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ", "drug1": "VERSED Syrup", "drug2": "secobarbital", "relation": "EFFECT", "source_file": "Midazolam.xml", "sentence_id": "DDI-DrugBank.d752.s10", "pair_id": "DDI-DrugBank.d752.s10.p7"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "Methscopolamine", "drug2": "antihistamines", "relation": "INT", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p11"} {"sentence": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "drug1": "Melatonin", "drug2": "NSAIDs", "relation": "INT", "source_file": "Melatonin.xml", "sentence_id": "DDI-DrugBank.d643.s0", "pair_id": "DDI-DrugBank.d643.s0.p1"} {"sentence": "Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ", "drug1": "Myfortic", "drug2": "aluminum", "relation": "MECHANISM", "source_file": "Mycophenolic acid.xml", "sentence_id": "DDI-DrugBank.d700.s0", "pair_id": "DDI-DrugBank.d700.s0.p6"} {"sentence": "When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). ", "drug1": "rimantadine HCl", "drug2": "cimetidine", "relation": "NONE", "source_file": "Rimantadine.xml", "sentence_id": "DDI-DrugBank.d710.s1", "pair_id": "DDI-DrugBank.d710.s1.p3"} {"sentence": "Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ", "drug1": "contraceptive", "drug2": "warfarin", "relation": "NONE", "source_file": "Pantoprazole.xml", "sentence_id": "DDI-DrugBank.d680.s1", "pair_id": "DDI-DrugBank.d680.s1.p250"} {"sentence": "Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). ", "drug1": "3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine", "drug2": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "relation": "NONE", "source_file": "21705423.xml", "sentence_id": "DDI-MedLine.d161.s4", "pair_id": "DDI-MedLine.d161.s4.p9"} {"sentence": "Administration of valproic acid decreases oral clearance of temozolomide by about 5%. ", "drug1": "valproic acid", "drug2": "temozolomide", "relation": "MECHANISM", "source_file": "Temozolomide.xml", "sentence_id": "DDI-DrugBank.d687.s0", "pair_id": "DDI-DrugBank.d687.s0.p0"} {"sentence": "Terbinafine decreases the clearance of caffeine by 19%. ", "drug1": "Terbinafine", "drug2": "caffeine", "relation": "MECHANISM", "source_file": "Terbinafine.xml", "sentence_id": "DDI-DrugBank.d645.s4", "pair_id": "DDI-DrugBank.d645.s4.p0"} {"sentence": "Fat-soluble Vitamin Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with XENICAL. ", "drug1": "Fat-soluble Vitamin Supplements", "drug2": "beta-carotene", "relation": "NONE", "source_file": "Orlistat.xml", "sentence_id": "DDI-DrugBank.d761.s3", "pair_id": "DDI-DrugBank.d761.s3.p0"} {"sentence": "Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ", "drug1": "aspirin", "drug2": "Nonsteroidal anti-inflammatory agents", "relation": "NONE", "source_file": "Piroxicam.xml", "sentence_id": "DDI-DrugBank.d656.s2", "pair_id": "DDI-DrugBank.d656.s2.p15"} {"sentence": "The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ", "drug1": "contraceptives", "drug2": "phenytoin", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s11", "pair_id": "DDI-DrugBank.d775.s11.p9"} {"sentence": "Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ", "drug1": "coumarin anticoagulants", "drug2": "imipramine", "relation": "NONE", "source_file": "Methylphenidate.xml", "sentence_id": "DDI-DrugBank.d638.s2", "pair_id": "DDI-DrugBank.d638.s2.p16"} {"sentence": "Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. ", "drug1": "Salicylates", "drug2": "antidiabetic drugs", "relation": "EFFECT", "source_file": "Salsalate.xml", "sentence_id": "DDI-DrugBank.d576.s5", "pair_id": "DDI-DrugBank.d576.s5.p0"} {"sentence": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "drug1": "paricalcitol", "drug2": "saquinavir", "relation": "ADVISE", "source_file": "Paricalcitol.xml", "sentence_id": "DDI-DrugBank.d726.s1", "pair_id": "DDI-DrugBank.d726.s1.p62"} {"sentence": "Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. ", "drug1": "roxithromycin", "drug2": "terfenadine", "relation": "ADVISE", "source_file": "Roxithromycin.xml", "sentence_id": "DDI-DrugBank.d709.s3", "pair_id": "DDI-DrugBank.d709.s3.p3"} {"sentence": "Sulfonamides can also displace methotrexate from plasma protein-binding sites, thus increasing free methotrexate concentrations. ", "drug1": "Sulfonamides", "drug2": "methotrexate", "relation": "MECHANISM", "source_file": "Sulfamethoxazole.xml", "sentence_id": "DDI-DrugBank.d577.s6", "pair_id": "DDI-DrugBank.d577.s6.p0"} {"sentence": "The effect of dasatinib, an inhibitor of Src and Abl kinases, on paclitaxel sensitivity was measured in ovarian cancer cells and HEY xenografts. ", "drug1": "dasatinib", "drug2": "paclitaxel", "relation": "NONE", "source_file": "21813412.xml", "sentence_id": "DDI-MedLine.d194.s4", "pair_id": "DDI-MedLine.d194.s4.p0"} {"sentence": "Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. ", "drug1": "troleandomycin", "drug2": "ketoconazole", "relation": "NONE", "source_file": "Prednisone.xml", "sentence_id": "DDI-DrugBank.d653.s2", "pair_id": "DDI-DrugBank.d653.s2.p0"} {"sentence": "The coadministration of fluconazole at doses lower than 400 mg/day with terfenadine should be carefully monitored. ", "drug1": "fluconazole", "drug2": "terfenadine", "relation": "ADVISE", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s24", "pair_id": "DDI-DrugBank.d776.s24.p0"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "MIVACRON", "drug2": "quinidine", "relation": "INT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p28"} {"sentence": "Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants", "drug1": "edrophonium", "drug2": "procaine", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s13", "pair_id": "DDI-DrugBank.d775.s13.p59"} {"sentence": "The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ", "drug1": "VERSED Syrup", "drug2": "meperidine", "relation": "EFFECT", "source_file": "Midazolam.xml", "sentence_id": "DDI-DrugBank.d752.s10", "pair_id": "DDI-DrugBank.d752.s10.p2"} {"sentence": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ", "drug1": "macrolide antibiotics", "drug2": "DETROL LA", "relation": "ADVISE", "source_file": "Tolterodine.xml", "sentence_id": "DDI-DrugBank.d765.s1", "pair_id": "DDI-DrugBank.d765.s1.p34"} {"sentence": "Due to low systemic exposure to retapamulin following topical application in patients, dosage adjustments for retapamulin are unnecessary when co-administered with CYP3A4 inhibitors, such as ketoconazole. ", "drug1": "retapamulin", "drug2": "ketoconazole", "relation": "NONE", "source_file": "Retapamulin.xml", "sentence_id": "DDI-DrugBank.d654.s1", "pair_id": "DDI-DrugBank.d654.s1.p1"} {"sentence": "Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.", "drug1": "propranolol", "drug2": "phenothiazines", "relation": "MECHANISM", "source_file": "Prochlorperazine.xml", "sentence_id": "DDI-DrugBank.d734.s2", "pair_id": "DDI-DrugBank.d734.s2.p0"} {"sentence": "Sympathomimetics: Metolazone may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. ", "drug1": "Metolazone", "drug2": "norepinephrine", "relation": "EFFECT", "source_file": "Metolazone.xml", "sentence_id": "DDI-DrugBank.d588.s11", "pair_id": "DDI-DrugBank.d588.s11.p2"} {"sentence": "A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir. ", "drug1": "megestrol acetate", "drug2": "indinavir", "relation": "MECHANISM", "source_file": "Megestrol.xml", "sentence_id": "DDI-DrugBank.d688.s1", "pair_id": "DDI-DrugBank.d688.s1.p0"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "polymyxins", "drug2": "clindamycin", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p76"} {"sentence": "Caution should be exercised when administering ZADAXIN therapy in combination with other immunomodulating drugs. ", "drug1": "ZADAXIN", "drug2": "immunomodulating drugs", "relation": "ADVISE", "source_file": "Thymalfasin.xml", "sentence_id": "DDI-DrugBank.d616.s1", "pair_id": "DDI-DrugBank.d616.s1.p0"} {"sentence": "Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ", "drug1": "metronidazole", "drug2": "amoxicillin", "relation": "NONE", "source_file": "Pantoprazole.xml", "sentence_id": "DDI-DrugBank.d680.s1", "pair_id": "DDI-DrugBank.d680.s1.p299"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "phenelzine", "drug2": "promethazine", "relation": "NONE", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p99"} {"sentence": "Mexitil does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum digoxin levels. ", "drug1": "digoxin", "drug2": "digoxin", "relation": "NONE", "source_file": "Mexiletine.xml", "sentence_id": "DDI-DrugBank.d633.s15", "pair_id": "DDI-DrugBank.d633.s15.p6"} {"sentence": "Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ", "drug1": "cimetidine", "drug2": "pramipexole", "relation": "MECHANISM", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s6", "pair_id": "DDI-DrugBank.d737.s6.p6"} {"sentence": "MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ", "drug1": "sympathomimetic pressor amines", "drug2": "monoamine oxidase inhibitors", "relation": "EFFECT", "source_file": "Phenylpropanolamine.xml", "sentence_id": "DDI-DrugBank.d689.s1", "pair_id": "DDI-DrugBank.d689.s1.p3"} {"sentence": "Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.", "drug1": "MAOIs", "drug2": "alcohol", "relation": "NONE", "source_file": "Mequitazine.xml", "sentence_id": "DDI-DrugBank.d699.s0", "pair_id": "DDI-DrugBank.d699.s0.p14"} {"sentence": "When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil , lowered Mexitil plasma levels have been reported. ", "drug1": "phenobarbital", "drug2": "Mexitil", "relation": "MECHANISM", "source_file": "Mexiletine.xml", "sentence_id": "DDI-DrugBank.d633.s9", "pair_id": "DDI-DrugBank.d633.s9.p7"} {"sentence": "Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ", "drug1": "carbamazepine", "drug2": "digoxin", "relation": "NONE", "source_file": "Pantoprazole.xml", "sentence_id": "DDI-DrugBank.d680.s1", "pair_id": "DDI-DrugBank.d680.s1.p115"} {"sentence": "Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ", "drug1": "levomepromazine", "drug2": "anticholinergic drugs", "relation": "ADVISE", "source_file": "Methotrimeprazine.xml", "sentence_id": "DDI-DrugBank.d756.s4", "pair_id": "DDI-DrugBank.d756.s4.p0"} {"sentence": "Phenytoin: DIFLUCAN increases the plasma concentrations of phenytoin. ", "drug1": "DIFLUCAN", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s10", "pair_id": "DDI-DrugBank.d776.s10.p2"} {"sentence": "Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ", "drug1": "MEPERIDINE", "drug2": "ANESTHETICS", "relation": "ADVISE", "source_file": "Meperidine.xml", "sentence_id": "DDI-DrugBank.d703.s0", "pair_id": "DDI-DrugBank.d703.s0.p11"} {"sentence": "Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. ", "drug1": "reserpine", "drug2": "beta-blocking agents", "relation": "EFFECT", "source_file": "Pindolol.xml", "sentence_id": "DDI-DrugBank.d666.s0", "pair_id": "DDI-DrugBank.d666.s0.p0"} {"sentence": "Administration of a higher dose of indinavir should be considered when coadministering with megestrol acetate. ", "drug1": "indinavir", "drug2": "megestrol acetate", "relation": "ADVISE", "source_file": "Megestrol.xml", "sentence_id": "DDI-DrugBank.d688.s2", "pair_id": "DDI-DrugBank.d688.s2.p0"} {"sentence": "Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. ", "drug1": "trimetrexate", "drug2": "erythromycin", "relation": "EFFECT", "source_file": "Trimetrexate.xml", "sentence_id": "DDI-DrugBank.d766.s1", "pair_id": "DDI-DrugBank.d766.s1.p0"} {"sentence": "Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ", "drug1": "dexamethasone", "drug2": "rifampin", "relation": "NONE", "source_file": "Sunitinib.xml", "sentence_id": "DDI-DrugBank.d639.s2", "pair_id": "DDI-DrugBank.d639.s2.p10"} {"sentence": "While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ", "drug1": "fluconazole", "drug2": "ethinyl estradiol", "relation": "NONE", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s41", "pair_id": "DDI-DrugBank.d776.s41.p12"} {"sentence": "Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ", "drug1": "verapamil", "drug2": "pramipexole", "relation": "MECHANISM", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s6", "pair_id": "DDI-DrugBank.d737.s6.p48"} {"sentence": "- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone. ", "drug1": "prednisone", "drug2": "prednisolone", "relation": "NONE", "source_file": "Montelukast.xml", "sentence_id": "DDI-DrugBank.d739.s5", "pair_id": "DDI-DrugBank.d739.s5.p2"} {"sentence": "You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ", "drug1": "mazindol", "drug2": "isocarboxazid", "relation": "ADVISE", "source_file": "Mazindol.xml", "sentence_id": "DDI-DrugBank.d716.s0", "pair_id": "DDI-DrugBank.d716.s0.p2"} {"sentence": "Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ", "drug1": "piroxicam", "drug2": "glyburide", "relation": "NONE", "source_file": "Pantoprazole.xml", "sentence_id": "DDI-DrugBank.d680.s1", "pair_id": "DDI-DrugBank.d680.s1.p197"} {"sentence": "Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ", "drug1": "EVISTA", "drug2": "clofibrate", "relation": "ADVISE", "source_file": "Raloxifene.xml", "sentence_id": "DDI-DrugBank.d648.s6", "pair_id": "DDI-DrugBank.d648.s6.p0"} {"sentence": "In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%). ", "drug1": "methadone", "drug2": "ZIAGEN", "relation": "MECHANISM", "source_file": "Abacavir.xml", "sentence_id": "DDI-DrugBank.d610.s4", "pair_id": "DDI-DrugBank.d610.s4.p0"} {"sentence": "The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ", "drug1": "VERSED Syrup", "drug2": "fentanyl", "relation": "EFFECT", "source_file": "Midazolam.xml", "sentence_id": "DDI-DrugBank.d752.s10", "pair_id": "DDI-DrugBank.d752.s10.p3"} {"sentence": "ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ", "drug1": "prazosin", "drug2": "ProAmatine", "relation": "EFFECT", "source_file": "Midodrine.xml", "sentence_id": "DDI-DrugBank.d603.s5", "pair_id": "DDI-DrugBank.d603.s5.p27"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "nondepolarizing agents", "drug2": "quinidine", "relation": "INT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p14"} {"sentence": "The action of Mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.", "drug1": "Mecamylamine", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Mecamylamine.xml", "sentence_id": "DDI-DrugBank.d579.s1", "pair_id": "DDI-DrugBank.d579.s1.p1"} {"sentence": "Concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth. ", "drug1": "erythromycin", "drug2": "penicillins", "relation": "EFFECT", "source_file": "Penicillin G.xml", "sentence_id": "DDI-DrugBank.d665.s0", "pair_id": "DDI-DrugBank.d665.s0.p4"} {"sentence": "The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ", "drug1": "SKELID", "drug2": "calcium", "relation": "MECHANISM", "source_file": "Tiludronate.xml", "sentence_id": "DDI-DrugBank.d721.s0", "pair_id": "DDI-DrugBank.d721.s0.p0"} {"sentence": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "drug1": "ketoconazole", "drug2": "atazanavir", "relation": "NONE", "source_file": "Paricalcitol.xml", "sentence_id": "DDI-DrugBank.d726.s1", "pair_id": "DDI-DrugBank.d726.s1.p44"} {"sentence": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "drug1": "paricalcitol", "drug2": "nefazodone", "relation": "ADVISE", "source_file": "Paricalcitol.xml", "sentence_id": "DDI-DrugBank.d726.s1", "pair_id": "DDI-DrugBank.d726.s1.p59"} {"sentence": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ", "drug1": "rifampin", "drug2": "methylprednisolone", "relation": "MECHANISM", "source_file": "Methylprednisolone.xml", "sentence_id": "DDI-DrugBank.d578.s4", "pair_id": "DDI-DrugBank.d578.s4.p7"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "nondepolarizing agents", "drug2": "polymyxins", "relation": "INT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p5"} {"sentence": "In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ", "drug1": "TOBI", "drug2": "(beta)-agonists", "relation": "EFFECT", "source_file": "Tobramycin.xml", "sentence_id": "DDI-DrugBank.d624.s0", "pair_id": "DDI-DrugBank.d624.s0.p9"} {"sentence": "Ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive. ", "drug1": "Ropivacaine", "drug2": "anesthetics", "relation": "ADVISE", "source_file": "Ropivacaine.xml", "sentence_id": "DDI-DrugBank.d591.s0", "pair_id": "DDI-DrugBank.d591.s0.p0"} {"sentence": "Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ", "drug1": "midazolam", "drug2": "calcium channel antagonists", "relation": "ADVISE", "source_file": "Midazolam.xml", "sentence_id": "DDI-DrugBank.d752.s0", "pair_id": "DDI-DrugBank.d752.s0.p2"} {"sentence": "Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. ", "drug1": "TRENTAL", "drug2": "theophylline", "relation": "MECHANISM", "source_file": "Pentoxifylline.xml", "sentence_id": "DDI-DrugBank.d659.s2", "pair_id": "DDI-DrugBank.d659.s2.p0"} {"sentence": "While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. ", "drug1": "fluconazole", "drug2": "levonorgestrel", "relation": "MECHANISM", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s41", "pair_id": "DDI-DrugBank.d776.s41.p1"} {"sentence": "This study investigates the ability of cyclooxygenase-2 inhibitors to sensitize cells from different origins to several chemotherapeutic agents. ", "drug1": "cyclooxygenase-2 inhibitors", "drug2": "chemotherapeutic agents", "relation": "NONE", "source_file": "21763710.xml", "sentence_id": "DDI-MedLine.d217.s2", "pair_id": "DDI-MedLine.d217.s2.p0"} {"sentence": "However, the extent of biotransformation of perindopril to the active metabolite, perindoprilat, is reduced approximately 43%, resulting in a reduction in the plasma ACE inhibition curve of approximately 20%, probably clinically insignificant. ", "drug1": "perindopril", "drug2": "perindoprilat", "relation": "NONE", "source_file": "Perindopril.xml", "sentence_id": "DDI-DrugBank.d781.s16", "pair_id": "DDI-DrugBank.d781.s16.p0"} {"sentence": "There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly. ", "drug1": "pantoprazole", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Pantoprazole.xml", "sentence_id": "DDI-DrugBank.d680.s5", "pair_id": "DDI-DrugBank.d680.s5.p2"} {"sentence": "Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ", "drug1": "EVISTA", "drug2": "ibuprofen", "relation": "ADVISE", "source_file": "Raloxifene.xml", "sentence_id": "DDI-DrugBank.d648.s6", "pair_id": "DDI-DrugBank.d648.s6.p3"} {"sentence": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "drug1": "ketoconazole", "drug2": "nelfinavir", "relation": "NONE", "source_file": "Paricalcitol.xml", "sentence_id": "DDI-DrugBank.d726.s1", "pair_id": "DDI-DrugBank.d726.s1.p10"} {"sentence": "Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ", "drug1": "Ritalin", "drug2": "phenylbutazone", "relation": "MECHANISM", "source_file": "Methylphenidate.xml", "sentence_id": "DDI-DrugBank.d638.s2", "pair_id": "DDI-DrugBank.d638.s2.p5"} {"sentence": "Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.", "drug1": "ketoconazole", "drug2": "ropivacaine", "relation": "NONE", "source_file": "Ropivacaine.xml", "sentence_id": "DDI-DrugBank.d591.s6", "pair_id": "DDI-DrugBank.d591.s6.p0"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "Methscopolamine", "drug2": "absorbent-type anti-diarrhea medicines", "relation": "INT", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p16"} {"sentence": "Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly. ", "drug1": "guanethidine", "drug2": "phenothiazines", "relation": "EFFECT", "source_file": "Prochlorperazine.xml", "sentence_id": "DDI-DrugBank.d734.s1", "pair_id": "DDI-DrugBank.d734.s1.p0"} {"sentence": "Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ", "drug1": "diazepam", "drug2": "mirtazapine", "relation": "MECHANISM", "source_file": "Mirtazapine.xml", "sentence_id": "DDI-DrugBank.d742.s9", "pair_id": "DDI-DrugBank.d742.s9.p9"} {"sentence": "Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT. ", "drug1": "hypoglycemic", "drug2": "SOMAVERT", "relation": "ADVISE", "source_file": "Pegvisomant.xml", "sentence_id": "DDI-DrugBank.d744.s0", "pair_id": "DDI-DrugBank.d744.s0.p2"} {"sentence": "Tacrolimus: There have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered. ", "drug1": "fluconazole", "drug2": "tacrolimus", "relation": "EFFECT", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s33", "pair_id": "DDI-DrugBank.d776.s33.p2"} {"sentence": "Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of pravastatin. ", "drug1": "XENICAL", "drug2": "pravastatin", "relation": "NONE", "source_file": "Orlistat.xml", "sentence_id": "DDI-DrugBank.d761.s10", "pair_id": "DDI-DrugBank.d761.s10.p5"} {"sentence": "Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ", "drug1": "thioxanthenes", "drug2": "MIRAPEX", "relation": "EFFECT", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s10", "pair_id": "DDI-DrugBank.d737.s10.p43"} {"sentence": "Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. ", "drug1": "ketoconazole", "drug2": "methylprednisolone", "relation": "MECHANISM", "source_file": "Methylprednisolone.xml", "sentence_id": "DDI-DrugBank.d578.s5", "pair_id": "DDI-DrugBank.d578.s5.p2"} {"sentence": "MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ", "drug1": "sympathomimetic pressor amines", "drug2": "monoamine oxidase inhibitors", "relation": "EFFECT", "source_file": "Phenylephrine.xml", "sentence_id": "DDI-DrugBank.d725.s1", "pair_id": "DDI-DrugBank.d725.s1.p3"} {"sentence": "CYP3A4 Inhibitors: Ketoconazole, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of tolterodine when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions). ", "drug1": "Ketoconazole", "drug2": "tolterodine", "relation": "MECHANISM", "source_file": "Tolterodine.xml", "sentence_id": "DDI-DrugBank.d765.s0", "pair_id": "DDI-DrugBank.d765.s0.p0"} {"sentence": "It has been reported that the incidence of bradycardia was increased when oxymorphone was combined with propofol for induction of anesthesia. ", "drug1": "oxymorphone", "drug2": "propofol", "relation": "EFFECT", "source_file": "Oxymorphone.xml", "sentence_id": "DDI-DrugBank.d753.s3", "pair_id": "DDI-DrugBank.d753.s3.p0"} {"sentence": "Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. ", "drug1": "methysergide", "drug2": "sumatriptan", "relation": "ADVISE", "source_file": "Sumatriptan.xml", "sentence_id": "DDI-DrugBank.d720.s1", "pair_id": "DDI-DrugBank.d720.s1.p9"} {"sentence": "Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ", "drug1": "terfenadine", "drug2": "macrolide antibiotics", "relation": "ADVISE", "source_file": "Terfenadine.xml", "sentence_id": "DDI-DrugBank.d743.s12", "pair_id": "DDI-DrugBank.d743.s12.p18"} {"sentence": "Because the action of metoclopramide will influence the delivery of food to the intestines and thus the rate of absorption, insulin dosage or timing of dosage may require adjustment.", "drug1": "metoclopramide", "drug2": "insulin", "relation": "ADVISE", "source_file": "Metoclopramide.xml", "sentence_id": "DDI-DrugBank.d652.s6", "pair_id": "DDI-DrugBank.d652.s6.p0"} {"sentence": "Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ", "drug1": "FELDENE", "drug2": "coumarin-type anticoagulants", "relation": "ADVISE", "source_file": "Piroxicam.xml", "sentence_id": "DDI-DrugBank.d656.s1", "pair_id": "DDI-DrugBank.d656.s1.p9"} {"sentence": "Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ", "drug1": "MEPERIDINE", "drug2": "TRICYCLIC ANTIDEPRESSANTS", "relation": "ADVISE", "source_file": "Meperidine.xml", "sentence_id": "DDI-DrugBank.d703.s0", "pair_id": "DDI-DrugBank.d703.s0.p16"} {"sentence": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ", "drug1": "azole antifungals", "drug2": "cyclosporine", "relation": "NONE", "source_file": "Tolterodine.xml", "sentence_id": "DDI-DrugBank.d765.s1", "pair_id": "DDI-DrugBank.d765.s1.p14"} {"sentence": "The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ", "drug1": "VERSED Syrup", "drug2": "narcotics", "relation": "EFFECT", "source_file": "Midazolam.xml", "sentence_id": "DDI-DrugBank.d752.s10", "pair_id": "DDI-DrugBank.d752.s10.p0"} {"sentence": "Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ", "drug1": "EVISTA", "drug2": "diazoxide", "relation": "ADVISE", "source_file": "Raloxifene.xml", "sentence_id": "DDI-DrugBank.d648.s6", "pair_id": "DDI-DrugBank.d648.s6.p5"} {"sentence": "This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil dose is changed. ", "drug1": "Mexitil", "drug2": "theophylline", "relation": "NONE", "source_file": "Mexiletine.xml", "sentence_id": "DDI-DrugBank.d633.s18", "pair_id": "DDI-DrugBank.d633.s18.p15"} {"sentence": "These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys. ", "drug1": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "drug2": "3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine", "relation": "EFFECT", "source_file": "21705423.xml", "sentence_id": "DDI-MedLine.d161.s6", "pair_id": "DDI-MedLine.d161.s6.p0"} {"sentence": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "drug1": "nefazodone", "drug2": "saquinavir", "relation": "NONE", "source_file": "Paricalcitol.xml", "sentence_id": "DDI-DrugBank.d726.s1", "pair_id": "DDI-DrugBank.d726.s1.p107"} {"sentence": "It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.", "drug1": "phenobarbital", "drug2": "montelukast", "relation": "ADVISE", "source_file": "Montelukast.xml", "sentence_id": "DDI-DrugBank.d739.s15", "pair_id": "DDI-DrugBank.d739.s15.p1"} {"sentence": "Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin. ", "drug1": "simethicone", "drug2": "oxybutynin", "relation": "NONE", "source_file": "Oxybutynin.xml", "sentence_id": "DDI-DrugBank.d784.s7", "pair_id": "DDI-DrugBank.d784.s7.p18"} {"sentence": "Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ", "drug1": "fluvoxamine", "drug2": "sumatriptan", "relation": "EFFECT", "source_file": "Sumatriptan.xml", "sentence_id": "DDI-DrugBank.d720.s3", "pair_id": "DDI-DrugBank.d720.s3.p32"} {"sentence": "Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ", "drug1": "metoclopramide", "drug2": "hypnotics", "relation": "EFFECT", "source_file": "Metoclopramide.xml", "sentence_id": "DDI-DrugBank.d652.s1", "pair_id": "DDI-DrugBank.d652.s1.p2"} {"sentence": "Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. ", "drug1": "roxithromycin", "drug2": "astemizole", "relation": "ADVISE", "source_file": "Roxithromycin.xml", "sentence_id": "DDI-DrugBank.d709.s3", "pair_id": "DDI-DrugBank.d709.s3.p4"} {"sentence": "Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ", "drug1": "terfenadine", "drug2": "clarithromycin", "relation": "ADVISE", "source_file": "Terfenadine.xml", "sentence_id": "DDI-DrugBank.d743.s12", "pair_id": "DDI-DrugBank.d743.s12.p0"} {"sentence": "Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ", "drug1": "quinpirole", "drug2": "amphetamine", "relation": "NONE", "source_file": "21753255.xml", "sentence_id": "DDI-MedLine.d184.s8", "pair_id": "DDI-MedLine.d184.s8.p0"} {"sentence": "The ratio of norketamine AUC(0- ) to ketamine AUC(0- ) was significantly decreased in the ticlopidine (P < 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ", "drug1": "norketamine", "drug2": "itraconazole", "relation": "NONE", "source_file": "21716267.xml", "sentence_id": "DDI-MedLine.d216.s4", "pair_id": "DDI-MedLine.d216.s4.p2"} {"sentence": "TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.", "drug1": "TOBI", "drug2": "mannitol", "relation": "ADVISE", "source_file": "Tobramycin.xml", "sentence_id": "DDI-DrugBank.d624.s3", "pair_id": "DDI-DrugBank.d624.s3.p3"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "Methscopolamine", "drug2": "phenelzine", "relation": "INT", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p3"} {"sentence": "Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ", "drug1": "metoclopramide", "drug2": "Permax", "relation": "ADVISE", "source_file": "Pergolide.xml", "sentence_id": "DDI-DrugBank.d650.s0", "pair_id": "DDI-DrugBank.d650.s0.p25"} {"sentence": "Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ", "drug1": "metoclopramide", "drug2": "acetaminophen", "relation": "MECHANISM", "source_file": "Metoclopramide.xml", "sentence_id": "DDI-DrugBank.d652.s3", "pair_id": "DDI-DrugBank.d652.s3.p6"} {"sentence": "Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ", "drug1": "tetracyclines", "drug2": "magnesium", "relation": "MECHANISM", "source_file": "Minocycline.xml", "sentence_id": "DDI-DrugBank.d711.s2", "pair_id": "DDI-DrugBank.d711.s2.p3"} {"sentence": "Thiazides may add to or potentiate the action of other antihypertensive drugs. ", "drug1": "Thiazides", "drug2": "antihypertensive drugs", "relation": "EFFECT", "source_file": "Methyclothiazide.xml", "sentence_id": "DDI-DrugBank.d736.s7", "pair_id": "DDI-DrugBank.d736.s7.p0"} {"sentence": "Methysergide may reverse the analgesic activity of narcotic analgesics. ", "drug1": "Methysergide", "drug2": "narcotic analgesics", "relation": "EFFECT", "source_file": "Methysergide.xml", "sentence_id": "DDI-DrugBank.d696.s0", "pair_id": "DDI-DrugBank.d696.s0.p0"} {"sentence": "TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.", "drug1": "TOBI", "drug2": "ethacrynic acid", "relation": "ADVISE", "source_file": "Tobramycin.xml", "sentence_id": "DDI-DrugBank.d624.s3", "pair_id": "DDI-DrugBank.d624.s3.p0"} {"sentence": "In experiment 2, the same regimen of GSLS was administered to chickens inoculated with inactivated AI vaccines, and an enhanced serum antibody response to AI vaccination was also observed. ", "drug1": "GSLS", "drug2": "inactivated AI vaccines", "relation": "EFFECT", "source_file": "21844260.xml", "sentence_id": "DDI-MedLine.d154.s5", "pair_id": "DDI-MedLine.d154.s5.p0"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "antidepressants", "drug2": "furazolidone", "relation": "NONE", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p29"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "polymyxins", "drug2": "procainamide", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p82"} {"sentence": "TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.", "drug1": "TOBI", "drug2": "furosemide", "relation": "ADVISE", "source_file": "Tobramycin.xml", "sentence_id": "DDI-DrugBank.d624.s3", "pair_id": "DDI-DrugBank.d624.s3.p1"} {"sentence": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "drug1": "Moxifloxacin", "drug2": "sucralfate", "relation": "MECHANISM", "source_file": "21715267.xml", "sentence_id": "DDI-MedLine.d231.s8", "pair_id": "DDI-MedLine.d231.s8.p1"} {"sentence": "Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).", "drug1": "Trilostane", "drug2": "mitotane", "relation": "INT", "source_file": "Trilostane.xml", "sentence_id": "DDI-DrugBank.d774.s0", "pair_id": "DDI-DrugBank.d774.s0.p1"} {"sentence": "Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ", "drug1": "SUTENT", "drug2": "rifabutin", "relation": "MECHANISM", "source_file": "Sunitinib.xml", "sentence_id": "DDI-DrugBank.d639.s2", "pair_id": "DDI-DrugBank.d639.s2.p4"} {"sentence": "Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants", "drug1": "antibiotics", "drug2": "muscle relaxants", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s13", "pair_id": "DDI-DrugBank.d775.s13.p45"} {"sentence": "Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. ", "drug1": "Cholestyramine", "drug2": "EVISTA", "relation": "ADVISE", "source_file": "Raloxifene.xml", "sentence_id": "DDI-DrugBank.d648.s0", "pair_id": "DDI-DrugBank.d648.s0.p4"} {"sentence": "When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). ", "drug1": "Cimetidine", "drug2": "cimetidine", "relation": "NONE", "source_file": "Rimantadine.xml", "sentence_id": "DDI-DrugBank.d710.s1", "pair_id": "DDI-DrugBank.d710.s1.p6"} {"sentence": "Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ", "drug1": "fluconazole", "drug2": "midazolam", "relation": "MECHANISM", "source_file": "Midazolam.xml", "sentence_id": "DDI-DrugBank.d752.s1", "pair_id": "DDI-DrugBank.d752.s1.p19"} {"sentence": "Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ", "drug1": "tetracyclines", "drug2": "calcium", "relation": "MECHANISM", "source_file": "Minocycline.xml", "sentence_id": "DDI-DrugBank.d711.s2", "pair_id": "DDI-DrugBank.d711.s2.p2"} {"sentence": "Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ", "drug1": "phenytoin", "drug2": "ondansetron", "relation": "MECHANISM", "source_file": "Ondansetron.xml", "sentence_id": "DDI-DrugBank.d763.s3", "pair_id": "DDI-DrugBank.d763.s3.p21"} {"sentence": "Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ", "drug1": "morphine", "drug2": "psychotropic drugs", "relation": "EFFECT", "source_file": "Morphine.xml", "sentence_id": "DDI-DrugBank.d637.s0", "pair_id": "DDI-DrugBank.d637.s0.p10"} {"sentence": "Nevertheless, during concomitant therapy with furosemide and MOBIC, patients should be observed closely for signs of declining renal function, as well as to assure diuretic efficacy. ", "drug1": "furosemide", "drug2": "MOBIC", "relation": "ADVISE", "source_file": "Meloxicam.xml", "sentence_id": "DDI-DrugBank.d597.s18", "pair_id": "DDI-DrugBank.d597.s18.p0"} {"sentence": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "drug1": "paricalcitol", "drug2": "voriconazole", "relation": "ADVISE", "source_file": "Paricalcitol.xml", "sentence_id": "DDI-DrugBank.d726.s1", "pair_id": "DDI-DrugBank.d726.s1.p64"} {"sentence": "These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ", "drug1": "Cyclosporine", "drug2": "Theophylline", "relation": "NONE", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s2", "pair_id": "DDI-DrugBank.d776.s2.p40"} {"sentence": "Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ", "drug1": "Warfarin", "drug2": "mirtazapine", "relation": "EFFECT", "source_file": "21731754.xml", "sentence_id": "DDI-MedLine.d218.s10", "pair_id": "DDI-MedLine.d218.s10.p4"} {"sentence": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "drug1": "thiazides", "drug2": "phenytoin", "relation": "NONE", "source_file": "Sulfamethizole.xml", "sentence_id": "DDI-DrugBank.d649.s1", "pair_id": "DDI-DrugBank.d649.s1.p5"} {"sentence": "Caution should be exercised when Methergine (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.", "drug1": "Methergine", "drug2": "ergot alkaloids", "relation": "ADVISE", "source_file": "Methylergonovine.xml", "sentence_id": "DDI-DrugBank.d675.s7", "pair_id": "DDI-DrugBank.d675.s7.p2"} {"sentence": "Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.", "drug1": "Mequitazine", "drug2": "MAOIs", "relation": "INT", "source_file": "Mequitazine.xml", "sentence_id": "DDI-DrugBank.d699.s0", "pair_id": "DDI-DrugBank.d699.s0.p3"} {"sentence": "It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast. ", "drug1": "phenobarbital", "drug2": "montelukast", "relation": "ADVISE", "source_file": "Montelukast.xml", "sentence_id": "DDI-DrugBank.d739.s8", "pair_id": "DDI-DrugBank.d739.s8.p1"} {"sentence": "MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ", "drug1": "sympathomimetic pressor amines", "drug2": "MAOI", "relation": "EFFECT", "source_file": "Phenylpropanolamine.xml", "sentence_id": "DDI-DrugBank.d689.s1", "pair_id": "DDI-DrugBank.d689.s1.p4"} {"sentence": "Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0- )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. ", "drug1": "Ticlopidine", "drug2": "ketamine", "relation": "MECHANISM", "source_file": "21716267.xml", "sentence_id": "DDI-MedLine.d216.s3", "pair_id": "DDI-MedLine.d216.s3.p0"} {"sentence": "Interactions for Vitamin B1 (Thiamine): Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants", "drug1": "Thiamine", "drug2": "Stavudine", "relation": "INT", "source_file": "Thiamine.xml", "sentence_id": "DDI-DrugBank.d697.s0", "pair_id": "DDI-DrugBank.d697.s0.p7"} {"sentence": "Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ", "drug1": "coumarin-type anticoagulants", "drug2": "FELDENE", "relation": "NONE", "source_file": "Piroxicam.xml", "sentence_id": "DDI-DrugBank.d656.s1", "pair_id": "DDI-DrugBank.d656.s1.p1"} {"sentence": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "drug1": "paricalcitol", "drug2": "atazanavir", "relation": "ADVISE", "source_file": "Paricalcitol.xml", "sentence_id": "DDI-DrugBank.d726.s1", "pair_id": "DDI-DrugBank.d726.s1.p55"} {"sentence": "Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ", "drug1": "alcohol", "drug2": "REMERON SolTab", "relation": "ADVISE", "source_file": "Mirtazapine.xml", "sentence_id": "DDI-DrugBank.d742.s9", "pair_id": "DDI-DrugBank.d742.s9.p0"} {"sentence": "Ritalin may decrease the hypotensive effect of guanethidine. ", "drug1": "Ritalin", "drug2": "guanethidine", "relation": "EFFECT", "source_file": "Methylphenidate.xml", "sentence_id": "DDI-DrugBank.d638.s0", "pair_id": "DDI-DrugBank.d638.s0.p0"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "Methscopolamine", "drug2": "furazolidone", "relation": "INT", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p8"} {"sentence": "Patients receiving tacrolimus and fluconazole concomitantly should be carefully monitored. ", "drug1": "tacrolimus", "drug2": "fluconazole", "relation": "ADVISE", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s34", "pair_id": "DDI-DrugBank.d776.s34.p0"} {"sentence": "Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ", "drug1": "Myfortic", "drug2": "Myfortic", "relation": "NONE", "source_file": "Mycophenolic acid.xml", "sentence_id": "DDI-DrugBank.d700.s0", "pair_id": "DDI-DrugBank.d700.s0.p8"} {"sentence": "Hyaluronidase: Hyaluronidase may increase the diffusion rate of procaine hydrochloride, resulting in a decreased time of onset, but an increase in systemic toxicity. ", "drug1": "Hyaluronidase", "drug2": "procaine hydrochloride", "relation": "MECHANISM", "source_file": "Procaine.xml", "sentence_id": "DDI-DrugBank.d780.s5", "pair_id": "DDI-DrugBank.d780.s5.p2"} {"sentence": "Patients with mild to moderate renal insufficiency should avoid taking NSAIDs with short elimination half-lives for a period of 2 days before, the day of, and 2 days following administration of ALIMTA. ", "drug1": "NSAIDs", "drug2": "ALIMTA", "relation": "ADVISE", "source_file": "Pemetrexed.xml", "sentence_id": "DDI-DrugBank.d641.s4", "pair_id": "DDI-DrugBank.d641.s4.p0"} {"sentence": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "drug1": "Melatonin", "drug2": "fluvoxamine", "relation": "INT", "source_file": "Melatonin.xml", "sentence_id": "DDI-DrugBank.d643.s0", "pair_id": "DDI-DrugBank.d643.s0.p3"} {"sentence": "The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ", "drug1": "MIVACRON", "drug2": "glucocorticoids", "relation": "EFFECT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s11", "pair_id": "DDI-DrugBank.d775.s11.p1"} {"sentence": "Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ", "drug1": "indinavir", "drug2": "sunitinib", "relation": "NONE", "source_file": "Sunitinib.xml", "sentence_id": "DDI-DrugBank.d639.s0", "pair_id": "DDI-DrugBank.d639.s0.p56"} {"sentence": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "drug1": "nelfinavir", "drug2": "ritonavir", "relation": "NONE", "source_file": "Paricalcitol.xml", "sentence_id": "DDI-DrugBank.d726.s1", "pair_id": "DDI-DrugBank.d726.s1.p110"} {"sentence": "In clinical studies, patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids. ", "drug1": "opioids", "drug2": "pegvisomant", "relation": "MECHANISM", "source_file": "Pegvisomant.xml", "sentence_id": "DDI-DrugBank.d744.s1", "pair_id": "DDI-DrugBank.d744.s1.p0"} {"sentence": "There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. ", "drug1": "PURINETHOL", "drug2": "Thioguanine", "relation": "EFFECT", "source_file": "Thioguanine.xml", "sentence_id": "DDI-DrugBank.d722.s0", "pair_id": "DDI-DrugBank.d722.s0.p2"} {"sentence": "Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants", "drug1": "cisplatin", "drug2": "bacitracin", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s13", "pair_id": "DDI-DrugBank.d775.s13.p49"} {"sentence": "The authors report the case of an infant with confirmed congenital hypothyroidism on levothyroxine who experienced a possible drug interaction with simeticone. ", "drug1": "levothyroxine", "drug2": "simeticone", "relation": "INT", "source_file": "21785118.xml", "sentence_id": "DDI-MedLine.d181.s4", "pair_id": "DDI-MedLine.d181.s4.p0"} {"sentence": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "drug1": "amoxapine", "drug2": "protriptyline", "relation": "NONE", "source_file": "Mazindol.xml", "sentence_id": "DDI-DrugBank.d716.s5", "pair_id": "DDI-DrugBank.d716.s5.p54"} {"sentence": "Coadministration with a high dose of antacid (170 mEq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from TRITEC. ", "drug1": "antacid", "drug2": "ranitidine", "relation": "MECHANISM", "source_file": "Ranitidine.xml", "sentence_id": "DDI-DrugBank.d590.s2", "pair_id": "DDI-DrugBank.d590.s2.p0"} {"sentence": "Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. ", "drug1": "SYMLIN", "drug2": "human insulin", "relation": "MECHANISM", "source_file": "Pramlintide.xml", "sentence_id": "DDI-DrugBank.d632.s6", "pair_id": "DDI-DrugBank.d632.s6.p5"} {"sentence": "Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ", "drug1": "morphine", "drug2": "sedatives", "relation": "EFFECT", "source_file": "Morphine.xml", "sentence_id": "DDI-DrugBank.d637.s0", "pair_id": "DDI-DrugBank.d637.s0.p8"} {"sentence": "Anticoagulants Anabolic steroids may increase sensitivity to oral anticoagulants. ", "drug1": "Anabolic steroids", "drug2": "anticoagulants", "relation": "EFFECT", "source_file": "Oxandrolone.xml", "sentence_id": "DDI-DrugBank.d584.s0", "pair_id": "DDI-DrugBank.d584.s0.p2"} {"sentence": "Therefore, the coadministration of probenecid with meropenem is not recommended. ", "drug1": "probenecid", "drug2": "meropenem", "relation": "ADVISE", "source_file": "Meropenem.xml", "sentence_id": "DDI-DrugBank.d762.s2", "pair_id": "DDI-DrugBank.d762.s2.p0"} {"sentence": "Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ", "drug1": "miconazole", "drug2": "terfenadine", "relation": "ADVISE", "source_file": "Terfenadine.xml", "sentence_id": "DDI-DrugBank.d743.s8", "pair_id": "DDI-DrugBank.d743.s8.p17"} {"sentence": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "drug1": "ketoconazole", "drug2": "paricalcitol", "relation": "MECHANISM", "source_file": "Paricalcitol.xml", "sentence_id": "DDI-DrugBank.d726.s1", "pair_id": "DDI-DrugBank.d726.s1.p0"} {"sentence": "Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol. ", "drug1": "Scopolamine", "drug2": "alcohol", "relation": "ADVISE", "source_file": "Scopolamine.xml", "sentence_id": "DDI-DrugBank.d771.s1", "pair_id": "DDI-DrugBank.d771.s1.p2"} {"sentence": "Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ", "drug1": "SUTENT", "drug2": "clarithromycin", "relation": "MECHANISM", "source_file": "Sunitinib.xml", "sentence_id": "DDI-DrugBank.d639.s0", "pair_id": "DDI-DrugBank.d639.s0.p2"} {"sentence": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "drug1": "Moxifloxacin", "drug2": "erythromycin", "relation": "MECHANISM", "source_file": "21715267.xml", "sentence_id": "DDI-MedLine.d231.s8", "pair_id": "DDI-MedLine.d231.s8.p3"} {"sentence": "Depending on clinical circumstances, consideration should be given to increasing the dose of DIFLUCAN when it is administered with rifampin. ", "drug1": "DIFLUCAN", "drug2": "rifampin", "relation": "ADVISE", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s17", "pair_id": "DDI-DrugBank.d776.s17.p0"} {"sentence": "Dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids. ", "drug1": "levomepromazine", "drug2": "opioids", "relation": "EFFECT", "source_file": "Methotrimeprazine.xml", "sentence_id": "DDI-DrugBank.d756.s0", "pair_id": "DDI-DrugBank.d756.s0.p2"} {"sentence": "Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ", "drug1": "quinidine", "drug2": "indomethacin", "relation": "NONE", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s6", "pair_id": "DDI-DrugBank.d737.s6.p59"} {"sentence": "Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ", "drug1": "clarithromycin", "drug2": "macrolide antibiotics", "relation": "NONE", "source_file": "Terfenadine.xml", "sentence_id": "DDI-DrugBank.d743.s12", "pair_id": "DDI-DrugBank.d743.s12.p9"} {"sentence": "Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). ", "drug1": "SYMLIN", "drug2": "atropine", "relation": "ADVISE", "source_file": "Pramlintide.xml", "sentence_id": "DDI-DrugBank.d632.s0", "pair_id": "DDI-DrugBank.d632.s0.p1"} {"sentence": "Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ", "drug1": "metronidazole", "drug2": "terfenadine", "relation": "ADVISE", "source_file": "Terfenadine.xml", "sentence_id": "DDI-DrugBank.d743.s8", "pair_id": "DDI-DrugBank.d743.s8.p14"} {"sentence": "It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.", "drug1": "rifampin", "drug2": "montelukast", "relation": "ADVISE", "source_file": "Montelukast.xml", "sentence_id": "DDI-DrugBank.d739.s15", "pair_id": "DDI-DrugBank.d739.s15.p2"} {"sentence": "In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ", "drug1": "TOBI", "drug2": "corticosteroids", "relation": "EFFECT", "source_file": "Tobramycin.xml", "sentence_id": "DDI-DrugBank.d624.s0", "pair_id": "DDI-DrugBank.d624.s0.p10"} {"sentence": "Mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin. ", "drug1": "Mitotane", "drug2": "warfarin", "relation": "MECHANISM", "source_file": "Mitotane.xml", "sentence_id": "DDI-DrugBank.d717.s0", "pair_id": "DDI-DrugBank.d717.s0.p0"} {"sentence": "This is especially true if the total dose of atropine has been large and the administration of pralidoxime has been delayed. ", "drug1": "atropine", "drug2": "pralidoxime", "relation": "NONE", "source_file": "Pralidoxime.xml", "sentence_id": "DDI-DrugBank.d622.s1", "pair_id": "DDI-DrugBank.d622.s1.p0"} {"sentence": "You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ", "drug1": "mazindol", "drug2": "Parnate", "relation": "ADVISE", "source_file": "Mazindol.xml", "sentence_id": "DDI-DrugBank.d716.s0", "pair_id": "DDI-DrugBank.d716.s0.p5"} {"sentence": "HEY cells treated with dasatinib plus paclitaxel formed fewer colonies than did cells treated with either agent alone. ", "drug1": "dasatinib", "drug2": "paclitaxel", "relation": "EFFECT", "source_file": "21813412.xml", "sentence_id": "DDI-MedLine.d194.s9", "pair_id": "DDI-MedLine.d194.s9.p0"} {"sentence": "Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors. ", "drug1": "TRENTAL", "drug2": "platelet aggregation inhibitors", "relation": "EFFECT", "source_file": "Pentoxifylline.xml", "sentence_id": "DDI-DrugBank.d659.s0", "pair_id": "DDI-DrugBank.d659.s0.p1"} {"sentence": "ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ", "drug1": "doxazosin", "drug2": "ProAmatine", "relation": "EFFECT", "source_file": "Midodrine.xml", "sentence_id": "DDI-DrugBank.d603.s5", "pair_id": "DDI-DrugBank.d603.s5.p46"} {"sentence": "MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ", "drug1": "sympathomimetic pressor amines", "drug2": "MAOI", "relation": "EFFECT", "source_file": "Phenylephrine.xml", "sentence_id": "DDI-DrugBank.d725.s1", "pair_id": "DDI-DrugBank.d725.s1.p4"} {"sentence": "Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ", "drug1": "SUTENT", "drug2": "itraconazole", "relation": "MECHANISM", "source_file": "Sunitinib.xml", "sentence_id": "DDI-DrugBank.d639.s0", "pair_id": "DDI-DrugBank.d639.s0.p1"} {"sentence": "Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.", "drug1": "Sunitinib", "drug2": "sunitinib", "relation": "NONE", "source_file": "21796416.xml", "sentence_id": "DDI-MedLine.d179.s10", "pair_id": "DDI-MedLine.d179.s10.p2"} {"sentence": "No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.", "drug1": "glycopyrrolate", "drug2": "hydroxyzine", "relation": "NONE", "source_file": "Midazolam.xml", "sentence_id": "DDI-DrugBank.d752.s12", "pair_id": "DDI-DrugBank.d752.s12.p12"} {"sentence": "The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine . Therefore, caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction. ", "drug1": "dihydroergotamine", "drug2": "ProAmatine", "relation": "EFFECT", "source_file": "Midodrine.xml", "sentence_id": "DDI-DrugBank.d603.s2", "pair_id": "DDI-DrugBank.d603.s2.p18"} {"sentence": "Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ", "drug1": "triamterene", "drug2": "chlorpropamide", "relation": "NONE", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s6", "pair_id": "DDI-DrugBank.d737.s6.p44"} {"sentence": "Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.", "drug1": "Isopto Carbachol", "drug2": "suprofen", "relation": "EFFECT", "source_file": "Suprofen.xml", "sentence_id": "DDI-DrugBank.d723.s0", "pair_id": "DDI-DrugBank.d723.s0.p14"} {"sentence": "Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ", "drug1": "Antiplatelet Agents", "drug2": "antiplatelet agents", "relation": "NONE", "source_file": "Streptokinase.xml", "sentence_id": "DDI-DrugBank.d777.s1", "pair_id": "DDI-DrugBank.d777.s1.p7"} {"sentence": "Patients who take both ezetimibe and cyclosporine should be carefully monitored. ", "drug1": "ezetimibe", "drug2": "cyclosporine", "relation": "ADVISE", "source_file": "Ezetimibe.xml", "sentence_id": "DDI-DrugBank.d572.s10", "pair_id": "DDI-DrugBank.d572.s10.p0"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "colistin", "drug2": "lithium", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p101"} {"sentence": "Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ", "drug1": "dasatinib", "drug2": "paclitaxel", "relation": "EFFECT", "source_file": "21813412.xml", "sentence_id": "DDI-MedLine.d194.s10", "pair_id": "DDI-MedLine.d194.s10.p0"} {"sentence": "Interactions for Vitamin B1 (Thiamine): Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants", "drug1": "Vitamin B1", "drug2": "Tricyclic Antidepressants", "relation": "INT", "source_file": "Thiamine.xml", "sentence_id": "DDI-DrugBank.d697.s0", "pair_id": "DDI-DrugBank.d697.s0.p4"} {"sentence": "ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ", "drug1": "procainamide", "drug2": "triamterene", "relation": "NONE", "source_file": "Midodrine.xml", "sentence_id": "DDI-DrugBank.d603.s5", "pair_id": "DDI-DrugBank.d603.s5.p85"} {"sentence": "Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.", "drug1": "Mephenytoin", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Mephenytoin.xml", "sentence_id": "DDI-DrugBank.d636.s3", "pair_id": "DDI-DrugBank.d636.s3.p1"} {"sentence": "Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. ", "drug1": "midazolam", "drug2": "fluconazole", "relation": "MECHANISM", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s35", "pair_id": "DDI-DrugBank.d776.s35.p3"} {"sentence": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "drug1": "paricalcitol", "drug2": "ketoconazole", "relation": "NONE", "source_file": "Paricalcitol.xml", "sentence_id": "DDI-DrugBank.d726.s1", "pair_id": "DDI-DrugBank.d726.s1.p31"} {"sentence": "Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ", "drug1": "heparin", "drug2": "TNKase", "relation": "EFFECT", "source_file": "Tenecteplase.xml", "sentence_id": "DDI-DrugBank.d773.s2", "pair_id": "DDI-DrugBank.d773.s2.p8"} {"sentence": "ARAMINE should be used with caution in digitalized patients, since the combination of digitalis and sympathomimetic amines may cause ectopic arrhythmias. ", "drug1": "digitalis", "drug2": "sympathomimetic amines", "relation": "EFFECT", "source_file": "Metaraminol.xml", "sentence_id": "DDI-DrugBank.d746.s0", "pair_id": "DDI-DrugBank.d746.s0.p2"} {"sentence": "Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ", "drug1": "naproxen", "drug2": "corticosteroids", "relation": "NONE", "source_file": "Salsalate.xml", "sentence_id": "DDI-DrugBank.d576.s6", "pair_id": "DDI-DrugBank.d576.s6.p51"} {"sentence": "Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ", "drug1": "midazolam", "drug2": "protease inhibitors", "relation": "ADVISE", "source_file": "Midazolam.xml", "sentence_id": "DDI-DrugBank.d752.s0", "pair_id": "DDI-DrugBank.d752.s0.p1"} {"sentence": "We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. ", "drug1": "DZNep", "drug2": "ABT-737", "relation": "EFFECT", "source_file": "21720561.xml", "sentence_id": "DDI-MedLine.d180.s10", "pair_id": "DDI-MedLine.d180.s10.p3"} {"sentence": "Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. ", "drug1": "Cholestyramine", "drug2": "raloxifene", "relation": "MECHANISM", "source_file": "Raloxifene.xml", "sentence_id": "DDI-DrugBank.d648.s0", "pair_id": "DDI-DrugBank.d648.s0.p3"} {"sentence": "Ticagrelor (Brilinta)--better than clopidogrel (Plavix)", "drug1": "Ticagrelor", "drug2": "Plavix", "relation": "NONE", "source_file": "21897348.xml", "sentence_id": "DDI-MedLine.d193.s0", "pair_id": "DDI-MedLine.d193.s0.p2"} {"sentence": "In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2. ", "drug1": "mexiletine", "drug2": "fluvoxamine", "relation": "MECHANISM", "source_file": "Mexiletine.xml", "sentence_id": "DDI-DrugBank.d633.s1", "pair_id": "DDI-DrugBank.d633.s1.p0"} {"sentence": "AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase. ", "drug1": "AAV2", "drug2": "chondroitin ABC lyase", "relation": "EFFECT", "source_file": "21750604.xml", "sentence_id": "DDI-MedLine.d190.s8", "pair_id": "DDI-MedLine.d190.s8.p1"} {"sentence": "Astemizole: The use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs. ", "drug1": "fluconazole", "drug2": "astemizole", "relation": "MECHANISM", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s28", "pair_id": "DDI-DrugBank.d776.s28.p2"} {"sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.", "drug1": "antibiotics", "drug2": "anticoagulants", "relation": "NONE", "source_file": "Secobarbital.xml", "sentence_id": "DDI-DrugBank.d601.s0", "pair_id": "DDI-DrugBank.d601.s0.p16"} {"sentence": "The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. ", "drug1": "isoflurane", "drug2": "DIPRIVAN", "relation": "NONE", "source_file": "Propofol.xml", "sentence_id": "DDI-DrugBank.d628.s4", "pair_id": "DDI-DrugBank.d628.s4.p2"} {"sentence": "Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ", "drug1": "midazolam", "drug2": "macrolide antibiotics", "relation": "ADVISE", "source_file": "Midazolam.xml", "sentence_id": "DDI-DrugBank.d752.s0", "pair_id": "DDI-DrugBank.d752.s0.p3"} {"sentence": "There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. ", "drug1": "mercaptopurine", "drug2": "TABLOID", "relation": "EFFECT", "source_file": "Thioguanine.xml", "sentence_id": "DDI-DrugBank.d722.s0", "pair_id": "DDI-DrugBank.d722.s0.p3"} {"sentence": "Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering Mitotane to patients on coumarin-type anticoagulants. ", "drug1": "Mitotane", "drug2": "coumarin-type anticoagulants", "relation": "ADVISE", "source_file": "Mitotane.xml", "sentence_id": "DDI-DrugBank.d717.s1", "pair_id": "DDI-DrugBank.d717.s1.p2"} {"sentence": "When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil , lowered Mexitil plasma levels have been reported. ", "drug1": "phenytoin", "drug2": "Mexitil", "relation": "MECHANISM", "source_file": "Mexiletine.xml", "sentence_id": "DDI-DrugBank.d633.s9", "pair_id": "DDI-DrugBank.d633.s9.p2"} {"sentence": "Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.", "drug1": "sunitinib", "drug2": "docetaxel", "relation": "INT", "source_file": "21796416.xml", "sentence_id": "DDI-MedLine.d179.s0", "pair_id": "DDI-MedLine.d179.s0.p0"} {"sentence": "There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. ", "drug1": "PURINETHOL", "drug2": "TABLOID", "relation": "EFFECT", "source_file": "Thioguanine.xml", "sentence_id": "DDI-DrugBank.d722.s0", "pair_id": "DDI-DrugBank.d722.s0.p1"} {"sentence": "Caution should be used when administering MOBIC with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.", "drug1": "MOBIC", "drug2": "warfarin", "relation": "ADVISE", "source_file": "Meloxicam.xml", "sentence_id": "DDI-DrugBank.d597.s30", "pair_id": "DDI-DrugBank.d597.s30.p0"} {"sentence": "however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects. ", "drug1": "NSAIDs", "drug2": "aspirin", "relation": "ADVISE", "source_file": "Meloxicam.xml", "sentence_id": "DDI-DrugBank.d597.s4", "pair_id": "DDI-DrugBank.d597.s4.p1"} {"sentence": "The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ", "drug1": "SKELID", "drug2": "SKELID", "relation": "NONE", "source_file": "Tiludronate.xml", "sentence_id": "DDI-DrugBank.d721.s0", "pair_id": "DDI-DrugBank.d721.s0.p6"} {"sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "drug1": "anticholinergic drugs", "drug2": "sympathomimetic agents", "relation": "EFFECT", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s0", "pair_id": "DDI-DrugBank.d585.s0.p12"} {"sentence": "In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis. ", "drug1": "ABT-737", "drug2": "DZNep", "relation": "EFFECT", "source_file": "21720561.xml", "sentence_id": "DDI-MedLine.d180.s12", "pair_id": "DDI-MedLine.d180.s12.p2"} {"sentence": "Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. ", "drug1": "Sulfoxone", "drug2": "tolbutamide", "relation": "EFFECT", "source_file": "Sulfoxone.xml", "sentence_id": "DDI-DrugBank.d682.s0", "pair_id": "DDI-DrugBank.d682.s0.p1"} {"sentence": "AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase. ", "drug1": "AAV2", "drug2": "heparinase III", "relation": "EFFECT", "source_file": "21750604.xml", "sentence_id": "DDI-MedLine.d190.s8", "pair_id": "DDI-MedLine.d190.s8.p0"} {"sentence": "While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.", "drug1": "hydroxychloroquine sulfate", "drug2": "ibuprofen", "relation": "NONE", "source_file": "Pilocarpine.xml", "sentence_id": "DDI-DrugBank.d627.s4", "pair_id": "DDI-DrugBank.d627.s4.p33"} {"sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "drug1": "anticholinergic drugs", "drug2": "antipsychotic agents", "relation": "EFFECT", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s0", "pair_id": "DDI-DrugBank.d585.s0.p4"} {"sentence": "The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ", "drug1": "VERSED Syrup", "drug2": "morphine", "relation": "EFFECT", "source_file": "Midazolam.xml", "sentence_id": "DDI-DrugBank.d752.s10", "pair_id": "DDI-DrugBank.d752.s10.p1"} {"sentence": "Concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth. ", "drug1": "tetracycline", "drug2": "penicillins", "relation": "EFFECT", "source_file": "Penicillin G.xml", "sentence_id": "DDI-DrugBank.d665.s0", "pair_id": "DDI-DrugBank.d665.s0.p5"} {"sentence": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "drug1": "Anafranil", "drug2": "Vivactil", "relation": "NONE", "source_file": "Mazindol.xml", "sentence_id": "DDI-DrugBank.d716.s5", "pair_id": "DDI-DrugBank.d716.s5.p127"} {"sentence": "While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.", "drug1": "multivitamins", "drug2": "omeprazole", "relation": "NONE", "source_file": "Pilocarpine.xml", "sentence_id": "DDI-DrugBank.d627.s4", "pair_id": "DDI-DrugBank.d627.s4.p69"} {"sentence": "Inhibition of Src family and Abl kinases with either siRNAs or dasatinib enhances paclitaxel sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.", "drug1": "dasatinib", "drug2": "paclitaxel", "relation": "EFFECT", "source_file": "21813412.xml", "sentence_id": "DDI-MedLine.d194.s17", "pair_id": "DDI-MedLine.d194.s17.p0"} {"sentence": "The molecular basis of this synergism is that the signaling pathways that were initially activated by docetaxel exposure were efficiently suppressed by the subsequent exposure to sunitinib. ", "drug1": "docetaxel", "drug2": "sunitinib", "relation": "EFFECT", "source_file": "21796416.xml", "sentence_id": "DDI-MedLine.d179.s8", "pair_id": "DDI-MedLine.d179.s8.p0"} {"sentence": "It is recommended that Myfortic and antacids not be administered simultaneously. ", "drug1": "Myfortic", "drug2": "antacids", "relation": "ADVISE", "source_file": "Mycophenolic acid.xml", "sentence_id": "DDI-DrugBank.d700.s1", "pair_id": "DDI-DrugBank.d700.s1.p0"} {"sentence": "Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered. ", "drug1": "fluconazole", "drug2": "cisapride", "relation": "EFFECT", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s25", "pair_id": "DDI-DrugBank.d776.s25.p2"} {"sentence": "Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ", "drug1": "Streptokinase", "drug2": "antiplatelet agents", "relation": "EFFECT", "source_file": "Streptokinase.xml", "sentence_id": "DDI-DrugBank.d777.s1", "pair_id": "DDI-DrugBank.d777.s1.p12"} {"sentence": "Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ", "drug1": "chlorpropamide", "drug2": "pramipexole", "relation": "MECHANISM", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s6", "pair_id": "DDI-DrugBank.d737.s6.p90"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "tranylcypromine", "drug2": "diphenhydramine", "relation": "NONE", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p123"} {"sentence": "Additionally, in one controlled study in five normal subjects and seven patients, the clearance of caffeine was decreased 50% following the administration of Mexitil .", "drug1": "caffeine", "drug2": "Mexitil", "relation": "MECHANISM", "source_file": "Mexiletine.xml", "sentence_id": "DDI-DrugBank.d633.s20", "pair_id": "DDI-DrugBank.d633.s20.p0"} {"sentence": "Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.", "drug1": "Sympathomimetics", "drug2": "veratrum alkaloids", "relation": "EFFECT", "source_file": "Pseudoephedrine.xml", "sentence_id": "DDI-DrugBank.d606.s1", "pair_id": "DDI-DrugBank.d606.s1.p3"} {"sentence": "Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ", "drug1": "modafinil", "drug2": "carbamazepine", "relation": "NONE", "source_file": "Thalidomide.xml", "sentence_id": "DDI-DrugBank.d604.s4", "pair_id": "DDI-DrugBank.d604.s4.p34"} {"sentence": "Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ", "drug1": "Sanctura", "drug2": "vancomycin", "relation": "MECHANISM", "source_file": "Trospium.xml", "sentence_id": "DDI-DrugBank.d713.s2", "pair_id": "DDI-DrugBank.d713.s2.p12"} {"sentence": "Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ", "drug1": "MEPERIDINE", "drug2": "CNS DEPRESSANTS", "relation": "ADVISE", "source_file": "Meperidine.xml", "sentence_id": "DDI-DrugBank.d703.s0", "pair_id": "DDI-DrugBank.d703.s0.p17"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "nondepolarizing agents", "drug2": "bacitracin", "relation": "INT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p4"} {"sentence": "Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.", "drug1": "Mequitazine", "drug2": "alcohol", "relation": "INT", "source_file": "Mequitazine.xml", "sentence_id": "DDI-DrugBank.d699.s0", "pair_id": "DDI-DrugBank.d699.s0.p4"} {"sentence": "However, ketoconazole, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing.", "drug1": "ketoconazole", "drug2": "mometasone furoate", "relation": "MECHANISM", "source_file": "Mometasone.xml", "sentence_id": "DDI-DrugBank.d580.s1", "pair_id": "DDI-DrugBank.d580.s1.p0"} {"sentence": "Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ", "drug1": "metoclopramide", "drug2": "narcotics", "relation": "EFFECT", "source_file": "Metoclopramide.xml", "sentence_id": "DDI-DrugBank.d652.s1", "pair_id": "DDI-DrugBank.d652.s1.p3"} {"sentence": "dasatinib + paclitaxel vs. ", "drug1": "dasatinib", "drug2": "paclitaxel", "relation": "NONE", "source_file": "21813412.xml", "sentence_id": "DDI-MedLine.d194.s11", "pair_id": "DDI-MedLine.d194.s11.p0"} {"sentence": "Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates. ", "drug1": "levomepromazine", "drug2": "barbiturates", "relation": "EFFECT", "source_file": "Methotrimeprazine.xml", "sentence_id": "DDI-DrugBank.d756.s2", "pair_id": "DDI-DrugBank.d756.s2.p1"} {"sentence": "The finding that metoclopramide releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving monoamine oxi-dase inhibitors. ", "drug1": "metoclopramide", "drug2": "monoamine oxi-dase inhibitors", "relation": "ADVISE", "source_file": "Metoclopramide.xml", "sentence_id": "DDI-DrugBank.d652.s2", "pair_id": "DDI-DrugBank.d652.s2.p0"} {"sentence": "In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ", "drug1": "ethinyl estradiol", "drug2": "terfenadine", "relation": "NONE", "source_file": "Montelukast.xml", "sentence_id": "DDI-DrugBank.d739.s10", "pair_id": "DDI-DrugBank.d739.s10.p39"} {"sentence": "This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition. ", "drug1": "cyclosporine", "drug2": "cyclosporine", "relation": "NONE", "source_file": "21753749.xml", "sentence_id": "DDI-MedLine.d213.s5", "pair_id": "DDI-MedLine.d213.s5.p1"} {"sentence": "Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ", "drug1": "HIV-protease inhibitors", "drug2": "penicillins", "relation": "NONE", "source_file": "Thalidomide.xml", "sentence_id": "DDI-DrugBank.d604.s4", "pair_id": "DDI-DrugBank.d604.s4.p19"} {"sentence": "The incremental LDL-C reduction due to adding ezetimibe to cholestyramine may be reduced by this interaction. ", "drug1": "ezetimibe", "drug2": "cholestyramine", "relation": "EFFECT", "source_file": "Ezetimibe.xml", "sentence_id": "DDI-DrugBank.d572.s1", "pair_id": "DDI-DrugBank.d572.s1.p0"} {"sentence": "When cells were exposed to docetaxel followed by sunitinib, synergism was observed. ", "drug1": "docetaxel", "drug2": "sunitinib", "relation": "EFFECT", "source_file": "21796416.xml", "sentence_id": "DDI-MedLine.d179.s7", "pair_id": "DDI-MedLine.d179.s7.p0"} {"sentence": "Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ", "drug1": "diazepam", "drug2": "ethinyl estradiol", "relation": "NONE", "source_file": "Pantoprazole.xml", "sentence_id": "DDI-DrugBank.d680.s1", "pair_id": "DDI-DrugBank.d680.s1.p138"} {"sentence": "Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.", "drug1": "aspirin", "drug2": "methazolamide", "relation": "ADVISE", "source_file": "Methazolamide.xml", "sentence_id": "DDI-DrugBank.d630.s1", "pair_id": "DDI-DrugBank.d630.s1.p0"} {"sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.", "drug1": "Barbiturates", "drug2": "anticoagulants", "relation": "INT", "source_file": "Secobarbital.xml", "sentence_id": "DDI-DrugBank.d601.s0", "pair_id": "DDI-DrugBank.d601.s0.p5"} {"sentence": "An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. ", "drug1": "gemfibrozil", "drug2": "rosiglitazone", "relation": "MECHANISM", "source_file": "Rosiglitazone.xml", "sentence_id": "DDI-DrugBank.d609.s0", "pair_id": "DDI-DrugBank.d609.s0.p0"} {"sentence": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ", "drug1": "clarithromycin", "drug2": "DETROL LA", "relation": "ADVISE", "source_file": "Tolterodine.xml", "sentence_id": "DDI-DrugBank.d765.s1", "pair_id": "DDI-DrugBank.d765.s1.p41"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "nondepolarizing agents", "drug2": "sodium colistimethate", "relation": "INT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p9"} {"sentence": "Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ", "drug1": "fluoxetine", "drug2": "sumatriptan", "relation": "EFFECT", "source_file": "Sumatriptan.xml", "sentence_id": "DDI-DrugBank.d720.s3", "pair_id": "DDI-DrugBank.d720.s3.p29"} {"sentence": "In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin. ", "drug1": "azole antifungals", "drug2": "fluconazole", "relation": "NONE", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s7", "pair_id": "DDI-DrugBank.d776.s7.p0"} {"sentence": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ", "drug1": "clarithromycin", "drug2": "delavirdine", "relation": "NONE", "source_file": "Methylergonovine.xml", "sentence_id": "DDI-DrugBank.d675.s2", "pair_id": "DDI-DrugBank.d675.s2.p41"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "MIVACRON", "drug2": "sodium colistimethate", "relation": "INT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p23"} {"sentence": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "drug1": "aspirin", "drug2": "melatonin", "relation": "NONE", "source_file": "Melatonin.xml", "sentence_id": "DDI-DrugBank.d643.s0", "pair_id": "DDI-DrugBank.d643.s0.p28"} {"sentence": "Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ", "drug1": "coumarin anticoagulants", "drug2": "phenylbutazone", "relation": "NONE", "source_file": "Methylphenidate.xml", "sentence_id": "DDI-DrugBank.d638.s2", "pair_id": "DDI-DrugBank.d638.s2.p14"} {"sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "drug1": "meperidine", "drug2": "tricyclic antidepressants", "relation": "NONE", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s0", "pair_id": "DDI-DrugBank.d585.s0.p98"} {"sentence": "Therefore, caution should be exercised with concomitant administration of warfarin and FLOMAX capsules. ", "drug1": "warfarin", "drug2": "FLOMAX", "relation": "ADVISE", "source_file": "Tamsulosin.xml", "sentence_id": "DDI-DrugBank.d704.s6", "pair_id": "DDI-DrugBank.d704.s6.p0"} {"sentence": "Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ", "drug1": "terfenadine", "drug2": "azithromycin", "relation": "ADVISE", "source_file": "Terfenadine.xml", "sentence_id": "DDI-DrugBank.d743.s12", "pair_id": "DDI-DrugBank.d743.s12.p19"} {"sentence": "Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ", "drug1": "phenytoin", "drug2": "ondansetron", "relation": "MECHANISM", "source_file": "Ondansetron.xml", "sentence_id": "DDI-DrugBank.d763.s3", "pair_id": "DDI-DrugBank.d763.s3.p20"} {"sentence": "Usage with Alcohol: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving pentazocine.", "drug1": "alcohol", "drug2": "pentazocine", "relation": "ADVISE", "source_file": "Pentazocine.xml", "sentence_id": "DDI-DrugBank.d757.s0", "pair_id": "DDI-DrugBank.d757.s0.p2"} {"sentence": "Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. ", "drug1": "Myfortic", "drug2": "activated charcoal", "relation": "ADVISE", "source_file": "Mycophenolic acid.xml", "sentence_id": "DDI-DrugBank.d700.s8", "pair_id": "DDI-DrugBank.d700.s8.p1"} {"sentence": "Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ", "drug1": "buprenorphine", "drug2": "opioid agonist analgesic", "relation": "ADVISE", "source_file": "Morphine.xml", "sentence_id": "DDI-DrugBank.d637.s2", "pair_id": "DDI-DrugBank.d637.s2.p20"} {"sentence": "Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ", "drug1": "dexamethasone", "drug2": "sunitinib", "relation": "NONE", "source_file": "Sunitinib.xml", "sentence_id": "DDI-DrugBank.d639.s2", "pair_id": "DDI-DrugBank.d639.s2.p14"} {"sentence": "Patients treated with proton pump inhibitors and warfarin concomitantly should be monitored for increases in INR and prothrombin time. ", "drug1": "proton pump inhibitors", "drug2": "warfarin", "relation": "ADVISE", "source_file": "Pantoprazole.xml", "sentence_id": "DDI-DrugBank.d680.s7", "pair_id": "DDI-DrugBank.d680.s7.p0"} {"sentence": "Changes in insulin and other diabetes drug therapies may be necessary during treatment with mazindol.", "drug1": "insulin", "drug2": "mazindol", "relation": "ADVISE", "source_file": "Mazindol.xml", "sentence_id": "DDI-DrugBank.d716.s1", "pair_id": "DDI-DrugBank.d716.s1.p0"} {"sentence": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "drug1": "Vivactil", "drug2": "desipramine", "relation": "NONE", "source_file": "Mazindol.xml", "sentence_id": "DDI-DrugBank.d716.s5", "pair_id": "DDI-DrugBank.d716.s5.p133"} {"sentence": "Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ", "drug1": "acetylsalicylic acid", "drug2": "TNKase", "relation": "EFFECT", "source_file": "Tenecteplase.xml", "sentence_id": "DDI-DrugBank.d773.s2", "pair_id": "DDI-DrugBank.d773.s2.p13"} {"sentence": "Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ", "drug1": "neuroleptics", "drug2": "MIRAPEX", "relation": "EFFECT", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s10", "pair_id": "DDI-DrugBank.d737.s10.p34"} {"sentence": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "drug1": "Melatonin", "drug2": "progestin", "relation": "INT", "source_file": "Melatonin.xml", "sentence_id": "DDI-DrugBank.d643.s0", "pair_id": "DDI-DrugBank.d643.s0.p8"} {"sentence": "The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. ", "drug1": "oxybutynin", "drug2": "anticholinergic drugs", "relation": "EFFECT", "source_file": "Oxybutynin.xml", "sentence_id": "DDI-DrugBank.d784.s0", "pair_id": "DDI-DrugBank.d784.s0.p0"} {"sentence": "However, the impairment of cognitive and motor skills produced by REMERON were shown to be additive with those produced by alcohol. ", "drug1": "REMERON", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Mirtazapine.xml", "sentence_id": "DDI-DrugBank.d742.s8", "pair_id": "DDI-DrugBank.d742.s8.p0"} {"sentence": "We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells. ", "drug1": "celecoxib", "drug2": "celecoxib", "relation": "NONE", "source_file": "21763710.xml", "sentence_id": "DDI-MedLine.d217.s5", "pair_id": "DDI-MedLine.d217.s5.p0"} {"sentence": "Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ", "drug1": "triamterene", "drug2": "cyclosporine", "relation": "NONE", "source_file": "Perindopril.xml", "sentence_id": "DDI-DrugBank.d781.s6", "pair_id": "DDI-DrugBank.d781.s6.p21"} {"sentence": "Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ", "drug1": "FELDENE", "drug2": "aspirin", "relation": "MECHANISM", "source_file": "Piroxicam.xml", "sentence_id": "DDI-DrugBank.d656.s2", "pair_id": "DDI-DrugBank.d656.s2.p7"} {"sentence": "Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ", "drug1": "diltiazem", "drug2": "midazolam", "relation": "MECHANISM", "source_file": "Midazolam.xml", "sentence_id": "DDI-DrugBank.d752.s1", "pair_id": "DDI-DrugBank.d752.s1.p10"} {"sentence": "The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of selegiline and meperidine. ", "drug1": "selegiline", "drug2": "meperidine", "relation": "EFFECT", "source_file": "Selegiline.xml", "sentence_id": "DDI-DrugBank.d619.s0", "pair_id": "DDI-DrugBank.d619.s0.p0"} {"sentence": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "drug1": "melatonin", "drug2": "corticosteroids", "relation": "NONE", "source_file": "Melatonin.xml", "sentence_id": "DDI-DrugBank.d643.s0", "pair_id": "DDI-DrugBank.d643.s0.p54"} {"sentence": "- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ", "drug1": "pimozide", "drug2": "macrolide antibacterials", "relation": "MECHANISM", "source_file": "Roxithromycin.xml", "sentence_id": "DDI-DrugBank.d709.s4", "pair_id": "DDI-DrugBank.d709.s4.p6"} {"sentence": "Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. ", "drug1": "Sulfamethizole", "drug2": "uricosurics", "relation": "EFFECT", "source_file": "Sulfamethizole.xml", "sentence_id": "DDI-DrugBank.d649.s0", "pair_id": "DDI-DrugBank.d649.s0.p2"} {"sentence": "The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ", "drug1": "propofol", "drug2": "nitrous oxide", "relation": "NONE", "source_file": "Midazolam.xml", "sentence_id": "DDI-DrugBank.d752.s10", "pair_id": "DDI-DrugBank.d752.s10.p36"} {"sentence": "Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ", "drug1": "coumarin-type anticoagulants", "drug2": "FELDENE", "relation": "NONE", "source_file": "Piroxicam.xml", "sentence_id": "DDI-DrugBank.d656.s1", "pair_id": "DDI-DrugBank.d656.s1.p2"} {"sentence": "Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ", "drug1": "Posicor", "drug2": "astemizole", "relation": "MECHANISM", "source_file": "Mibefradil.xml", "sentence_id": "DDI-DrugBank.d783.s0", "pair_id": "DDI-DrugBank.d783.s0.p1"} {"sentence": "Salicylates and Other Non-Steroidal Anti-Inflammatory Drugs: May decrease the antihypertensive effects of MYKROX Tablets. ", "drug1": "Non-Steroidal Anti-Inflammatory Drugs", "drug2": "MYKROX", "relation": "EFFECT", "source_file": "Metolazone.xml", "sentence_id": "DDI-DrugBank.d588.s10", "pair_id": "DDI-DrugBank.d588.s10.p2"} {"sentence": "Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ", "drug1": "quinidine", "drug2": "pramipexole", "relation": "MECHANISM", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s6", "pair_id": "DDI-DrugBank.d737.s6.p56"} {"sentence": "Calcium doses 1000 mg diminished nonheme iron absorption by an average of 49.6%.", "drug1": "Calcium", "drug2": "nonheme iron", "relation": "MECHANISM", "source_file": "21795430.xml", "sentence_id": "DDI-MedLine.d169.s8", "pair_id": "DDI-MedLine.d169.s8.p0"} {"sentence": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ", "drug1": "itraconazole", "drug2": "oxybutynin", "relation": "MECHANISM", "source_file": "Oxybutynin.xml", "sentence_id": "DDI-DrugBank.d784.s4", "pair_id": "DDI-DrugBank.d784.s4.p10"} {"sentence": "Curariform Drugs: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea. ", "drug1": "Diuretic", "drug2": "tubocurarine", "relation": "EFFECT", "source_file": "Metolazone.xml", "sentence_id": "DDI-DrugBank.d588.s8", "pair_id": "DDI-DrugBank.d588.s8.p4"} {"sentence": "Montelukast at Doses of 100 mg Daily Dosed to Pharmacokinetic Steady State: - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg. ", "drug1": "Montelukast", "drug2": "estradiol", "relation": "NONE", "source_file": "Montelukast.xml", "sentence_id": "DDI-DrugBank.d739.s4", "pair_id": "DDI-DrugBank.d739.s4.p2"} {"sentence": "Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron. ", "drug1": "Calcium", "drug2": "heme iron", "relation": "MECHANISM", "source_file": "21795430.xml", "sentence_id": "DDI-MedLine.d169.s1", "pair_id": "DDI-MedLine.d169.s1.p1"} {"sentence": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "drug1": "Melatonin", "drug2": "benzodiazepenes", "relation": "INT", "source_file": "Melatonin.xml", "sentence_id": "DDI-DrugBank.d643.s0", "pair_id": "DDI-DrugBank.d643.s0.p11"} {"sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.", "drug1": "Barbiturates", "drug2": "beta blockers", "relation": "INT", "source_file": "Secobarbital.xml", "sentence_id": "DDI-DrugBank.d601.s0", "pair_id": "DDI-DrugBank.d601.s0.p6"} {"sentence": "Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of ethinyl estradiol were studied. ", "drug1": "ethinyl estradiol", "drug2": "norethindrone acetate", "relation": "NONE", "source_file": "Thalidomide.xml", "sentence_id": "DDI-DrugBank.d604.s2", "pair_id": "DDI-DrugBank.d604.s2.p7"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "tranylcypromine", "drug2": "potassium chloride", "relation": "NONE", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p125"} {"sentence": "Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ", "drug1": "ketoconazole", "drug2": "mifepristone", "relation": "MECHANISM", "source_file": "Mifepristone.xml", "sentence_id": "DDI-DrugBank.d668.s0", "pair_id": "DDI-DrugBank.d668.s0.p6"} {"sentence": "Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate. ", "drug1": "methyldopa", "drug2": "ferrous gluconate", "relation": "MECHANISM", "source_file": "Methyldopa.xml", "sentence_id": "DDI-DrugBank.d779.s7", "pair_id": "DDI-DrugBank.d779.s7.p1"} {"sentence": "Concomitant treatment with NEXAVAR resulted in a 21% increase in the AUC of doxorubicin. ", "drug1": "NEXAVAR", "drug2": "doxorubicin", "relation": "MECHANISM", "source_file": "Sorafenib.xml", "sentence_id": "DDI-DrugBank.d602.s1", "pair_id": "DDI-DrugBank.d602.s1.p0"} {"sentence": "Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of Zemplar Capsules.", "drug1": "fat-soluble vitamins", "drug2": "cholestyramine", "relation": "MECHANISM", "source_file": "Paricalcitol.xml", "sentence_id": "DDI-DrugBank.d726.s3", "pair_id": "DDI-DrugBank.d726.s3.p0"} {"sentence": "norepinephrine and dobutamine are incompatible with sodium bicarbonate solution. ", "drug1": "dobutamine", "drug2": "sodium bicarbonate", "relation": "INT", "source_file": "Sodium bicarbonate.xml", "sentence_id": "DDI-DrugBank.d595.s1", "pair_id": "DDI-DrugBank.d595.s1.p2"} {"sentence": "Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ", "drug1": "pantoprazole", "drug2": "warfarin", "relation": "NONE", "source_file": "Pantoprazole.xml", "sentence_id": "DDI-DrugBank.d680.s1", "pair_id": "DDI-DrugBank.d680.s1.p19"} {"sentence": "Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).", "drug1": "methsuximide", "drug2": "phenobarbital", "relation": "MECHANISM", "source_file": "Methsuximide.xml", "sentence_id": "DDI-DrugBank.d587.s0", "pair_id": "DDI-DrugBank.d587.s0.p13"} {"sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "drug1": "anticholinergic drugs", "drug2": "tricyclic antidepressants", "relation": "EFFECT", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s0", "pair_id": "DDI-DrugBank.d585.s0.p13"} {"sentence": "Evidence of spontaneous recovery from succinylcholine should be observed before the administration of MIVACRON. ", "drug1": "succinylcholine", "drug2": "MIVACRON", "relation": "ADVISE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s2", "pair_id": "DDI-DrugBank.d775.s2.p0"} {"sentence": "One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication (ephedrine).", "drug1": "selegiline", "drug2": "sympathomimetic medication", "relation": "EFFECT", "source_file": "Selegiline.xml", "sentence_id": "DDI-DrugBank.d619.s5", "pair_id": "DDI-DrugBank.d619.s5.p0"} {"sentence": "Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ", "drug1": "Phenothiazines", "drug2": "barbiturates", "relation": "EFFECT", "source_file": "Thiethylperazine.xml", "sentence_id": "DDI-DrugBank.d677.s0", "pair_id": "DDI-DrugBank.d677.s0.p1"} {"sentence": "Lithium: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. ", "drug1": "NSAIDs", "drug2": "lithium", "relation": "MECHANISM", "source_file": "Meloxicam.xml", "sentence_id": "DDI-DrugBank.d597.s19", "pair_id": "DDI-DrugBank.d597.s19.p3"} {"sentence": "Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ", "drug1": "Salicylate", "drug2": "sulfinpyrazone", "relation": "MECHANISM", "source_file": "Salsalate.xml", "sentence_id": "DDI-DrugBank.d576.s6", "pair_id": "DDI-DrugBank.d576.s6.p5"} {"sentence": "In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. ", "drug1": "sulfamethizole", "drug2": "teniposide", "relation": "MECHANISM", "source_file": "Teniposide.xml", "sentence_id": "DDI-DrugBank.d575.s0", "pair_id": "DDI-DrugBank.d575.s0.p5"} {"sentence": "An increase in intracellular levels of methotrexate was observed in vitro in the presence of teniposide.", "drug1": "methotrexate", "drug2": "teniposide", "relation": "MECHANISM", "source_file": "Teniposide.xml", "sentence_id": "DDI-DrugBank.d575.s5", "pair_id": "DDI-DrugBank.d575.s5.p0"} {"sentence": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ", "drug1": "rifampin", "drug2": "corticosteroid", "relation": "MECHANISM", "source_file": "Prednisone.xml", "sentence_id": "DDI-DrugBank.d653.s1", "pair_id": "DDI-DrugBank.d653.s1.p8"} {"sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "drug1": "anticholinergic drugs", "drug2": "nitrates", "relation": "EFFECT", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s0", "pair_id": "DDI-DrugBank.d585.s0.p10"} {"sentence": "Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ", "drug1": "naproxen", "drug2": "digoxin", "relation": "NONE", "source_file": "Pantoprazole.xml", "sentence_id": "DDI-DrugBank.d680.s1", "pair_id": "DDI-DrugBank.d680.s1.p181"} {"sentence": "While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. ", "drug1": "carbamazepine", "drug2": "MIVACRON", "relation": "EFFECT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s12", "pair_id": "DDI-DrugBank.d775.s12.p2"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "Methscopolamine", "drug2": "quinidine", "relation": "INT", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p9"} {"sentence": "Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ", "drug1": "desmethyldiazepam", "drug2": "warfarin", "relation": "NONE", "source_file": "Pantoprazole.xml", "sentence_id": "DDI-DrugBank.d680.s1", "pair_id": "DDI-DrugBank.d680.s1.p159"} {"sentence": "Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants", "drug1": "carbamazepine", "drug2": "succinylcholine", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s13", "pair_id": "DDI-DrugBank.d775.s13.p34"} {"sentence": "Acute administration of hemantane or doxycycline failed to influence locomotion in mice, while their combination normalized motor activity. ", "drug1": "hemantane", "drug2": "doxycycline", "relation": "EFFECT", "source_file": "21809690.xml", "sentence_id": "DDI-MedLine.d214.s5", "pair_id": "DDI-MedLine.d214.s5.p0"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "MIVACRON", "drug2": "clindamycin", "relation": "INT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p21"} {"sentence": "Do not exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors. ", "drug1": "VESIcare", "drug2": "ketoconazole", "relation": "ADVISE", "source_file": "Solifenacin.xml", "sentence_id": "DDI-DrugBank.d738.s0", "pair_id": "DDI-DrugBank.d738.s0.p0"} {"sentence": "Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate. ", "drug1": "methyldopa", "drug2": "ferrous sulfate", "relation": "MECHANISM", "source_file": "Methyldopa.xml", "sentence_id": "DDI-DrugBank.d779.s7", "pair_id": "DDI-DrugBank.d779.s7.p0"} {"sentence": "In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. ", "drug1": "ethinylestradiol", "drug2": "cyclosporine", "relation": "NONE", "source_file": "Terbinafine.xml", "sentence_id": "DDI-DrugBank.d645.s0", "pair_id": "DDI-DrugBank.d645.s0.p8"} {"sentence": "ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ", "drug1": "Alpha-adrenergic blocking agents", "drug2": "triamterene", "relation": "NONE", "source_file": "Midodrine.xml", "sentence_id": "DDI-DrugBank.d603.s5", "pair_id": "DDI-DrugBank.d603.s5.p22"} {"sentence": "If at all possible guanethidine should be discontinued well before minoxidil is begun. ", "drug1": "guanethidine", "drug2": "minoxidil", "relation": "ADVISE", "source_file": "Minoxidil.xml", "sentence_id": "DDI-DrugBank.d573.s1", "pair_id": "DDI-DrugBank.d573.s1.p0"} {"sentence": "In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration. ", "drug1": "NSAIDs", "drug2": "ALIMTA", "relation": "ADVISE", "source_file": "Pemetrexed.xml", "sentence_id": "DDI-DrugBank.d641.s5", "pair_id": "DDI-DrugBank.d641.s5.p5"} {"sentence": "If a diuretic is also used, the risk of lithium toxicity may be increased. ", "drug1": "diuretic", "drug2": "lithium", "relation": "EFFECT", "source_file": "Moexipril.xml", "sentence_id": "DDI-DrugBank.d640.s8", "pair_id": "DDI-DrugBank.d640.s8.p0"} {"sentence": "Interactions for Vitamin B1 (Thiamine): Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants", "drug1": "Vitamin B1", "drug2": "Loop Diuretics", "relation": "INT", "source_file": "Thiamine.xml", "sentence_id": "DDI-DrugBank.d697.s0", "pair_id": "DDI-DrugBank.d697.s0.p1"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "Methscopolamine", "drug2": "linezolid", "relation": "INT", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p4"} {"sentence": "Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ", "drug1": "quinpirole", "drug2": "amphetamine", "relation": "NONE", "source_file": "21753255.xml", "sentence_id": "DDI-MedLine.d184.s8", "pair_id": "DDI-MedLine.d184.s8.p3"} {"sentence": "These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ", "drug1": "Cisapride", "drug2": "Rifabutin", "relation": "NONE", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s2", "pair_id": "DDI-DrugBank.d776.s2.p78"} {"sentence": "Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ", "drug1": "Nonsteroidal anti-inflammatory agents", "drug2": "lithium", "relation": "MECHANISM", "source_file": "Piroxicam.xml", "sentence_id": "DDI-DrugBank.d656.s2", "pair_id": "DDI-DrugBank.d656.s2.p26"} {"sentence": "Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ", "drug1": "Warfarin", "drug2": "paroxetine", "relation": "EFFECT", "source_file": "21731754.xml", "sentence_id": "DDI-MedLine.d218.s10", "pair_id": "DDI-MedLine.d218.s10.p2"} {"sentence": "These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ", "drug1": "GH", "drug2": "sex steroids", "relation": "MECHANISM", "source_file": "Somatropin recombinant.xml", "sentence_id": "DDI-DrugBank.d599.s7", "pair_id": "DDI-DrugBank.d599.s7.p1"} {"sentence": "A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.", "drug1": "fluconazole", "drug2": "cisapride", "relation": "MECHANISM", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s26", "pair_id": "DDI-DrugBank.d776.s26.p0"} {"sentence": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ", "drug1": "miconazole", "drug2": "DETROL LA", "relation": "ADVISE", "source_file": "Tolterodine.xml", "sentence_id": "DDI-DrugBank.d765.s1", "pair_id": "DDI-DrugBank.d765.s1.p29"} {"sentence": "Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.", "drug1": "Leukine", "drug2": "corticosteroids", "relation": "EFFECT", "source_file": "Sargramostim.xml", "sentence_id": "DDI-DrugBank.d607.s1", "pair_id": "DDI-DrugBank.d607.s1.p1"} {"sentence": "Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). ", "drug1": "SYMLIN", "drug2": "alpha glucosidase inhibitors", "relation": "ADVISE", "source_file": "Pramlintide.xml", "sentence_id": "DDI-DrugBank.d632.s0", "pair_id": "DDI-DrugBank.d632.s0.p2"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "tranylcypromine", "drug2": "pectin", "relation": "NONE", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p129"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "selegiline", "drug2": "amantadine", "relation": "NONE", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p150"} {"sentence": "Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ", "drug1": "Posicor", "drug2": "cisapride", "relation": "MECHANISM", "source_file": "Mibefradil.xml", "sentence_id": "DDI-DrugBank.d783.s0", "pair_id": "DDI-DrugBank.d783.s0.p2"} {"sentence": "Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. ", "drug1": "Ropivacaine", "drug2": "ropivacaine", "relation": "NONE", "source_file": "Ropivacaine.xml", "sentence_id": "DDI-DrugBank.d591.s3", "pair_id": "DDI-DrugBank.d591.s3.p4"} {"sentence": "e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants. ", "drug1": "belladonna alkaloids", "drug2": "tricyclic antidepressants", "relation": "NONE", "source_file": "Scopolamine.xml", "sentence_id": "DDI-DrugBank.d771.s3", "pair_id": "DDI-DrugBank.d771.s3.p2"} {"sentence": "The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine . Therefore, caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction. ", "drug1": "phenylephrine", "drug2": "ProAmatine", "relation": "EFFECT", "source_file": "Midodrine.xml", "sentence_id": "DDI-DrugBank.d603.s2", "pair_id": "DDI-DrugBank.d603.s2.p4"} {"sentence": "Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers. ", "drug1": "antibiotics", "drug2": "ganglion blockers", "relation": "ADVISE", "source_file": "Mecamylamine.xml", "sentence_id": "DDI-DrugBank.d579.s0", "pair_id": "DDI-DrugBank.d579.s0.p1"} {"sentence": "Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ", "drug1": "Salicylate", "drug2": "methotrexate", "relation": "MECHANISM", "source_file": "Salsalate.xml", "sentence_id": "DDI-DrugBank.d576.s6", "pair_id": "DDI-DrugBank.d576.s6.p8"} {"sentence": "The incubations were performed in the absence and presence of the non-specific CYP inhibitor, 1-aminobenzotriazole (ABT) and isoform-specific inhibitors. ", "drug1": "1-aminobenzotriazole", "drug2": "ABT", "relation": "NONE", "source_file": "21741958.xml", "sentence_id": "DDI-MedLine.d189.s3", "pair_id": "DDI-MedLine.d189.s3.p0"} {"sentence": "However, the co administration of SPIRIVA with other anticholinergic containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.", "drug1": "SPIRIVA", "drug2": "anticholinergic", "relation": "ADVISE", "source_file": "Tiotropium.xml", "sentence_id": "DDI-DrugBank.d702.s2", "pair_id": "DDI-DrugBank.d702.s2.p0"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "phenothiazines", "drug2": "chlorpromazine", "relation": "NONE", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p250"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "MIVACRON", "drug2": "colistin", "relation": "INT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p22"} {"sentence": "Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ", "drug1": "ranitidine", "drug2": "pramipexole", "relation": "MECHANISM", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s6", "pair_id": "DDI-DrugBank.d737.s6.p18"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "MAO inhibitors", "drug2": "isocarboxazid", "relation": "NONE", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p66"} {"sentence": "After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. ", "drug1": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "drug2": "3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine", "relation": "EFFECT", "source_file": "21705423.xml", "sentence_id": "DDI-MedLine.d161.s5", "pair_id": "DDI-MedLine.d161.s5.p5"} {"sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "drug1": "anticholinergic drugs", "drug2": "amantadine", "relation": "EFFECT", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s0", "pair_id": "DDI-DrugBank.d585.s0.p0"} {"sentence": "The metabolism of Metopirone is accelerated by phenytoin; ", "drug1": "Metopirone", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Metyrapone.xml", "sentence_id": "DDI-DrugBank.d678.s1", "pair_id": "DDI-DrugBank.d678.s1.p0"} {"sentence": "Furthermore, we present a case report in which a second Herceptin treatment following lapatinib resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer. ", "drug1": "Herceptin", "drug2": "lapatinib", "relation": "EFFECT", "source_file": "21868551.xml", "sentence_id": "DDI-MedLine.d164.s4", "pair_id": "DDI-MedLine.d164.s4.p0"} {"sentence": "Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ", "drug1": "Central Nervous System Depressants", "drug2": "SEDATIVE-HYPNOTICS", "relation": "NONE", "source_file": "Meperidine.xml", "sentence_id": "DDI-DrugBank.d703.s0", "pair_id": "DDI-DrugBank.d703.s0.p5"} {"sentence": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ", "drug1": "phenobarbital", "drug2": "corticosteroids", "relation": "MECHANISM", "source_file": "Prednisone.xml", "sentence_id": "DDI-DrugBank.d653.s1", "pair_id": "DDI-DrugBank.d653.s1.p2"} {"sentence": "Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.", "drug1": "lapatinib", "drug2": "Herceptin", "relation": "NONE", "source_file": "21868551.xml", "sentence_id": "DDI-MedLine.d164.s1", "pair_id": "DDI-MedLine.d164.s1.p2"} {"sentence": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ", "drug1": "phenobarbital", "drug2": "methylprednisolone", "relation": "ADVISE", "source_file": "Methylprednisolone.xml", "sentence_id": "DDI-DrugBank.d578.s4", "pair_id": "DDI-DrugBank.d578.s4.p3"} {"sentence": "The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ", "drug1": "ticagrelor", "drug2": "aspirin", "relation": "EFFECT", "source_file": "21897348.xml", "sentence_id": "DDI-MedLine.d193.s1", "pair_id": "DDI-MedLine.d193.s1.p2"} {"sentence": "No cross-resistance with other chemotherapeutic agents, radiotherapy or steroids has been demonstrated.", "drug1": "chemotherapeutic agents", "drug2": "steroids", "relation": "NONE", "source_file": "Procarbazine.xml", "sentence_id": "DDI-DrugBank.d676.s4", "pair_id": "DDI-DrugBank.d676.s4.p0"} {"sentence": "These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ", "drug1": "hypoglycemics", "drug2": "Astemizole", "relation": "NONE", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s2", "pair_id": "DDI-DrugBank.d776.s2.p7"} {"sentence": "Interactions for Vitamin B1 (Thiamine): Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants", "drug1": "Thiamine", "drug2": "Loop Diuretics", "relation": "INT", "source_file": "Thiamine.xml", "sentence_id": "DDI-DrugBank.d697.s0", "pair_id": "DDI-DrugBank.d697.s0.p5"} {"sentence": "Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.", "drug1": "DEMSER", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Metyrosine.xml", "sentence_id": "DDI-DrugBank.d715.s1", "pair_id": "DDI-DrugBank.d715.s1.p0"} {"sentence": "Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.", "drug1": "acetylcholine chloride", "drug2": "suprofen", "relation": "EFFECT", "source_file": "Suprofen.xml", "sentence_id": "DDI-DrugBank.d723.s0", "pair_id": "DDI-DrugBank.d723.s0.p4"} {"sentence": "Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem. ", "drug1": "Probenecid", "drug2": "meropenem", "relation": "MECHANISM", "source_file": "Meropenem.xml", "sentence_id": "DDI-DrugBank.d762.s0", "pair_id": "DDI-DrugBank.d762.s0.p0"} {"sentence": "Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. ", "drug1": "NSAIDs", "drug2": "thiazide diuretics", "relation": "EFFECT", "source_file": "Meloxicam.xml", "sentence_id": "DDI-DrugBank.d597.s14", "pair_id": "DDI-DrugBank.d597.s14.p4"} {"sentence": "Thiazides may decrease arterial responsiveness to norepinephrine. ", "drug1": "Thiazides", "drug2": "norepinephrine", "relation": "EFFECT", "source_file": "Methyclothiazide.xml", "sentence_id": "DDI-DrugBank.d736.s3", "pair_id": "DDI-DrugBank.d736.s3.p0"} {"sentence": "Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ", "drug1": "diltiazem", "drug2": "pramipexole", "relation": "MECHANISM", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s6", "pair_id": "DDI-DrugBank.d737.s6.p29"} {"sentence": "The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ", "drug1": "MIVACRON", "drug2": "contraceptives", "relation": "EFFECT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s11", "pair_id": "DDI-DrugBank.d775.s11.p0"} {"sentence": "Distinct and statistically significant synergism was observed between methylglyoxal and piperacillin by disc diffusion tests when compared with their individual effects. ", "drug1": "methylglyoxal", "drug2": "piperacillin", "relation": "EFFECT", "source_file": "21800506.xml", "sentence_id": "DDI-MedLine.d204.s9", "pair_id": "DDI-MedLine.d204.s9.p0"} {"sentence": "ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ", "drug1": "desglymidodrine", "drug2": "metformin", "relation": "MECHANISM", "source_file": "Midodrine.xml", "sentence_id": "DDI-DrugBank.d603.s5", "pair_id": "DDI-DrugBank.d603.s5.p63"} {"sentence": "Oral hypoglycemic agents Oxandrolone may inhibit the metabolism of oral hypoglycemic agents. ", "drug1": "Oxandrolone", "drug2": "hypoglycemic agents", "relation": "MECHANISM", "source_file": "Oxandrolone.xml", "sentence_id": "DDI-DrugBank.d584.s9", "pair_id": "DDI-DrugBank.d584.s9.p2"} {"sentence": "Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ", "drug1": "Streptokinase", "drug2": "anticoagulants", "relation": "EFFECT", "source_file": "Streptokinase.xml", "sentence_id": "DDI-DrugBank.d777.s1", "pair_id": "DDI-DrugBank.d777.s1.p13"} {"sentence": "SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.", "drug1": "SKELAXIN", "drug2": "barbiturates", "relation": "EFFECT", "source_file": "Metaxalone.xml", "sentence_id": "DDI-DrugBank.d605.s0", "pair_id": "DDI-DrugBank.d605.s0.p1"} {"sentence": "While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.", "drug1": "medroxyprogesterone acetate", "drug2": "methotrexate", "relation": "NONE", "source_file": "Pilocarpine.xml", "sentence_id": "DDI-DrugBank.d627.s4", "pair_id": "DDI-DrugBank.d627.s4.p57"} {"sentence": "The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants, including alcohol. ", "drug1": "propoxyphene", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Propoxyphene.xml", "sentence_id": "DDI-DrugBank.d690.s0", "pair_id": "DDI-DrugBank.d690.s0.p1"} {"sentence": "Interactions for Vitamin B1 (Thiamine): Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants", "drug1": "Vitamin B1", "drug2": "Contraceptives", "relation": "INT", "source_file": "Thiamine.xml", "sentence_id": "DDI-DrugBank.d697.s0", "pair_id": "DDI-DrugBank.d697.s0.p2"} {"sentence": "The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine . Therefore, caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction. ", "drug1": "pseudoephedrine", "drug2": "ProAmatine", "relation": "EFFECT", "source_file": "Midodrine.xml", "sentence_id": "DDI-DrugBank.d603.s2", "pair_id": "DDI-DrugBank.d603.s2.p9"} {"sentence": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "drug1": "Asendin", "drug2": "doxepin", "relation": "NONE", "source_file": "Mazindol.xml", "sentence_id": "DDI-DrugBank.d716.s5", "pair_id": "DDI-DrugBank.d716.s5.p58"} {"sentence": "In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase therapy.", "drug1": "aspirin", "drug2": "Retavase", "relation": "EFFECT", "source_file": "Reteplase.xml", "sentence_id": "DDI-DrugBank.d618.s1", "pair_id": "DDI-DrugBank.d618.s1.p11"} {"sentence": "Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%. ", "drug1": "fluoxetine", "drug2": "endoxifen", "relation": "MECHANISM", "source_file": "21751753.xml", "sentence_id": "DDI-MedLine.d209.s5", "pair_id": "DDI-MedLine.d209.s5.p2"} {"sentence": "Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ", "drug1": "dexamethasone", "drug2": "phenobarbital", "relation": "NONE", "source_file": "Sunitinib.xml", "sentence_id": "DDI-DrugBank.d639.s2", "pair_id": "DDI-DrugBank.d639.s2.p13"} {"sentence": "Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. ", "drug1": "Sulfamethizole", "drug2": "tolbutamide", "relation": "EFFECT", "source_file": "Sulfamethizole.xml", "sentence_id": "DDI-DrugBank.d649.s0", "pair_id": "DDI-DrugBank.d649.s0.p1"} {"sentence": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "drug1": "melatonin", "drug2": "benzodiazepenes", "relation": "NONE", "source_file": "Melatonin.xml", "sentence_id": "DDI-DrugBank.d643.s0", "pair_id": "DDI-DrugBank.d643.s0.p116"} {"sentence": "Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ", "drug1": "Posicor", "drug2": "cyclosporine", "relation": "MECHANISM", "source_file": "Mibefradil.xml", "sentence_id": "DDI-DrugBank.d783.s0", "pair_id": "DDI-DrugBank.d783.s0.p3"} {"sentence": "ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ", "drug1": "ProAmatine", "drug2": "terazosin", "relation": "NONE", "source_file": "Midodrine.xml", "sentence_id": "DDI-DrugBank.d603.s5", "pair_id": "DDI-DrugBank.d603.s5.p2"} {"sentence": "If concomitant treatment with sumatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.", "drug1": "sumatriptan", "drug2": "SSRI", "relation": "ADVISE", "source_file": "Sumatriptan.xml", "sentence_id": "DDI-DrugBank.d720.s4", "pair_id": "DDI-DrugBank.d720.s4.p0"} {"sentence": "Pindolol has been shown to increase serum thioridazine levels when both drugs are co-administered. ", "drug1": "Pindolol", "drug2": "thioridazine", "relation": "MECHANISM", "source_file": "Pindolol.xml", "sentence_id": "DDI-DrugBank.d666.s3", "pair_id": "DDI-DrugBank.d666.s3.p0"} {"sentence": "Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ", "drug1": "ketoconazole", "drug2": "atazanavir", "relation": "NONE", "source_file": "Sunitinib.xml", "sentence_id": "DDI-DrugBank.d639.s0", "pair_id": "DDI-DrugBank.d639.s0.p14"} {"sentence": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "drug1": "Asendin", "drug2": "desipramine", "relation": "NONE", "source_file": "Mazindol.xml", "sentence_id": "DDI-DrugBank.d716.s5", "pair_id": "DDI-DrugBank.d716.s5.p68"} {"sentence": "In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ", "drug1": "TOBI", "drug2": "anti-pseudomonal antibiotics", "relation": "EFFECT", "source_file": "Tobramycin.xml", "sentence_id": "DDI-DrugBank.d624.s0", "pair_id": "DDI-DrugBank.d624.s0.p11"} {"sentence": "Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ", "drug1": "Matulane", "drug2": "tyramine", "relation": "ADVISE", "source_file": "Procarbazine.xml", "sentence_id": "DDI-DrugBank.d676.s2", "pair_id": "DDI-DrugBank.d676.s2.p4"} {"sentence": "In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. ", "drug1": "sodium salicylate", "drug2": "teniposide", "relation": "MECHANISM", "source_file": "Teniposide.xml", "sentence_id": "DDI-DrugBank.d575.s0", "pair_id": "DDI-DrugBank.d575.s0.p4"} {"sentence": "Terbinafine increases the clearance of cyclosporine by 15%. ", "drug1": "Terbinafine", "drug2": "cyclosporine", "relation": "MECHANISM", "source_file": "Terbinafine.xml", "sentence_id": "DDI-DrugBank.d645.s5", "pair_id": "DDI-DrugBank.d645.s5.p0"} {"sentence": "While co-administration of ZAVESCA appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme. ", "drug1": "ZAVESCA", "drug2": "Cerezyme", "relation": "MECHANISM", "source_file": "Miglustat.xml", "sentence_id": "DDI-DrugBank.d695.s0", "pair_id": "DDI-DrugBank.d695.s0.p0"} {"sentence": "Other Antihypertensives: When MYKROX Tablets are used with other antihypertensive drugs, care must be taken, especially during initial therapy. ", "drug1": "MYKROX", "drug2": "antihypertensive drugs", "relation": "ADVISE", "source_file": "Metolazone.xml", "sentence_id": "DDI-DrugBank.d588.s1", "pair_id": "DDI-DrugBank.d588.s1.p2"} {"sentence": "Paliperidone may antagonize the effect of levodopa and other dopamine agonists. ", "drug1": "Paliperidone", "drug2": "levodopa", "relation": "EFFECT", "source_file": "Paliperidone.xml", "sentence_id": "DDI-DrugBank.d670.s7", "pair_id": "DDI-DrugBank.d670.s7.p0"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "antacids", "drug2": "absorbent-type anti-diarrhea medicines", "relation": "NONE", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p232"} {"sentence": "Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. ", "drug1": "Terbinafine", "drug2": "cimetidine", "relation": "MECHANISM", "source_file": "Terbinafine.xml", "sentence_id": "DDI-DrugBank.d645.s7", "pair_id": "DDI-DrugBank.d645.s7.p1"} {"sentence": "Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ", "drug1": "ranitidine", "drug2": "indomethacin", "relation": "NONE", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s6", "pair_id": "DDI-DrugBank.d737.s6.p21"} {"sentence": "The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. ", "drug1": "tricyclic antidepressants", "drug2": "triprolidine", "relation": "EFFECT", "source_file": "Triprolidine.xml", "sentence_id": "DDI-DrugBank.d615.s1", "pair_id": "DDI-DrugBank.d615.s1.p5"} {"sentence": "Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ", "drug1": "EVISTA", "drug2": "diazepam", "relation": "ADVISE", "source_file": "Raloxifene.xml", "sentence_id": "DDI-DrugBank.d648.s6", "pair_id": "DDI-DrugBank.d648.s6.p4"} {"sentence": "Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ", "drug1": "digoxin", "drug2": "perindopril", "relation": "MECHANISM", "source_file": "Perindopril.xml", "sentence_id": "DDI-DrugBank.d781.s11", "pair_id": "DDI-DrugBank.d781.s11.p12"} {"sentence": "Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid). ", "drug1": "ZOLINZA", "drug2": "valproic acid", "relation": "EFFECT", "source_file": "Vorinostat.xml", "sentence_id": "DDI-DrugBank.d769.s2", "pair_id": "DDI-DrugBank.d769.s2.p4"} {"sentence": "Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. ", "drug1": "DEMSER", "drug2": "phenothiazines", "relation": "ADVISE", "source_file": "Metyrosine.xml", "sentence_id": "DDI-DrugBank.d715.s0", "pair_id": "DDI-DrugBank.d715.s0.p0"} {"sentence": "Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ", "drug1": "Phenothiazines", "drug2": "opiates", "relation": "EFFECT", "source_file": "Thiethylperazine.xml", "sentence_id": "DDI-DrugBank.d677.s0", "pair_id": "DDI-DrugBank.d677.s0.p3"} {"sentence": "Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR = 1.73 [95% CI, 1.25-2.38]), fluoxetine (OR = 1.63 [95% CI, 1.11-2.38]), paroxetine (OR = 1.64 [95% CI, 1.27-2.12]), amitriptyline (OR = 1.47 [95% CI, 1.02-2.11]). ", "drug1": "Warfarin", "drug2": "citalopram", "relation": "EFFECT", "source_file": "21731754.xml", "sentence_id": "DDI-MedLine.d218.s8", "pair_id": "DDI-MedLine.d218.s8.p0"} {"sentence": "Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ", "drug1": "phenobarbital", "drug2": "phenylbutazone", "relation": "NONE", "source_file": "Methylphenidate.xml", "sentence_id": "DDI-DrugBank.d638.s2", "pair_id": "DDI-DrugBank.d638.s2.p29"} {"sentence": "We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells. ", "drug1": "celecoxib", "drug2": "doxorubicin", "relation": "EFFECT", "source_file": "21763710.xml", "sentence_id": "DDI-MedLine.d217.s5", "pair_id": "DDI-MedLine.d217.s5.p2"} {"sentence": "Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ", "drug1": "carbamazepine", "drug2": "midazolam", "relation": "MECHANISM", "source_file": "Midazolam.xml", "sentence_id": "DDI-DrugBank.d752.s6", "pair_id": "DDI-DrugBank.d752.s6.p4"} {"sentence": "Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. ", "drug1": "rivastigmine", "drug2": "warfarin", "relation": "NONE", "source_file": "Rivastigmine.xml", "sentence_id": "DDI-DrugBank.d596.s6", "pair_id": "DDI-DrugBank.d596.s6.p1"} {"sentence": "Concomitant administration of CHEMET with other chelation therapy, such as CaNa 2 EDTA is not recommended. ", "drug1": "CHEMET", "drug2": "CaNa 2 EDTA", "relation": "ADVISE", "source_file": "Succimer.xml", "sentence_id": "DDI-DrugBank.d732.s2", "pair_id": "DDI-DrugBank.d732.s2.p0"} {"sentence": "Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ", "drug1": "clarithromycin", "drug2": "terfenadine", "relation": "MECHANISM", "source_file": "Terfenadine.xml", "sentence_id": "DDI-DrugBank.d743.s9", "pair_id": "DDI-DrugBank.d743.s9.p7"} {"sentence": "HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ", "drug1": "ezetimibe", "drug2": "pravastatin", "relation": "NONE", "source_file": "Ezetimibe.xml", "sentence_id": "DDI-DrugBank.d572.s8", "pair_id": "DDI-DrugBank.d572.s8.p8"} {"sentence": "Therefore, when concomitant use of thiabendazole and xanthine derivatives is anticipated, it may be necessary to monitor blood levels and/or reduce the dosage of such compounds. ", "drug1": "thiabendazole", "drug2": "xanthine derivatives", "relation": "ADVISE", "source_file": "Thiabendazole.xml", "sentence_id": "DDI-DrugBank.d686.s1", "pair_id": "DDI-DrugBank.d686.s1.p0"} {"sentence": "Furthermore, in patients receiving both drugs, careful monitoring of the INR or PT, and adjustment of the warfarin dosage if indicated are recommended when the oxandrolone dose is changed or discontinued. ", "drug1": "warfarin", "drug2": "oxandrolone", "relation": "ADVISE", "source_file": "Oxandrolone.xml", "sentence_id": "DDI-DrugBank.d584.s7", "pair_id": "DDI-DrugBank.d584.s7.p0"} {"sentence": "Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ", "drug1": "dopamine agonist", "drug2": "thioxanthenes", "relation": "NONE", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s10", "pair_id": "DDI-DrugBank.d737.s10.p21"} {"sentence": "It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin. ", "drug1": "sulfamethoxazole", "drug2": "anticoagulant", "relation": "NONE", "source_file": "Sulfamethoxazole.xml", "sentence_id": "DDI-DrugBank.d577.s1", "pair_id": "DDI-DrugBank.d577.s1.p0"} {"sentence": "When the rapid onset of a concomitant orally administered agent is a critical determinant of effectiveness (such as analgesics), the agent should be administered at least 1 hour prior to or 2 hours after SYMLIN injection. ", "drug1": "analgesics", "drug2": "SYMLIN", "relation": "ADVISE", "source_file": "Pramlintide.xml", "sentence_id": "DDI-DrugBank.d632.s3", "pair_id": "DDI-DrugBank.d632.s3.p0"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "tricyclic", "drug2": "anticholinergics", "relation": "NONE", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p54"} {"sentence": "But the use of fixed combination amlodipine/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). ", "drug1": "amlodipine", "drug2": "valsartan", "relation": "EFFECT", "source_file": "21878082.xml", "sentence_id": "DDI-MedLine.d200.s8", "pair_id": "DDI-MedLine.d200.s8.p0"} {"sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.", "drug1": "Barbiturates", "drug2": "contraceptives", "relation": "INT", "source_file": "Secobarbital.xml", "sentence_id": "DDI-DrugBank.d601.s0", "pair_id": "DDI-DrugBank.d601.s0.p0"} {"sentence": "Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.", "drug1": "Mequitazine", "drug2": "CNS depressant", "relation": "INT", "source_file": "Mequitazine.xml", "sentence_id": "DDI-DrugBank.d699.s0", "pair_id": "DDI-DrugBank.d699.s0.p0"} {"sentence": "Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days. ", "drug1": "Digoxin", "drug2": "digoxin", "relation": "NONE", "source_file": "Sitagliptin.xml", "sentence_id": "DDI-DrugBank.d694.s0", "pair_id": "DDI-DrugBank.d694.s0.p0"} {"sentence": "Anticoagulants (oral): The activity of oral anticoagulants may be potentiated by anti-vitamin-K activity attributed to methimazole. ", "drug1": "anticoagulants", "drug2": "methimazole", "relation": "EFFECT", "source_file": "Methimazole.xml", "sentence_id": "DDI-DrugBank.d634.s0", "pair_id": "DDI-DrugBank.d634.s0.p2"} {"sentence": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ", "drug1": "ritonavir", "drug2": "delavirdine", "relation": "NONE", "source_file": "Methylergonovine.xml", "sentence_id": "DDI-DrugBank.d675.s2", "pair_id": "DDI-DrugBank.d675.s2.p65"} {"sentence": "Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. ", "drug1": "fluvoxamine", "drug2": "Ropivacaine", "relation": "INT", "source_file": "Ropivacaine.xml", "sentence_id": "DDI-DrugBank.d591.s3", "pair_id": "DDI-DrugBank.d591.s3.p0"} {"sentence": "Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ", "drug1": "desmethyldiazepam", "drug2": "contraceptive", "relation": "NONE", "source_file": "Pantoprazole.xml", "sentence_id": "DDI-DrugBank.d680.s1", "pair_id": "DDI-DrugBank.d680.s1.p153"} {"sentence": "Furthermore, rifampin, dexamethasone, St. ", "drug1": "rifampin", "drug2": "dexamethasone", "relation": "NONE", "source_file": "Mifepristone.xml", "sentence_id": "DDI-DrugBank.d668.s1", "pair_id": "DDI-DrugBank.d668.s1.p0"} {"sentence": "John s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ", "drug1": "phenobarbital", "drug2": "mifepristone", "relation": "MECHANISM", "source_file": "Mifepristone.xml", "sentence_id": "DDI-DrugBank.d668.s2", "pair_id": "DDI-DrugBank.d668.s2.p10"} {"sentence": "Interaction with Guanethidine: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects. ", "drug1": "minoxidil", "drug2": "guanethidine", "relation": "EFFECT", "source_file": "Minoxidil.xml", "sentence_id": "DDI-DrugBank.d573.s0", "pair_id": "DDI-DrugBank.d573.s0.p2"} {"sentence": "Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ", "drug1": "erythromycin", "drug2": "mifepristone", "relation": "MECHANISM", "source_file": "Mifepristone.xml", "sentence_id": "DDI-DrugBank.d668.s0", "pair_id": "DDI-DrugBank.d668.s0.p9"} {"sentence": "Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ", "drug1": "MEPERIDINE", "drug2": "BARBITURATES", "relation": "ADVISE", "source_file": "Meperidine.xml", "sentence_id": "DDI-DrugBank.d703.s0", "pair_id": "DDI-DrugBank.d703.s0.p15"} {"sentence": "Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ", "drug1": "Sanctura", "drug2": "procainamide", "relation": "MECHANISM", "source_file": "Trospium.xml", "sentence_id": "DDI-DrugBank.d713.s2", "pair_id": "DDI-DrugBank.d713.s2.p9"} {"sentence": "You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ", "drug1": "mazindol", "drug2": "MAOI", "relation": "ADVISE", "source_file": "Mazindol.xml", "sentence_id": "DDI-DrugBank.d716.s0", "pair_id": "DDI-DrugBank.d716.s0.p1"} {"sentence": "Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ", "drug1": "Triprolidine", "drug2": "sedatives", "relation": "EFFECT", "source_file": "Triprolidine.xml", "sentence_id": "DDI-DrugBank.d615.s0", "pair_id": "DDI-DrugBank.d615.s0.p5"} {"sentence": "Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%. ", "drug1": "phenytoin", "drug2": "phenytoin", "relation": "NONE", "source_file": "Trimethoprim.xml", "sentence_id": "DDI-DrugBank.d598.s1", "pair_id": "DDI-DrugBank.d598.s1.p2"} {"sentence": "During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). ", "drug1": "DIPRIVAN", "drug2": "opioids", "relation": "ADVISE", "source_file": "Propofol.xml", "sentence_id": "DDI-DrugBank.d628.s3", "pair_id": "DDI-DrugBank.d628.s3.p2"} {"sentence": "Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ", "drug1": "citalopram", "drug2": "amitriptyline", "relation": "NONE", "source_file": "21731754.xml", "sentence_id": "DDI-MedLine.d218.s10", "pair_id": "DDI-MedLine.d218.s10.p7"} {"sentence": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ", "drug1": "ketoconazole", "drug2": "DETROL LA", "relation": "ADVISE", "source_file": "Tolterodine.xml", "sentence_id": "DDI-DrugBank.d765.s1", "pair_id": "DDI-DrugBank.d765.s1.p8"} {"sentence": "Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ", "drug1": "caffeine", "drug2": "ethinyl estradiol", "relation": "NONE", "source_file": "Pantoprazole.xml", "sentence_id": "DDI-DrugBank.d680.s1", "pair_id": "DDI-DrugBank.d680.s1.p101"} {"sentence": "Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ", "drug1": "diazepam", "drug2": "clarithromycin", "relation": "NONE", "source_file": "Pantoprazole.xml", "sentence_id": "DDI-DrugBank.d680.s1", "pair_id": "DDI-DrugBank.d680.s1.p144"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "Methscopolamine", "drug2": "kaolin", "relation": "INT", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p17"} {"sentence": "Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ", "drug1": "phenytoin", "drug2": "midazolam", "relation": "MECHANISM", "source_file": "Midazolam.xml", "sentence_id": "DDI-DrugBank.d752.s6", "pair_id": "DDI-DrugBank.d752.s6.p5"} {"sentence": "Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants", "drug1": "neostigmine", "drug2": "anesthetics", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s13", "pair_id": "DDI-DrugBank.d775.s13.p65"} {"sentence": "Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ", "drug1": "Hormonal Contraceptives", "drug2": "HIV-protease inhibitors", "relation": "NONE", "source_file": "Thalidomide.xml", "sentence_id": "DDI-DrugBank.d604.s4", "pair_id": "DDI-DrugBank.d604.s4.p9"} {"sentence": "MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ", "drug1": "MAO Inhibitors", "drug2": "MAOI", "relation": "NONE", "source_file": "Phenylephrine.xml", "sentence_id": "DDI-DrugBank.d725.s1", "pair_id": "DDI-DrugBank.d725.s1.p2"} {"sentence": "Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).", "drug1": "Melatonin", "drug2": "beta blockers", "relation": "INT", "source_file": "Melatonin.xml", "sentence_id": "DDI-DrugBank.d643.s0", "pair_id": "DDI-DrugBank.d643.s0.p5"} {"sentence": "There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly. ", "drug1": "proton pump inhibitors", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Pantoprazole.xml", "sentence_id": "DDI-DrugBank.d680.s5", "pair_id": "DDI-DrugBank.d680.s5.p1"} {"sentence": "These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ", "drug1": "sex steroids", "drug2": "cyclosporin", "relation": "NONE", "source_file": "Somatropin recombinant.xml", "sentence_id": "DDI-DrugBank.d599.s7", "pair_id": "DDI-DrugBank.d599.s7.p8"} {"sentence": "Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. ", "drug1": "SUTENT", "drug2": "saquinavir", "relation": "MECHANISM", "source_file": "Sunitinib.xml", "sentence_id": "DDI-DrugBank.d639.s0", "pair_id": "DDI-DrugBank.d639.s0.p8"} {"sentence": "Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.", "drug1": "succinylcholine", "drug2": "neuromuscular blocking agents", "relation": "NONE", "source_file": "Rivastigmine.xml", "sentence_id": "DDI-DrugBank.d596.s9", "pair_id": "DDI-DrugBank.d596.s9.p15"} {"sentence": "Therefore, FLOMAX capsules should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg. ", "drug1": "FLOMAX", "drug2": "cimetidine", "relation": "ADVISE", "source_file": "Tamsulosin.xml", "sentence_id": "DDI-DrugBank.d704.s4", "pair_id": "DDI-DrugBank.d704.s4.p0"} {"sentence": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ", "drug1": "erythromycin", "drug2": "DETROL LA", "relation": "ADVISE", "source_file": "Tolterodine.xml", "sentence_id": "DDI-DrugBank.d765.s1", "pair_id": "DDI-DrugBank.d765.s1.p38"} {"sentence": "Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ", "drug1": "Warfarin", "drug2": "citalopram", "relation": "EFFECT", "source_file": "21731754.xml", "sentence_id": "DDI-MedLine.d218.s10", "pair_id": "DDI-MedLine.d218.s10.p0"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "Methscopolamine", "drug2": "amantadine", "relation": "INT", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p10"} {"sentence": "(ii) acetyl-l-carnitine elicits a significant protective effect on DEB induced toxicity, which was potentiated by alpha-lipoic acid.", "drug1": "acetyl-l-carnitine", "drug2": "alpha-lipoic acid", "relation": "EFFECT", "source_file": "21807063.xml", "sentence_id": "DDI-MedLine.d159.s6", "pair_id": "DDI-MedLine.d159.s6.p0"} {"sentence": "Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ", "drug1": "potassium-sparing diuretics", "drug2": "ACE inhibitors", "relation": "EFFECT", "source_file": "Moexipril.xml", "sentence_id": "DDI-DrugBank.d640.s3", "pair_id": "DDI-DrugBank.d640.s3.p4"} {"sentence": "Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ", "drug1": "Levodopa", "drug2": "pramipexole", "relation": "NONE", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s0", "pair_id": "DDI-DrugBank.d737.s0.p9"} {"sentence": "Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. ", "drug1": "phenytoin", "drug2": "rifapentin", "relation": "NONE", "source_file": "Sunitinib.xml", "sentence_id": "DDI-DrugBank.d639.s2", "pair_id": "DDI-DrugBank.d639.s2.p18"} {"sentence": "Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0- )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. ", "drug1": "Ticlopidine", "drug2": "S-ketamine", "relation": "NONE", "source_file": "21716267.xml", "sentence_id": "DDI-MedLine.d216.s3", "pair_id": "DDI-MedLine.d216.s3.p2"} {"sentence": "Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. ", "drug1": "procaine hydrochloride", "drug2": "anticholinesterases", "relation": "NONE", "source_file": "Procaine.xml", "sentence_id": "DDI-DrugBank.d780.s0", "pair_id": "DDI-DrugBank.d780.s0.p5"} {"sentence": "You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ", "drug1": "mazindol", "drug2": "phenelzine", "relation": "ADVISE", "source_file": "Mazindol.xml", "sentence_id": "DDI-DrugBank.d716.s0", "pair_id": "DDI-DrugBank.d716.s0.p6"} {"sentence": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ", "drug1": "clarithromycin", "drug2": "oxybutynin", "relation": "MECHANISM", "source_file": "Oxybutynin.xml", "sentence_id": "DDI-DrugBank.d784.s4", "pair_id": "DDI-DrugBank.d784.s4.p20"} {"sentence": "Probenecid: Probenecid, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence pramipexole pharmacokinetics (N= 12). ", "drug1": "Probenecid", "drug2": "pramipexole", "relation": "NONE", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s5", "pair_id": "DDI-DrugBank.d737.s5.p1"} {"sentence": "Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ", "drug1": "Dopamine antagonists", "drug2": "Permax", "relation": "ADVISE", "source_file": "Pergolide.xml", "sentence_id": "DDI-DrugBank.d650.s0", "pair_id": "DDI-DrugBank.d650.s0.p5"} {"sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "drug1": "amantadine", "drug2": "quinidine", "relation": "NONE", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s0", "pair_id": "DDI-DrugBank.d585.s0.p15"} {"sentence": "Synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.", "drug1": "methylglyoxal", "drug2": "amikacin", "relation": "EFFECT", "source_file": "21800506.xml", "sentence_id": "DDI-MedLine.d204.s11", "pair_id": "DDI-MedLine.d204.s11.p1"} {"sentence": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ", "drug1": "itraconazole", "drug2": "erythromycin", "relation": "NONE", "source_file": "Tolterodine.xml", "sentence_id": "DDI-DrugBank.d765.s1", "pair_id": "DDI-DrugBank.d765.s1.p19"} {"sentence": "DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. ", "drug1": "DIFLUCAN", "drug2": "glipizide", "relation": "MECHANISM", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s4", "pair_id": "DDI-DrugBank.d776.s4.p2"} {"sentence": "Cyclosporine: DIFLUCAN may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment. ", "drug1": "DIFLUCAN", "drug2": "cyclosporine", "relation": "MECHANISM", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s13", "pair_id": "DDI-DrugBank.d776.s13.p2"} {"sentence": "If diuretics cannot be interrupted, close medical supervision should be provided with the first dose of ACEON Tablets, for at least two hours and until blood pressure has stabilized for another hour. ", "drug1": "diuretics", "drug2": "ACEON", "relation": "ADVISE", "source_file": "Perindopril.xml", "sentence_id": "DDI-DrugBank.d781.s2", "pair_id": "DDI-DrugBank.d781.s2.p0"} {"sentence": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ", "drug1": "lithium", "drug2": "lithium", "relation": "NONE", "source_file": "Moexipril.xml", "sentence_id": "DDI-DrugBank.d640.s6", "pair_id": "DDI-DrugBank.d640.s6.p6"} {"sentence": "Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ", "drug1": "paclitaxel", "drug2": "paclitaxel", "relation": "NONE", "source_file": "21813412.xml", "sentence_id": "DDI-MedLine.d194.s10", "pair_id": "DDI-MedLine.d194.s10.p5"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "Methscopolamine", "drug2": "potassium chloride", "relation": "INT", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p14"} {"sentence": "The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.", "drug1": "adrenergic agents", "drug2": "tricyclic antidepressants", "relation": "EFFECT", "source_file": "Phenylephrine.xml", "sentence_id": "DDI-DrugBank.d725.s3", "pair_id": "DDI-DrugBank.d725.s3.p0"} {"sentence": "Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.", "drug1": "Miochol", "drug2": "suprofen", "relation": "EFFECT", "source_file": "Suprofen.xml", "sentence_id": "DDI-DrugBank.d723.s0", "pair_id": "DDI-DrugBank.d723.s0.p8"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "MIVACRON", "drug2": "antibiotics", "relation": "INT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p15"} {"sentence": "As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy. ", "drug1": "olsalazine", "drug2": "thioguanine", "relation": "MECHANISM", "source_file": "Thioguanine.xml", "sentence_id": "DDI-DrugBank.d722.s1", "pair_id": "DDI-DrugBank.d722.s1.p6"} {"sentence": "Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ", "drug1": "thiopental", "drug2": "phenytoin", "relation": "NONE", "source_file": "Salsalate.xml", "sentence_id": "DDI-DrugBank.d576.s6", "pair_id": "DDI-DrugBank.d576.s6.p21"} {"sentence": "Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.", "drug1": "CNS depressant", "drug2": "antichlolinergic", "relation": "NONE", "source_file": "Mequitazine.xml", "sentence_id": "DDI-DrugBank.d699.s0", "pair_id": "DDI-DrugBank.d699.s0.p5"} {"sentence": "Pilocarpine should be administered with caution to patients taking beta adrenergic antagonists because of the possibility of conduction disturbances. ", "drug1": "Pilocarpine", "drug2": "beta adrenergic antagonists", "relation": "ADVISE", "source_file": "Pilocarpine.xml", "sentence_id": "DDI-DrugBank.d627.s0", "pair_id": "DDI-DrugBank.d627.s0.p0"} {"sentence": "Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ", "drug1": "troleandomycin", "drug2": "azithromycin", "relation": "NONE", "source_file": "Terfenadine.xml", "sentence_id": "DDI-DrugBank.d743.s12", "pair_id": "DDI-DrugBank.d743.s12.p17"} {"sentence": "The concomitant use of Sanctura with other anticholinergic agents that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects. ", "drug1": "Sanctura", "drug2": "anticholinergic agents", "relation": "EFFECT", "source_file": "Trospium.xml", "sentence_id": "DDI-DrugBank.d713.s0", "pair_id": "DDI-DrugBank.d713.s0.p0"} {"sentence": "This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. ", "drug1": "NSAIDs", "drug2": "ACE inhibitors", "relation": "ADVISE", "source_file": "Meloxicam.xml", "sentence_id": "DDI-DrugBank.d597.s1", "pair_id": "DDI-DrugBank.d597.s1.p0"} {"sentence": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "drug1": "amoxapine", "drug2": "Norpramin", "relation": "NONE", "source_file": "Mazindol.xml", "sentence_id": "DDI-DrugBank.d716.s5", "pair_id": "DDI-DrugBank.d716.s5.p57"} {"sentence": "Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold. ", "drug1": "fenofibrate", "drug2": "ezetimibe", "relation": "MECHANISM", "source_file": "Ezetimibe.xml", "sentence_id": "DDI-DrugBank.d572.s6", "pair_id": "DDI-DrugBank.d572.s6.p2"} {"sentence": "Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. ", "drug1": "roxithromycin", "drug2": "astemizole", "relation": "NONE", "source_file": "Roxithromycin.xml", "sentence_id": "DDI-DrugBank.d709.s3", "pair_id": "DDI-DrugBank.d709.s3.p2"} {"sentence": "However, interactions may be expected and FLOMAX capsules should NOT be used in combination with other alpha-adrenergic blocking agents. ", "drug1": "FLOMAX", "drug2": "alpha-adrenergic blocking agents", "relation": "ADVISE", "source_file": "Tamsulosin.xml", "sentence_id": "DDI-DrugBank.d704.s1", "pair_id": "DDI-DrugBank.d704.s1.p0"} {"sentence": "An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. ", "drug1": "rosiglitazone", "drug2": "rifampin", "relation": "NONE", "source_file": "Rosiglitazone.xml", "sentence_id": "DDI-DrugBank.d609.s0", "pair_id": "DDI-DrugBank.d609.s0.p3"} {"sentence": "An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. ", "drug1": "gemfibrozil", "drug2": "rifampin", "relation": "NONE", "source_file": "Rosiglitazone.xml", "sentence_id": "DDI-DrugBank.d609.s0", "pair_id": "DDI-DrugBank.d609.s0.p1"} {"sentence": "One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication (ephedrine).", "drug1": "selegiline", "drug2": "ephedrine", "relation": "EFFECT", "source_file": "Selegiline.xml", "sentence_id": "DDI-DrugBank.d619.s5", "pair_id": "DDI-DrugBank.d619.s5.p1"} {"sentence": "If glucocorticoid replacement is required, the glucocorticoid dose should be carefully adjusted. ", "drug1": "glucocorticoid", "drug2": "glucocorticoid", "relation": "NONE", "source_file": "Somatropin recombinant.xml", "sentence_id": "DDI-DrugBank.d599.s4", "pair_id": "DDI-DrugBank.d599.s4.p0"} {"sentence": "These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ", "drug1": "GH", "drug2": "corticosteroids", "relation": "MECHANISM", "source_file": "Somatropin recombinant.xml", "sentence_id": "DDI-DrugBank.d599.s7", "pair_id": "DDI-DrugBank.d599.s7.p0"} {"sentence": "Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. ", "drug1": "troleandomycin", "drug2": "methylprednisolone", "relation": "MECHANISM", "source_file": "Methylprednisolone.xml", "sentence_id": "DDI-DrugBank.d578.s5", "pair_id": "DDI-DrugBank.d578.s5.p1"} {"sentence": "A calcium dose of 800 mg diminished absorption of 5 mg heme iron by 37.7%. ", "drug1": "calcium", "drug2": "heme iron", "relation": "MECHANISM", "source_file": "21795430.xml", "sentence_id": "DDI-MedLine.d169.s9", "pair_id": "DDI-MedLine.d169.s9.p0"} {"sentence": "Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; ", "drug1": "Fluconazole", "drug2": "levonorgestrel", "relation": "MECHANISM", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s38", "pair_id": "DDI-DrugBank.d776.s38.p1"} {"sentence": "Cholestyramine and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with mycophenolate mofetil. ", "drug1": "MPA", "drug2": "mycophenolate mofetil", "relation": "NONE", "source_file": "Mycophenolic acid.xml", "sentence_id": "DDI-DrugBank.d700.s7", "pair_id": "DDI-DrugBank.d700.s7.p2"} {"sentence": "Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ", "drug1": "Posicor", "drug2": "terfenadine", "relation": "MECHANISM", "source_file": "Mibefradil.xml", "sentence_id": "DDI-DrugBank.d783.s0", "pair_id": "DDI-DrugBank.d783.s0.p0"} {"sentence": "Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended. ", "drug1": "methyldopa", "drug2": "ferrous sulfate", "relation": "ADVISE", "source_file": "Methyldopa.xml", "sentence_id": "DDI-DrugBank.d779.s9", "pair_id": "DDI-DrugBank.d779.s9.p0"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "lincomycin", "drug2": "clindamycin", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p84"} {"sentence": "Thiabendazole may compete with other drugs, such as theophylline, for sites of metabolism in the liver, thus elevating the serum levels of such compounds to potentially toxic levels. ", "drug1": "Thiabendazole", "drug2": "theophylline", "relation": "MECHANISM", "source_file": "Thiabendazole.xml", "sentence_id": "DDI-DrugBank.d686.s0", "pair_id": "DDI-DrugBank.d686.s0.p0"} {"sentence": "Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.", "drug1": "CNS depression-producing drugs", "drug2": "methyprylon", "relation": "EFFECT", "source_file": "Methyprylon.xml", "sentence_id": "DDI-DrugBank.d600.s1", "pair_id": "DDI-DrugBank.d600.s1.p2"} {"sentence": "Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ", "drug1": "morphine", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Morphine.xml", "sentence_id": "DDI-DrugBank.d637.s0", "pair_id": "DDI-DrugBank.d637.s0.p7"} {"sentence": "Concomitant administration of low-dose aspirin with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone. ", "drug1": "aspirin", "drug2": "MOBIC", "relation": "EFFECT", "source_file": "Meloxicam.xml", "sentence_id": "DDI-DrugBank.d597.s5", "pair_id": "DDI-DrugBank.d597.s5.p0"} {"sentence": "norepinephrine and dobutamine are incompatible with sodium bicarbonate solution. ", "drug1": "norepinephrine", "drug2": "sodium bicarbonate", "relation": "INT", "source_file": "Sodium bicarbonate.xml", "sentence_id": "DDI-DrugBank.d595.s1", "pair_id": "DDI-DrugBank.d595.s1.p1"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "quinidine", "drug2": "potassium chloride", "relation": "NONE", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p179"} {"sentence": "There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between LAMISIL Tablets and these changes has not been established. ", "drug1": "terbinafine", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Terbinafine.xml", "sentence_id": "DDI-DrugBank.d645.s6", "pair_id": "DDI-DrugBank.d645.s6.p0"} {"sentence": "The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ", "drug1": "neuromuscular blocking agents", "drug2": "carbamazepine", "relation": "EFFECT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s11", "pair_id": "DDI-DrugBank.d775.s11.p19"} {"sentence": "However, increased prothrombin time and bleeding have been reported in patients on concomitant TOLECTIN and warfarin therapy. ", "drug1": "TOLECTIN", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Tolmetin.xml", "sentence_id": "DDI-DrugBank.d608.s1", "pair_id": "DDI-DrugBank.d608.s1.p0"} {"sentence": "Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ", "drug1": "Ritalin", "drug2": "phenobarbital", "relation": "MECHANISM", "source_file": "Methylphenidate.xml", "sentence_id": "DDI-DrugBank.d638.s2", "pair_id": "DDI-DrugBank.d638.s2.p2"} {"sentence": "Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol. ", "drug1": "tranquilizers", "drug2": "alcohol", "relation": "NONE", "source_file": "Scopolamine.xml", "sentence_id": "DDI-DrugBank.d771.s1", "pair_id": "DDI-DrugBank.d771.s1.p5"} {"sentence": "Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ", "drug1": "triamterene", "drug2": "hydrochlorothiazide", "relation": "NONE", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s6", "pair_id": "DDI-DrugBank.d737.s6.p43"} {"sentence": "Use of neuroleptics in conjunction with oral morphine may increase the risk of respiratory depression, hypotension and profound sedation or coma. ", "drug1": "neuroleptics", "drug2": "morphine", "relation": "EFFECT", "source_file": "Morphine.xml", "sentence_id": "DDI-DrugBank.d637.s1", "pair_id": "DDI-DrugBank.d637.s1.p0"} {"sentence": "These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; ", "drug1": "DIFLUCAN", "drug2": "hypoglycemic agents", "relation": "EFFECT", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s2", "pair_id": "DDI-DrugBank.d776.s2.p104"} {"sentence": "In an in vitro assay, lapatinib induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of Herceptin-mediated ADCC. ", "drug1": "lapatinib", "drug2": "Herceptin", "relation": "EFFECT", "source_file": "21868551.xml", "sentence_id": "DDI-MedLine.d164.s3", "pair_id": "DDI-MedLine.d164.s3.p0"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "Methscopolamine", "drug2": "promethazine", "relation": "INT", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p21"} {"sentence": "Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants", "drug1": "antibiotics", "drug2": "neostigmine", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s13", "pair_id": "DDI-DrugBank.d775.s13.p38"} {"sentence": "Fibrates: The safety and effectiveness of ezetimibe administered with fibrates have not been established. ", "drug1": "Fibrates", "drug2": "ezetimibe", "relation": "NONE", "source_file": "Ezetimibe.xml", "sentence_id": "DDI-DrugBank.d572.s2", "pair_id": "DDI-DrugBank.d572.s2.p0"} {"sentence": "Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. ", "drug1": "procaine hydrochloride", "drug2": "anticholinesterase agents", "relation": "EFFECT", "source_file": "Procaine.xml", "sentence_id": "DDI-DrugBank.d780.s0", "pair_id": "DDI-DrugBank.d780.s0.p4"} {"sentence": "It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).", "drug1": "thiazides", "drug2": "phenytoin", "relation": "NONE", "source_file": "Sulfoxone.xml", "sentence_id": "DDI-DrugBank.d682.s1", "pair_id": "DDI-DrugBank.d682.s1.p6"} {"sentence": "Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants", "drug1": "phenytoin", "drug2": "procaine", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s13", "pair_id": "DDI-DrugBank.d775.s13.p21"} {"sentence": "Digitalis Glycosides: Diuretic-induced hypokalemia can increase the sensitivity of the myocardium to digitalis. ", "drug1": "Diuretic", "drug2": "digitalis", "relation": "EFFECT", "source_file": "Metolazone.xml", "sentence_id": "DDI-DrugBank.d588.s4", "pair_id": "DDI-DrugBank.d588.s4.p2"} {"sentence": "The CNS depressant effects of oxycodone hydrochloride may be additive with that of other CNS depressants..", "drug1": "oxycodone hydrochloride", "drug2": "CNS depressants", "relation": "EFFECT", "source_file": "Oxycodone.xml", "sentence_id": "DDI-DrugBank.d758.s0", "pair_id": "DDI-DrugBank.d758.s0.p0"} {"sentence": "This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil dose is changed. ", "drug1": "Mexitil", "drug2": "theophylline", "relation": "ADVISE", "source_file": "Mexiletine.xml", "sentence_id": "DDI-DrugBank.d633.s18", "pair_id": "DDI-DrugBank.d633.s18.p22"} {"sentence": "MAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine. ", "drug1": "MAO inhibitors", "drug2": "pseudoephedrine", "relation": "EFFECT", "source_file": "Pseudoephedrine.xml", "sentence_id": "DDI-DrugBank.d606.s0", "pair_id": "DDI-DrugBank.d606.s0.p1"} {"sentence": "Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ", "drug1": "ketoconazole", "drug2": "midazolam", "relation": "MECHANISM", "source_file": "Midazolam.xml", "sentence_id": "DDI-DrugBank.d752.s1", "pair_id": "DDI-DrugBank.d752.s1.p17"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "Methscopolamine", "drug2": "chlorpromazine", "relation": "INT", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p20"} {"sentence": "Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ", "drug1": "Sanctura", "drug2": "metformin", "relation": "MECHANISM", "source_file": "Trospium.xml", "sentence_id": "DDI-DrugBank.d713.s2", "pair_id": "DDI-DrugBank.d713.s2.p13"} {"sentence": "Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). ", "drug1": "atropine", "drug2": "alpha glucosidase inhibitors", "relation": "NONE", "source_file": "Pramlintide.xml", "sentence_id": "DDI-DrugBank.d632.s0", "pair_id": "DDI-DrugBank.d632.s0.p5"} {"sentence": "Also mirtazapine, which is not believed to interact with warfarin, increased the risk of GI bleeding (OR = 1.75 [95% CI, 1.30-2.35]). ", "drug1": "mirtazapine", "drug2": "warfarin", "relation": "EFFECT", "source_file": "21731754.xml", "sentence_id": "DDI-MedLine.d218.s9", "pair_id": "DDI-MedLine.d218.s9.p0"} {"sentence": "Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants", "drug1": "carbamazepine", "drug2": "anesthetics", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s13", "pair_id": "DDI-DrugBank.d775.s13.p33"} {"sentence": "While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.", "drug1": "calcium", "drug2": "naproxen", "relation": "NONE", "source_file": "Pilocarpine.xml", "sentence_id": "DDI-DrugBank.d627.s4", "pair_id": "DDI-DrugBank.d627.s4.p19"} {"sentence": "Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ", "drug1": "cephalosporins", "drug2": "pramipexole", "relation": "MECHANISM", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s6", "pair_id": "DDI-DrugBank.d737.s6.p80"} {"sentence": "- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone. ", "drug1": "prednisone", "drug2": "prednisolone", "relation": "NONE", "source_file": "Montelukast.xml", "sentence_id": "DDI-DrugBank.d739.s5", "pair_id": "DDI-DrugBank.d739.s5.p5"} {"sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "drug1": "anticholinergic drugs", "drug2": "meperidine", "relation": "EFFECT", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s0", "pair_id": "DDI-DrugBank.d585.s0.p9"} {"sentence": "Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT. ", "drug1": "insulin", "drug2": "SOMAVERT", "relation": "ADVISE", "source_file": "Pegvisomant.xml", "sentence_id": "DDI-DrugBank.d744.s0", "pair_id": "DDI-DrugBank.d744.s0.p1"} {"sentence": "Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.", "drug1": "warfarin", "drug2": "XENICAL", "relation": "ADVISE", "source_file": "Orlistat.xml", "sentence_id": "DDI-DrugBank.d761.s13", "pair_id": "DDI-DrugBank.d761.s13.p5"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "nondepolarizing agents", "drug2": "anesthetics", "relation": "INT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p12"} {"sentence": "Decreased seizure threshold has been reported in patients receiving CYLERT concomitantly with antiepileptic medications.", "drug1": "CYLERT", "drug2": "antiepileptic medications", "relation": "EFFECT", "source_file": "Pemoline.xml", "sentence_id": "DDI-DrugBank.d671.s2", "pair_id": "DDI-DrugBank.d671.s2.p0"} {"sentence": "Interactions for Vitamin B1 (Thiamine): Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants", "drug1": "Thiamine", "drug2": "Contraceptives", "relation": "INT", "source_file": "Thiamine.xml", "sentence_id": "DDI-DrugBank.d697.s0", "pair_id": "DDI-DrugBank.d697.s0.p6"} {"sentence": "In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ", "drug1": "TOBI", "drug2": "PULMOZYME", "relation": "NONE", "source_file": "Tobramycin.xml", "sentence_id": "DDI-DrugBank.d624.s0", "pair_id": "DDI-DrugBank.d624.s0.p2"} {"sentence": "Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.", "drug1": "tetracyclines", "drug2": "contraceptives", "relation": "EFFECT", "source_file": "Minocycline.xml", "sentence_id": "DDI-DrugBank.d711.s4", "pair_id": "DDI-DrugBank.d711.s4.p0"} {"sentence": "Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ", "drug1": "erythromycin", "drug2": "azithromycin", "relation": "NONE", "source_file": "Terfenadine.xml", "sentence_id": "DDI-DrugBank.d743.s12", "pair_id": "DDI-DrugBank.d743.s12.p14"} {"sentence": "When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil , lowered Mexitil plasma levels have been reported. ", "drug1": "phenytoin", "drug2": "rifampin", "relation": "NONE", "source_file": "Mexiletine.xml", "sentence_id": "DDI-DrugBank.d633.s9", "pair_id": "DDI-DrugBank.d633.s9.p0"} {"sentence": "Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine", "drug1": "Vindesine", "drug2": "Killed virus vaccines", "relation": "INT", "source_file": "Vindesine.xml", "sentence_id": "DDI-DrugBank.d782.s0", "pair_id": "DDI-DrugBank.d782.s0.p4"} {"sentence": "Careful monitoring of phenytoin concentrations in patients receiving DIFLUCAN and phenytoin is recommended. ", "drug1": "phenytoin", "drug2": "phenytoin", "relation": "NONE", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s11", "pair_id": "DDI-DrugBank.d776.s11.p1"} {"sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "drug1": "anticholinergic drugs", "drug2": "MAO inhibitors", "relation": "EFFECT", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s0", "pair_id": "DDI-DrugBank.d585.s0.p7"} {"sentence": "Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.", "drug1": "Leukine", "drug2": "lithium", "relation": "EFFECT", "source_file": "Sargramostim.xml", "sentence_id": "DDI-DrugBank.d607.s1", "pair_id": "DDI-DrugBank.d607.s1.p0"} {"sentence": "Monoamine oxidase inhibitors or tricyclic antidepressants may potentiate the action of sympathomimetic amines. ", "drug1": "Monoamine oxidase inhibitors", "drug2": "sympathomimetic amines", "relation": "EFFECT", "source_file": "Metaraminol.xml", "sentence_id": "DDI-DrugBank.d746.s1", "pair_id": "DDI-DrugBank.d746.s1.p1"} {"sentence": "We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.", "drug1": "dexmedetomidine", "drug2": "dexmedetomidine", "relation": "NONE", "source_file": "21876510.xml", "sentence_id": "DDI-MedLine.d227.s9", "pair_id": "DDI-MedLine.d227.s9.p1"} {"sentence": "In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron. ", "drug1": "calcium", "drug2": "nonheme iron", "relation": "MECHANISM", "source_file": "21795430.xml", "sentence_id": "DDI-MedLine.d169.s10", "pair_id": "DDI-MedLine.d169.s10.p0"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "nondepolarizing agents", "drug2": "clindamycin", "relation": "INT", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p7"} {"sentence": "Limited published data indicate that GH treatment increases cytochrome P450 (CP450) mediated antipyrine clearance in man. ", "drug1": "GH", "drug2": "antipyrine", "relation": "MECHANISM", "source_file": "Somatropin recombinant.xml", "sentence_id": "DDI-DrugBank.d599.s6", "pair_id": "DDI-DrugBank.d599.s6.p0"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "bacitracin", "drug2": "magnesium", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p70"} {"sentence": "Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ", "drug1": "carbamazepine", "drug2": "ondansetron", "relation": "MECHANISM", "source_file": "Ondansetron.xml", "sentence_id": "DDI-DrugBank.d763.s3", "pair_id": "DDI-DrugBank.d763.s3.p23"} {"sentence": "Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ", "drug1": "tetracyclines", "drug2": "aluminum", "relation": "MECHANISM", "source_file": "Minocycline.xml", "sentence_id": "DDI-DrugBank.d711.s2", "pair_id": "DDI-DrugBank.d711.s2.p1"} {"sentence": "Cimetidine: Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N= 12). ", "drug1": "Cimetidine", "drug2": "pramipexole", "relation": "MECHANISM", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s4", "pair_id": "DDI-DrugBank.d737.s4.p2"} {"sentence": "one fatality has been reported from hypoglycemia in association with combined DIFLUCAN and glyburide use. ", "drug1": "DIFLUCAN", "drug2": "glyburide", "relation": "EFFECT", "source_file": "Fluconazole.xml", "sentence_id": "DDI-DrugBank.d776.s3", "pair_id": "DDI-DrugBank.d776.s3.p0"} {"sentence": "Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. ", "drug1": "Thalidomide", "drug2": "barbiturates", "relation": "EFFECT", "source_file": "Thalidomide.xml", "sentence_id": "DDI-DrugBank.d604.s0", "pair_id": "DDI-DrugBank.d604.s0.p0"} {"sentence": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). ", "drug1": "imipramine", "drug2": "desipramine", "relation": "NONE", "source_file": "Mazindol.xml", "sentence_id": "DDI-DrugBank.d716.s5", "pair_id": "DDI-DrugBank.d716.s5.p113"} {"sentence": "Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ", "drug1": "EVISTA", "drug2": "indomethacin", "relation": "ADVISE", "source_file": "Raloxifene.xml", "sentence_id": "DDI-DrugBank.d648.s6", "pair_id": "DDI-DrugBank.d648.s6.p1"} {"sentence": "Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).", "drug1": "Trilostane", "drug2": "aminoglutethimide", "relation": "INT", "source_file": "Trilostane.xml", "sentence_id": "DDI-DrugBank.d774.s0", "pair_id": "DDI-DrugBank.d774.s0.p0"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "Methscopolamine", "drug2": "tranylcypromine", "relation": "INT", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p5"} {"sentence": "This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants, -blockers, selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window. ", "drug1": "selective serotonin reuptake inhibitors", "drug2": "monoamine oxidase inhibitors (MAO-Is) Type B", "relation": "NONE", "source_file": "Terbinafine.xml", "sentence_id": "DDI-DrugBank.d645.s2", "pair_id": "DDI-DrugBank.d645.s2.p4"} {"sentence": "There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100 g/mL total valproate).", "drug1": "meropenem", "drug2": "valproic acid", "relation": "MECHANISM", "source_file": "Meropenem.xml", "sentence_id": "DDI-DrugBank.d762.s3", "pair_id": "DDI-DrugBank.d762.s3.p0"} {"sentence": "When oxandrolone therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved. ", "drug1": "oxandrolone", "drug2": "warfarin", "relation": "ADVISE", "source_file": "Oxandrolone.xml", "sentence_id": "DDI-DrugBank.d584.s6", "pair_id": "DDI-DrugBank.d584.s6.p0"} {"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "drug1": "Methscopolamine", "drug2": "anticholinergics", "relation": "INT", "source_file": "Methylscopolamine.xml", "sentence_id": "DDI-DrugBank.d655.s0", "pair_id": "DDI-DrugBank.d655.s0.p13"} {"sentence": "Given the primary CNS effects of paliperidone, INVEGA should be used with caution in combination with other centrally acting drugs and alcohol. ", "drug1": "INVEGA", "drug2": "alcohol", "relation": "ADVISE", "source_file": "Paliperidone.xml", "sentence_id": "DDI-DrugBank.d670.s6", "pair_id": "DDI-DrugBank.d670.s6.p4"} {"sentence": "Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ", "drug1": "sertraline", "drug2": "sumatriptan", "relation": "EFFECT", "source_file": "Sumatriptan.xml", "sentence_id": "DDI-DrugBank.d720.s3", "pair_id": "DDI-DrugBank.d720.s3.p35"} {"sentence": "The use of MIVACRON before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied. ", "drug1": "MIVACRON", "drug2": "succinylcholine", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s3", "pair_id": "DDI-DrugBank.d775.s3.p1"} {"sentence": "The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ", "drug1": "Brilinta", "drug2": "aspirin", "relation": "EFFECT", "source_file": "21897348.xml", "sentence_id": "DDI-MedLine.d193.s1", "pair_id": "DDI-MedLine.d193.s1.p4"} {"sentence": "Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ", "drug1": "Ritalin", "drug2": "primidone", "relation": "MECHANISM", "source_file": "Methylphenidate.xml", "sentence_id": "DDI-DrugBank.d638.s2", "pair_id": "DDI-DrugBank.d638.s2.p4"} {"sentence": "When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. ", "drug1": "atropine", "drug2": "pralidoxime", "relation": "EFFECT", "source_file": "Pralidoxime.xml", "sentence_id": "DDI-DrugBank.d622.s0", "pair_id": "DDI-DrugBank.d622.s0.p0"} {"sentence": "The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ", "drug1": "phenothiazines", "drug2": "opioids", "relation": "NONE", "source_file": "Oxymorphone.xml", "sentence_id": "DDI-DrugBank.d753.s0", "pair_id": "DDI-DrugBank.d753.s0.p35"} {"sentence": "A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ", "drug1": "atazanavir", "drug2": "indinavir", "relation": "NONE", "source_file": "Paricalcitol.xml", "sentence_id": "DDI-DrugBank.d726.s1", "pair_id": "DDI-DrugBank.d726.s1.p76"} {"sentence": "Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ", "drug1": "fluconazole", "drug2": "terfenadine", "relation": "ADVISE", "source_file": "Terfenadine.xml", "sentence_id": "DDI-DrugBank.d743.s8", "pair_id": "DDI-DrugBank.d743.s8.p10"} {"sentence": "Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.", "drug1": "warfarin", "drug2": "anti-infective medicines", "relation": "NONE", "source_file": "Mephenytoin.xml", "sentence_id": "DDI-DrugBank.d636.s3", "pair_id": "DDI-DrugBank.d636.s3.p11"} {"sentence": "Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. ", "drug1": "clotrimazole", "drug2": "trimetrexate", "relation": "MECHANISM", "source_file": "Trimetrexate.xml", "sentence_id": "DDI-DrugBank.d766.s3", "pair_id": "DDI-DrugBank.d766.s3.p6"} {"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ", "drug1": "polymyxins", "drug2": "anesthetics", "relation": "NONE", "source_file": "Mivacurium.xml", "sentence_id": "DDI-DrugBank.d775.s10", "pair_id": "DDI-DrugBank.d775.s10.p81"} {"sentence": "Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ", "drug1": "digoxin", "drug2": "ethanol", "relation": "NONE", "source_file": "Metoclopramide.xml", "sentence_id": "DDI-DrugBank.d652.s3", "pair_id": "DDI-DrugBank.d652.s3.p4"} {"sentence": "Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ", "drug1": "Salicylate", "drug2": "penicillin", "relation": "MECHANISM", "source_file": "Salsalate.xml", "sentence_id": "DDI-DrugBank.d576.s6", "pair_id": "DDI-DrugBank.d576.s6.p0"} {"sentence": "Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ", "drug1": "Ritalin", "drug2": "coumarin anticoagulants", "relation": "MECHANISM", "source_file": "Methylphenidate.xml", "sentence_id": "DDI-DrugBank.d638.s2", "pair_id": "DDI-DrugBank.d638.s2.p0"} {"sentence": "Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. ", "drug1": "reserpine", "drug2": "beta-blocking agents", "relation": "EFFECT", "source_file": "Metoprolol.xml", "sentence_id": "DDI-DrugBank.d706.s0", "pair_id": "DDI-DrugBank.d706.s0.p0"} {"sentence": "Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. ", "drug1": "Matulane", "drug2": "tricyclic antidepressant", "relation": "ADVISE", "source_file": "Procarbazine.xml", "sentence_id": "DDI-DrugBank.d676.s2", "pair_id": "DDI-DrugBank.d676.s2.p1"} {"sentence": "patients receiving lithium and Neulasta should have more frequent monitoring of neutrophil counts.", "drug1": "lithium", "drug2": "Neulasta", "relation": "ADVISE", "source_file": "Pegfilgrastim.xml", "sentence_id": "DDI-DrugBank.d581.s2", "pair_id": "DDI-DrugBank.d581.s2.p0"} {"sentence": "Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ", "drug1": "oxandrolone", "drug2": "warfarin", "relation": "MECHANISM", "source_file": "Oxandrolone.xml", "sentence_id": "DDI-DrugBank.d584.s3", "pair_id": "DDI-DrugBank.d584.s3.p4"} {"sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ", "drug1": "antiarrhythmic agents of class I", "drug2": "nitrates", "relation": "NONE", "source_file": "Mepenzolate.xml", "sentence_id": "DDI-DrugBank.d585.s0", "pair_id": "DDI-DrugBank.d585.s0.p35"} {"sentence": "Sulfamethoxazole may inhibit the hepatic metabolism of phenytoin. ", "drug1": "Sulfamethoxazole", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Sulfamethoxazole.xml", "sentence_id": "DDI-DrugBank.d577.s3", "pair_id": "DDI-DrugBank.d577.s3.p0"} {"sentence": "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide celecoxib following different incubation schedules were analyzed.", "drug1": "5-FU", "drug2": "cisplatin", "relation": "NONE", "source_file": "21763710.xml", "sentence_id": "DDI-MedLine.d217.s4", "pair_id": "DDI-MedLine.d217.s4.p0"} {"sentence": "There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ", "drug1": "MYCAMINE", "drug2": "mycophenolate mofetil", "relation": "NONE", "source_file": "Micafungin.xml", "sentence_id": "DDI-DrugBank.d735.s2", "pair_id": "DDI-DrugBank.d735.s2.p0"} {"sentence": "Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ", "drug1": "hydrochlorothiazide", "drug2": "pramipexole", "relation": "MECHANISM", "source_file": "Pramipexole.xml", "sentence_id": "DDI-DrugBank.d737.s6", "pair_id": "DDI-DrugBank.d737.s6.p89"} {"sentence": "convulsions have been reported with concurrent use of methylprednisolone and cyclosporin. ", "drug1": "methylprednisolone", "drug2": "cyclosporin", "relation": "EFFECT", "source_file": "Methylprednisolone.xml", "sentence_id": "DDI-DrugBank.d578.s3", "pair_id": "DDI-DrugBank.d578.s3.p0"} {"sentence": "Coumarin-Derivative Anticoagulants: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving ZOLINZA concomitantly with coumarin-derivative anticoagulants. ", "drug1": "ZOLINZA", "drug2": "coumarin-derivative anticoagulants", "relation": "EFFECT", "source_file": "Vorinostat.xml", "sentence_id": "DDI-DrugBank.d769.s0", "pair_id": "DDI-DrugBank.d769.s0.p2"} {"sentence": "This is typical of the interaction of meperidine and MAOIs. ", "drug1": "meperidine", "drug2": "MAOIs", "relation": "INT", "source_file": "Selegiline.xml", "sentence_id": "DDI-DrugBank.d619.s2", "pair_id": "DDI-DrugBank.d619.s2.p0"} {"sentence": "Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. ", "drug1": "sumatriptan succinate", "drug2": "MAO-A inhibitors", "relation": "ADVISE", "source_file": "Sumatriptan.xml", "sentence_id": "DDI-DrugBank.d720.s3", "pair_id": "DDI-DrugBank.d720.s3.p0"} {"sentence": "Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. ", "drug1": "trimetrexate", "drug2": "fluconazole", "relation": "EFFECT", "source_file": "Trimetrexate.xml", "sentence_id": "DDI-DrugBank.d766.s1", "pair_id": "DDI-DrugBank.d766.s1.p4"} {"sentence": "You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. ", "drug1": "mazindol", "drug2": "monoamine oxidase inhibitor", "relation": "ADVISE", "source_file": "Mazindol.xml", "sentence_id": "DDI-DrugBank.d716.s0", "pair_id": "DDI-DrugBank.d716.s0.p0"} {"sentence": "There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.", "drug1": "theophyllines", "drug2": "phenytoins", "relation": "NONE", "source_file": "Terbinafine.xml", "sentence_id": "DDI-DrugBank.d645.s9", "pair_id": "DDI-DrugBank.d645.s9.p11"}